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ABSTRACT 
 
SYNTHESIS OF BICYCLIC THIENO[2,3-d]PYRIMIDINES, TRICYCLIC 
THIENO[2,3-d]PYRIMIDINES AND THIENO[3,2-d]PYRIMIDINES  AS CLASSICAL  
AND NONCLASSICAL ANTIFOLATES 
 
 
By 
Xilin Zhou 
December 2012 
 
Thesis Supervised by Dr. Aleem Gangjee, PhD 
An introduction, background and research progress in the areas of antifolates and 
antimitotic agents has been reviewed and discussed. Thymidylate synthase (TS), 
dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase 
(GARFTase) are important folate dependent enzymes that are targets for cancer 
chemotherapy and the treatment of infectious diseases. As a part of this study, thirty-five 
novel compounds were designed and synthesized on the basis of existing clinically active 
compounds and their crystal structures. These compounds were synthesized and 
evaluated as single and/or muliple targeted classical and nonclassical antifolates to 
decrease toxicity and improve the antitumor activity and selectivity of existing 
therapeutic agents.  
v 
 
 In addition, bicyclic substituted thieno[2,3-d]- and theino[3,2-d]pyrimidines were 
synthesized as antimitotic agents. These compounds allowed potent inhibition of tumor 
cells in culture and extended the structure-activity relationship in the antimitotic area. 
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I. BIOCHEMICAL REVIEW 
More than twenty interrelated enzymatic reactions in cellular metabolism require 
folate coenzymes. These reactions are essential to maintain de novo synthesis of 
deoxyribonucleic acid (DNA) and some important amino acids.
1
 Folate metabolism has 
long been considered as an attractive target for cancer chemotherapy because of its 
crucial role in the biosynthesis of nucleic acid precursors. Antifolates interfere with 
metabolism pathway of nucleotides. They are clinically used as antimicrobial, antifungal, 
antiprotozoal, and antitumor agents.
2, 
Hitchings, G. A. Folate Antogonists as 
Antibacterial and Antiprotozoal Agents. Ann. N. Y. Acad. Sci. 1971, 186, 444-451.  
1. An overview of the folate pathway  
 
Figure 1. Chemical structure of folic acid 
                                            
Folic acid (FA) (Figure 1) is a water-soluble vitamin of the B-complex group. It 
was first reported more than 70 years ago as an anti-anemia agent in animals and as a 
growth factor in bacteria. The chemical structure of the vitamin is composed of three 
distinct chemical moieties: a hetero-bicyclic pteridine, a p-aminobenzoic acid (PABA) 
and a glutamic acid (Figure 1). Folic acid plays a crucial role in the biosynthesis of 
nucleic acid precursors and hence in DNA synthesis and cell replication.
1, 4-6  
2 
 
 
 
Figure 2. The reduction pathway of folic acid 
In eukaryotes and prokaryotes, folates are obtained through two different  
pathways.
 
Prokaryotes can de novo synthesize 7,8-dihydropteroate (FH2) from p-
aminobenzoic acid, which is then reduced to 5,6,7,8-tetrahydrofolate (FH4) catalyzed by 
dihydrofolate reductase (DHFR) (Figure 2).
7, 8 
However, mammalian cells (including 
human) are incapable of synthesizing FA and acquire it from the diet. 
 
Figure 3. The de novo synthesis of dTMP from dUMP 
3 
 
Folic acid exists in several oxidative states, each of which is an essential cofactor 
in metabolism. In order to work as cofactors, folates must be reduced to FH4, and is 
catalyzed by dihydrofolate reductase (DHFR) in two steps: first to FH2 and then to FH4 
(Figure 2). 
Folates are especially important in the de novo synthesis of 2‟-deoxythymidylate-
5‟-monophosphate (dTMP) from 2‟-deoxyuridylate-5‟- monophosphate (dUMP), which 
is catalyzed by the enzyme, thymidylate synthase (TS) (Figure 3).  
During this process, N
5
, N
10
- methylene -FH4 works as a one-carbon unit donor 
and a reductant. It is a cofactor in this conversion and its one-carbon unit is transferred to 
the 5-position of dUMP to form the 5-methyl group of dTMP (Figure 3). 
This process represents the only de novo source of dTMP. Hence, inhibition of TS 
leads to “thymineless death” in the absence of salvage.10, 11 „„Thymineless death‟‟ is 
usually observed in mammalian cells when severe deoxythymidine-triphosphate (dTTP) 
depletion takes place due to methotrexate (MTX) or 5-fluorouracil (5-FU) treatment. This 
effect is unusual in that deprivation of many other nutritional requirements has a 
biostatic, but not lethal effect.
12-16 
DHFR then completes the cycle by regenerating FH4 
from FH2. DHFR thus controls the overall intracellular concentration of FH4, which is 
crucial for cell proliferation.
17, 18
 Thus inhibition of DHFR leads to a partial depletion of 
the intracellular reduced folate pool, which consequently limits cell growth.
19-21 
Because 
of the essential role in DNA replication, inhibition of these folate dependent enzymes (TS 
and DHFR) are important strategies for chemotherapy, typified by antitumor agent 5-
fluorouracil (5-FU), antimicrobial agent trimethoprim (TMP) and antiprotozoal agent 
pyrimethamine.
4, 22 
4 
 
 
Figure 4. The de novo synthesis of purines 
  The de novo synthesis of purines occurs primarily in proliferating cells such as 
liver and bone marrow and also to some extent, in mononuclear cells and lymphocytes. 
N
10
-Formyl tetrahydrofolate ( N
10
-formyl FH4) is a cofactor that transfers one carbon 
units in the de novo biosynthesis of purine nucleotides (Figure 4). Glycinamide-
ribonucleotide transformylase (GARFTase) is the first folate-dependent enzyme in this 
pathway, which catalyzes the conversion of glycinamide ribosyl-5-phosphate (GAR) to 
formyl-glycinamide ribosyl-5-phosphate (fGAR), utilizing N
10
-formyl-FH4  (Figure 4). 
Amino-imidazolecarboxamide ribosyl-5-phosphate formyl transferase (AICARFTase) is 
another folate-dependent enzyme in the biosynthesis of purines. It utilizes N
10
-CHO-FH4 
and converts amino-imidazocarboxamide ribosyl-5-phosphate (AICAR) to formyl-amino-
imidazolecarboxamide ribosyl-5phosphate (fAICAR). These two folate-dependent 
enzymes are responsible for the insertion of carbon atoms at positions 2 and 8 in inosine-
5 
 
5‟- monophosphate (IMP) (Figure 4), the precursor of adenosine-5‟-triphosphate (ATP) 
and guanosine-5‟-triphosphate (GTP) for ribonucleic acid (RNA) synthesis and of 2‟-
deoxyadenosine-5‟-triphosphate (dATP) and 2‟-deoxyguanosine-5‟-triphosphate (dGTP) 
necessary for DNA synthesis.
20, 23
 
Intracellularly, FA and derived coenzymes are converted to their  polyglutamylated 
derivatives with additional glutamic acid residues to the γ-carboxylic acid via amide 
bonds by the enzyme folylpolyglutamate synthetase (FPGS).
24
 The number of glutamate 
residues varies widely in naturally occurring folates. Usually 2-9 glutamate residues are 
added to the γ-carboxylic acid group of the FA. This is an important mechanism for 
trapping folates or classical antifolates within the cell.  
Most folate enzymes have a higher affinity for polyglutamate forms than 
monoglutamate form. This polyglutamylation reaction has several biologically important 
consequences: (1) The hydrophilicity of the molecule is enhanced due to a increase in 
negative carboxylate groups by polyglutamylation together with a greater intracellular 
retention, which is enabled with a decreased cellular efflux. (2) In some cases, the 
polyglutamylated folate species are thought to have higher binding affinity to some folate 
dependent enzymes.
25
 For example, after polyglutamylation, a classical TS inhibitor may 
also possess the ability to inhibit DHFR and vice versa.
25-27 
Antifolates are classified into 
two types: classical and nonclassical, on the basis of their mechanism of transport and the 
ability to be polyglutamylated.
28, 29
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Figure 5. Representative examples of classical antifolates and their principal 
target(s) 
The classical antifolates (Figure 5) are analogs that contains an L-glutamate side 
chain such as raltitrexed (ZD1694, Tomudex)(RTX), GW1843(OSI-7904), methotrexate 
(MTX), pemetrexed (LY231514, Alimta)(PMX) and PDDF (N
10
-propargyl-5,8-
dideazafolate). However, tumor cells may be resistant or develop resistance to classical 
folate-based antimetabolites through reduced expression of FPGS.
30
 This fact has 
prompted the search for a complementary class of agents which would not be substrates 
for FPGS. 
Lipophilic side chains instead of the L-glutamate is the characteristic feature of 
„non-classical‟ antifolates.  
7 
 
  
Figure 6. Representative examples of nonclassical antifolates and their principal target 
These nonclassical analogues are represented by structures (Figure 6) such as 
AG337, trimethoprim (TMP), trimetrexate (TMQ), pyrimethamine, and piritrexim. 
Nonclassical antifolates cannot be polyglutamylated by FPGS and thus do not undergo 
prolonged retention within the cell as compared to the „classical‟ analogues. 
2.  Folates and antifolates transport systems 
It is necessary to maintain a high concentration of the folate pool for normal 
activity of the cell. Since animals and human lack the de novo biosynthesis of folates, 
cellular uptake of these derivatives is essential for tissue regeneration and cell growth. At 
physiological pH, the α- and γ-carboxyl groups of the glutamate side chain are negatively 
charged. Because of this,  folates poorly pass biological membranes by diffusion alone. 
Folate transport is required not only for cellular uptake but also for intracellular 
compartmentation of the cofactors. Transport of folates and antifolates into the cell is 
usually accomplished by three carrier proteins present on the cell surface: the reduced 
folate carrier (RFC), the membrane folate receptor (FR) and the proton-coupled folate 
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transporter (PCFT).
31
 A summary of biochemical and functional properties of these 
transporters is provided in Table 1. 
Table 1.  Folate transports in mammalian cells 
RFC FR PCFT 
Integral protein anchored in plasma 
membranes by a glycosyl 
phosphatidylinositol (GPI) 
anchor
 32, 33
 
A member of the 
superfamily of facilitative 
carriers
34, 35 
 
Anion exchange 
mechanism (driven by 
anion gradients)
32
 
Endocytotic mechanism
 32
 H
+ 
symporter 
The primary transporter of 
folates and antifolates
32
 
 Transport a wide range of 
folates and antifolates  
High affinity for reduced 
FA (Km ~1-5 µM);  
Low affinity for FA (Ki ~ 
200 µM) 
High affinity for FA (1 
nM) 
and reduced folates (5-10 
nM) 
 
Ubiquitously expressed in 
normal tissues and tumor 
cells
32
 
Most normal cells do not 
express FRα; over 
expression of the FRα on 
the surface of some tumor 
cells
36
 
Wide but likely more 
restricted expression than 
hRFC
34, 35
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Optimum at physiological 
pH (~7.4)
 24
 
 Optimum at acidic pH 
(5.5~6.5)
34, 35
 
 
The functional properties for RFC were first documented in 1968 by Goldman
37 
in 
murine leukemia cells. It is a member of the major facilitator superfamily of transporters 
with the characteristics of an anion exchanger. And is an integral transmembrane protein 
with high affinity for reduced folates (Km ~1-5 µM) and a low affinity for FA (Ki ~ 200 
µM) with a neutral pH optimum.
32
 RFC is ubiquitously expressed in normal tissues and 
tumor cells. It is the major transport system for folates in mammalian cells. And more 
importantly, it is the primary transporter of antifolate drugs used for the cancer 
chemotherapy, including MTX, PMX, RTX and others. The decrease of RFC level or  its 
function is a common mode of antifolate resistance.
38, 39
 Impaired RFC function is an 
important mechanism of resistance to MTX and other antifolates in vitro.
32, 39
 
FRs are anchored in plasma membranes by a glycosyl phosphatidylinositol (GPI) 
anchor and mediate an endocytic mechanism. It shows high affinity for FA (1 nM) and 
reduced folates (5-10 nM). FRs are high affinity folate binding proteins encoded by three 
distinct genes(α, β and γ).40  FRα is overexpressed in some epithelial tumors, especially 
the kidney, placenta and choroid plexus, and has a restricted distribution in normal 
tissues
41-43
, which provides an opportunity for the development of antifolates specifically 
targeted at FRα overexpressing tumors.44, 45 Antifolate toxicity mainly occur in 
proliferating tissues such as bone marrow and gut.
46
 This might be because: (1) Most 
antifolates are primarily transported into cells by the
 
ubiquitously expressed RFC. (2)
 
Proliferative tissues are highly dependent on the
 
enzymes that antifolates target. Thus 
10 
 
antifolates that are specifically transported by FRα should show very low toxicity to 
normal tissues.  
PCFT was recently identified as a third transporter for folates. It is a member of 
the superfamily of facilitative carriers and implicated as the major FA transport
 
 system at 
the acidic pH in the upper small intestine.
34, 35 
PCFT is widely expressed, but has a likely 
more restricted expression than hRFC. PCFT is a proton-folate symporter that functions 
optimally at acidic pH (5.5~6.5)
35
, which is one of the important aspects of  PCFT in the 
treatment of cancer. It is known that acidic microenvironment is a characteristic of solid 
tumors.
47
 Recently, Goldman reported that at pH 5.5, PCFT increased the inhibitory 
activity of PMX, which illustrated the unique property of PCFT as a transporter of 
antifolates.  
3. Thymidylate Synthase (TS) 
3.1 Enzyme description and Catalytic Mechanism 
11 
 
 
Figure 7. Proposed catalytic mechanism of humanTS. (Adapted from Ref. 59) 
TS (EC 2.1.1.45) is a two-substrate enzyme that accepts both dUMP and N
5
, N
10
- 
methylene -FH4 to form a ternary complex and carries out the reductive methylation of 
dUMP, which is the only de novo biosynthesis of dTMP.
7
 TS inhibition results in a 
thymineless state, which prevents the growth of actively dividing cells.
7, 48, 49 
TS has long 
been considered a key target in anticancer chemotherapy.
 
 
The catalytic mechanism of TS has been reviewed extensively.
22, 50-53
 The detailed 
catalytic mechanism is described in Figure 7. 
TS first forms a noncovalent binary complex 1 with dUMP (TS-dUMP), which then 
binds to the active form of cofactor N
5
, N
10
-methylene-FH4 2 to form the noncovalent 
12 
 
ternary complex 3 (TS-dUMP-cofactor). The protonation of the cofactor at the N
10
 
position changes it from an inactive form to the active form 2 which is in an iminium ion 
at N
5
.
21
  dUMP is activated at the C5 position by a nucleophilic attack on the C6 of the 
uracil ring of dUMP by a catalytic thiol (Cys-195, human TS) which results in the 
formation of a Michael-type adduct 1 (Figure 7). The iminium ion of 2 is very reactive 
and rapidly allows the C5 of dUMP to attack to form ternary complex 3. The proton at C5 
of the uracil ring is abstracted by an unidentified base in the enzyme active site to form 4, 
which is followed by double bond formation between the C5 of uracil and the carbon unit 
accompanied by its cleavage from the cofactor 5. The resulting double bond in 5 is 
reduced through hydride transfer from C6 of the reduced cofactor 6, which is 
simultaneously oxidized to form FH2; at the same time, the enzymatic thiol group 
undergoes -elimination to reform the double bond and affords dTMP and free TS.54 
3.2 The structure of TS 
TS is a macromolecular homodimeric protein with a identical subunits of 30-35 kDa 
each and a primary sequence of
 
approximately 316 amino acids long.
55-57
 TS from more 
than thirty species have been isolated, and contain about 316 amino acids. The primary 
structures of about 30 TS enzymes including those of humans, bacteriophages, and plants 
have been determined. TS is one of the most highly conserved enzymes known.
55 
The 
primary structure of TS is highly conserved: approximately 27 amino acids are 
completely conserved and 165 amino acids (80%) are conserved in more than 60% of the 
organisms.
58
 X-ray crystal structures of TS from E. coli,
55
 L.casei,
59, 60 
Leishmania 
major,
61
 and P. carinii
62
 and human have been reported in the literature. In addition, 
many crystal structures of TS complexed with substrates and ligands are available as 
13 
 
well.
63-67
 A comparison of these structures indicates that the tertiary structure is well 
conserved.  
 
 
 
 
Figure 8. X-ray crystal structure of E. coli TS with inhibitor PDDF (CB3717)
68 
 
The subunit interface is formed by a stranded twisted β-sheet composed of about 
twenty five residues that packs against the same sheet formed by the other subunit of the 
dimmer. Each subunit has a deep active site cavity that contains a bound inorganic 
phosphate, which has been observed in all solved TS structures, in the absence of 
nucleotides.
68
 
The active site of dUMP is formed by 32 amino acids, of which 16 are conserved. 
The X-ray crystal structure of E. coli TS bound to dUMP and inhibitor PDDF (CB3717) 
showed that TS consists of a series of 8 α-helices, 10 strands of β-sheet, and several 
14 
 
segments of coil that join the secondary structural elements together. The subunit 
interface is formed by a stranded twisted β-sheet composed of about 25 residues that 
packs against the same sheet formed by the other subunit of the dimmer. Each subunit has 
a deep active site cavity that contains a bound inorganic phosphate, which has been 
observed in all solved TS structures, in the absence of nucleotides (Figure 8). Cys198 is 
on the side of the cavity, and three Arg residues and Ser219 are at the base of the cavity 
coordinated to the bound phosphate.
68, 69
 
The crystal structures of PMX and RTX with human TS have also been obtained 
in 2001.
70, 71 
These structures are important for the understanding of both the mechanism 
and the inhibition of hTS. Several crystal structures of TS complexed with substrates and 
inhibitors have also been reported.
63-67
 These crystal structures allow a structure-based 
rational design of TS inhibitors. 
 
3.2 Representative TS Inhibitors 
These can be broadly divided into five categories:  
1. Nucleotide Analogues 
2. 6-6 Ring Fused Bicyclic Classical Analogues 
3. 6-5 Ring Fused Bicyclic Classical Analogues 
4. Tricyclic Classical Analogues 
5. Nonclassical TS Inhibitors 
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3.2.1. Nucleotide Analogues 
 
Figure 9. The structures of 5-FU and FdUMP 
TS possesses two substrates: dUMP and N
5
, N
10
-methylene-FH4, thus both dUMP 
and folate analogs can be designed as the inhibitors of this enzyme.
72
 The dUMP 
analogue 5-fluorouracil (5-FU) (Figure 9) belongs to the fluoropyrimidine class of 
antineoplastic agents and was first synthesized by Heidelberger and coworkers in1957.
73, 
74
 
5-FU was rationally designed based on the postulation that a chemically modified 
uracil molecule might be effective in disrupting tumor DNA biosynthesis. Since its 
introduction some 55 years ago, 5-FU remains an active agent with broad-spectrum 
activity against many solid tumors, including colorectal, pancreas, breast, head and neck, 
gastric and ovarian cancers.
75
 In the past few years, numerous efforts have been made to 
improve the efficacy of 5-FU. Biochemical modulation of 5-FU with other agents have 
been attempted in the clinic
76 
including interferon (IFN), MTX, leucovorin (LV). LV has 
been the most successful thus far. For the past 15–20 years, the combination of 5-FU and 
LV has been considered the gold standard for treating patients with advanced colorectal 
cancer.
 
LV is intracellularly metabolized to N
5
, N
10
-methylene-FH4, which can form a 
ternary complex with FdUMP and TS to maintain the enzyme in a maximally inhibited 
state. This effect of maintaining the enzyme in an inhibited state is critical since the TS-
16 
 
catalyzed reaction provides the essential nucleotide precursors for DNA biosynthesis. 
Subsequent work confirmed that 5-FU cytotoxicity was significantly enhanced upon 
addition of LV.
77
 
5-FU has several mechanisms of action including inhibition of TS, incorporation into 
DNA, and/or incorporation into RNA.
78 
5-FU is inactive in its original form and must be 
intracellularly converted to various nucleotide forms. For example, 5-fluoro-2‟-
deoxyuridine-5‟-monophosphate (FdUMP) (Figure 9) is a critical nucleotide metabolite 
which forms a covalent ternary complex with TS in the presence of N
5
, N
10
-methylene-
FH4, resulting in inhibition of the enzyme. Nucleotide kinases phosphorylate FdUMP to 
5-Fluoro-2‟-deoxyuridine-5‟-triphosphate (FdUTP), which incorporates into DNA 
leading to inhibition of DNA synthesis and function.  
3.2.2. 6-6 Ring Fused Bicyclic Classical Analogues 
 
Figure 10. The structure of PDDF (CB3717) and its analogues 
PDDF (CB3717) (Figure 10) is the first quinazoline-based antifolate analogue that 
was first investigated in the 1980s.
79, 80
 It is a potent TS inhibitor in vitro and shows 
broad-spectrum activity in patients with breast, liver, and cisplatin-refractory ovarian 
cancers in phase I studies. Unfortunately, unpredictable severe life-threatening renal- and 
hepatotoxicity observed in further clinical studies, which resulted in discontinuation of 
further clinical trial. The poor solubility, attributed to the presence of a 2-amino group in 
17 
 
PDDF, probably caused the drug to precipitate in the acidic pH of the renal tubules, 
thereby resulting in renal toxicity.
79 
The metabolism of PDDF is typical of the classical 
antifolates: it is transported via RFC and polyglutamylated by FPGS inside the cell. 
  Structural alterations to the 2-substitutent in pyrimidine A ring (Figure 10) with a 
2- methyl  substituent (8) or simply a proton (9) did not cause the drug to lose its TS 
inhibitory activity.  
 
Figure 11. The structure of Raltitrexed (ZD1694) 
Raltitrexed (RTX) (Figure 11) is a water-soluble analogue of PDDF and it does 
not cause renal toxicity due to its improved water solubility at low pH.
83 
Like most 
classical antifolates, it is transported into cells by RFC and undergoes rapid 
polyglutamylation by FPGS. Although the activity of raltitrexed is 20-fold less than CB 
3717, it is a good substrate for FPGS and once polyglutamylated, it is 60-fold more 
potent than the monoglutamylated form. The retention of polyglutamylated raltitrexed 
within cells is significantly prolonged compared to its monoglutamate form.
80
 
RTX was approved as first-line therapy for advanced colorectal cancer in several 
European countries, Australia, Canada, and Japan. Currently, much attention is focused 
on combination of raltitrexed with some other approved anticancer agents, such as 
topoisomerase I inhibitor irinotecan.
84, 85 
In a phase I study, the combination of raltitrexed 
with irinotecan was well tolerated.
85
 In phase II studies, raltitrexed combined with 
18 
 
oxaliplatin for the treatment of patients with previously untreated metastatic colorectal 
carcinoma.
86
 This combination showed a 47% response rate with a median overall 
survival of >14.5 months.  
 
Figure 12. The structure of 10 (ZD9331) 
Compound 10 (Figure 12) was rationally designed as TS inhibitor based on the X-
ray crystal structure of E. coli TS enzyme ternary complexes of CB 3717 and its 
tetraglutamate derivative.
87, 88
 Unlike RTX, 10 does not require polyglutamylation by 
FPGS for activation and therefore retains cytotoxic activity in tumors expressing low 
levels of FPGS. Preclinical studies have shown 10 have a broad spectrum of antitumor 
activity in human cancer cell lines and tumor xenografts. In phase I studies, the dose-
limiting toxicities were myelosuppression, nausea, vomiting, skin rash, and diarrhea.
89, 90 
In phase II trials, 10 has shown promising activity as second- and third-line therapy in 
patients with ovarian and colorectal cancer.
91, 92 
This agent is currently under 
investigation in other solid tumors, including non-small-cell lung, gastric, and pancreas 
cancer both as a single agent and in combination with other cytotoxic agents.  
19 
 
 
Figure 13. The structure of 11 and 12 
Webber and coworkers
93 
designed another series of 5-ary1thio quinazolinone 
analogues 11 and 12 (Figure 13) based on crystallographic analysis of protein-ligand 
structures. The binding site of the glutamic acid side-chain was from the 5-position 
instead of the 6-position. Moreover, a thio-bridge was utilized between the quinazoline 
and the benzoylglutamate side-chain. Molecular modeling indicated that this 
transposition from the 6- to the 5-position of the side chain resulted in a void at the C6 
position, originally occupied by the methylene moiety of PDDF, which interacts with 
Trp80 (hTS). Both 11 and 12 were excellent inhibitors of human recombinant TS (Ki = 13 
nM and 0.124 nM respectively).
93
 The cytotoxicity of the 2-amino derivative 11 was 
comparable to that of CB3717, whereas the 2-methyl version 12 was significantly less 
active than raltitrexed. The differences may be due to changes in active transport and/or 
polyglutamylation.  
3.2.3. 6-5 Ring Fused Bicyclic Classical Analogues 
 
Figure 14. The structures of DDATHF and pemetrexed 
20 
 
 In 1985, Taylor et al.
94
 reported a novel “tight-binding” inhibitor, (6R)-5,10-
dideazatetrahydrofolic acid LMX (Figure 14), of GARFTase with potent antitumor 
activity in a number of murine and human xenograft solid tumors. Taylor et al.
95
 reported 
PMX, the B-ring contracted analogue of DDATHF, as a moderate inhibitor of mouse 
recombinant TS (Ki = 0.34 μM), but a potent cytotoxic agent with IC50 values of 22 nM 
and 16 nM against the growth of L1210 and CCRF-CEM cells in culture respectively.  
PMX is a 6-5 fused pyrrolo[2,3-d]pyrimidine instead of the more common 6-6 fused 
pteridine or quinazoline ring structure. Preliminary studies
96 
revealed that pemetrexed 
polyglutamates are multi-targeted antifolate (MTA): it is not only potent inhibitors of TS 
but also of DHFR and GARFTase and AICARFTase. PMX has been approved for the 
treatment of malignant pleural mesothelioma in combination with cisplatin in the United 
States and has provided a renewed interest in classical antifolates as antitumor agents. 
Like raltitrexed, it utilizes the RFC to gain entry into cells and requires polyglutamylation 
for maximal inhibitory effects on the various target enzymes. It has shown activity in 
vitro against colon, renal, liver, and lung cancers.
97
 
  
Figure 15. The structures of 13-17 
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   Taylor et al.
98
 further reported 13 in which the B-ring of PMX is replaced with a 
pyrazole (Figure 15) that abolished the cytotoxic activity of the drug. The replacement of 
B-ring of PMX with a thiophene ring resulted the design of 14 and 15. Preliminary 
biological evaluation revealed that both 14 and 15 were inactive as inhibitors of the 
growth of tumor cells in culture.
99 
 
  The position of attachment of the side chain to the heterocycle is important for TS 
inhibitory activity. After moving the side chain of PMX from the 5- position to the 6- 
position, the resulting compound 16 (Figure 15) lost its TS activity completely. 
Interestingly, 17, the 5,6-dihydro derivative of 16, did show potent GARFT inhibitory 
activity.
100, 101
 
 
Figure 16. The structure of 18 
Gangjee et al.
102 
reported 18 (Figure 16), as a structural analogue of pemetrexed, 
in which a methyl group was introduced in the C6 position of pyrrolo[2,3-d]pyrimidine 
moiety and the bridge -CH2-CH2- was replaced with -S- moiety. This compound was an 
potent inhibitor of human TS (IC50 = 42 nM) and L. casei TS (IC50 = 21 nM). Further, it 
was more potent than PDDF in its inhibition of the growth of human CCRF-CEM cells 
in culture (EC50 = 450 nM). The addition of a methyl group at the 6-position rendered the 
drug a non-substrate for FPGS.  
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3.2.4. Tricyclic Classical Analogues 
 
Figure 17. The structures of 19-22 
Tricylic analogues of 5,10-methylene-tetrahydrofolate 19-22 were reported,
103, 104
 
but none showed potent inhibitory activities against TS. 
 
Figure 18. The structure of BW1843 (OSI-7904) 
In 1993, Pendergast et al.
105 
reported BW1843 in a series of benzo-quinazolines 
analogues. BW 1843 is an extremely potent noncompetitive inhibitor of TS (Ki = 0.09 
nM). Although it is a good substrate for FPGS, the main cellular metabolite is the 
diglutamate rather than tri- or penta glutamate seen with most other antifolates. It has 
potent activity against human cancer cells in culture with IC50 values less than 1.0 nM.
106
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Figure 19. The structure of 23 
In 2002, Bavetsias et al
107
 reported analogue 23 (Figure 19) as tricyclic tetrazole 
analogue of a potent TS inhibitor with Ki of 0.2 nM and IC50 of 0.44 μM against L1210 
TS. 
3.2.5. Nonclassical TS Inhibitors 
Classical compounds depend on folate transporter systems for their transportation 
into the cell. The impairment of the RFC can lead to drug resistance. Additionally, some 
classical antifolates depend on FPGS for polyglumatamylation, in part, for potent 
antitumor activity. The impairment of FPGS can also lead to drug resistance. Lipophilic 
nonclassical inhibitors of TS have been developed to overcome the problems mentioned 
above. Thus compounds that are not subject to metabolic activation through 
polyglutamylation need to have high intrinsic potency against TS as well as tumor cells. 
24 
 
 
 Figure 20. The structure of 24-27 
Compounds 24 and 25 (Figure 20) were designed specifically on the basis of the 
crystal structure of ecTS as a surrogate for hTS. They enter cells via passive diffusion and 
are not dependent on the RFC or other specific transport systems to cross the cell 
membrane. Compound 24 was found to cause severe liver toxicity in phase I testing and 
further evaluation was subsequently terminated.
108, 109
 Compound 25 shows good 
inhibitory activities in both E.coli (Ki = 490 nM) as well as human TS inhibition (Ki = 15 
nM). Compound 25 is well tolerated in the initial phase I, II and III studies, and shows 
promising activity against head and neck, pancreatic, and hepatocellular cancer. A phase 
II trial in patients with squamous cell cancer of the head and neck shows complete 
responses in 2 and partial responses in 2 of 22 patients to give an overall response rate of 
18%.
110
 A large phase III randomized trial of 25 is currently ongoing in North America 
where patients with unresectable hepatocellular carcinoma are randomized to receive 
either nolatrexed or doxorubicin (the control arm). Replacing the 2-amino group of 25 
with a methyl group (26 in Figure 20) decreased the TS inhibitory activity.
111
 Removal of 
25 
 
the 6-methyl group of 25 afforded 27 (Figure 20), which has a 10-20 fold decrease in 
human TS inhibition. 
 
Figure 21. The structures of 28-31 
Gangjee et al.
102 
reported 28 (Figure 21) as a structural analogue of  25. This 
analogue was a potent inhibitor of human TS (IC50 = 340 nM), but a weak inhibitor of E. 
coli TS and S. faecium TS. As an extension of this work, Gangjee et al.
112
 reported a 
serials of nonclassical analogues 29-31, which also show potent inhibition of human TS. 
4. Dihydrofolate Reductase (DHFR) 
4.1 Enzyme description and Catalytic Mechanism 
DHFR functions as a catalyst for the reduction of FH2 to FH4 by using 
nicotinamide adenine dinucleotide phosphate (NADPH) as the cofactor.
113 
The inhibition 
of DHFR leads to partial depletion of intracellular reduced folates with subsequent 
limitation of cell growth.
19
  
DHFRs are relatively small, water-soluble, monomeric enzymes and possess 159-
189 amino acid residues with a molecular weight of 18-22 kDa.
114
 The sequence of the 
bacterial DHFR is about 30 amino acid residues shorter than that of the vertebrate 
enzymes. The first crystal structure of a DHFR enzyme was reported by Matthews and 
coworkers in 1977.
115
 Since then, X-ray crystal structures and solution NMR structures 
have been reported for complexes of the protein from various species (bacteria, avian and 
26 
 
mammalian). These 3D-structures of DHFR are used in structure-based drug design and 
to acquire information on inhibitor binding, enzyme-inhibitor-cofactor complexes and in 
particular to determine differences in amino acid location between parasite and host 
DHFR.  
   DHFR structures from bacterial forms and higher organisms were established by 
X-ray diffraction analysis and NMR spectroscopy. Early in 2004, the RCSB protein data 
bank (PDB) contained 115 structures of DHFR from Escherichia coli (ec), Lactobacillus 
casei (lc), Pneumocystis carinii (pc), Mycobacterium tuberculosis, Thermotoga maritime, 
Candida albicans, and Haloferax volcanii, human DHFR, and the chicken liver (cl) 
enzyme. The homology among vertebrate DHFR is 75-90% while in bacterial DHFR it is 
only 25-40%. Homology is greatest at the N-terminal and least at the C-terminal.
55, 116
  
 
Figure 22. Proposed catalytic mechanism of DHFR 
The mechanism of DHFR is not totally understood, although it has been 
extensively studied.
117
 DHFR catalyzes a hydride transfer from NADPH to the C6 of 7,8-
FH2, and at a much slower rate to the C7 of folate to form tetrahydrofolate.
117-119
 It is 
known that initial protonation of N5 followed by a hydride transfer from the C4 of the 
cofactor NADPH to the adjacent FH2 C6, followed by the reduction of folate or FH2 is 
accompanied by the transfer of the hydrogen atom located in the 4-pro-R position of 
NADPH to the C7 of folate or C6 of FH2 (Figure 22).  
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4.2 Species-differences among DHFR 
The species-differences among the DHFR
120
 have been used to design discover 
compounds with particular selectivity. Three opportunistic pathogens that infect 
immunocompromised patients,  especially those with acquired immune deficiency 
syndrome (AIDS), are Pneumocystis jirovecii(P. jirovecii), Toxoplasma gondii (T. 
gondii), and Mycobacterium avium (M. avium). The most notable differences between 
these pathogen DHFR and human (h) DHFR are discussed below. 
The differences of the amino acid sequences among various DHFR in the active site 
has been exploited to design inhibitors that are selective for pathogen DHFR over human 
DHFR (that are lethal to pathogens but relatively harmless to mammals). 
4.2.1 Pneumocystis carinii (P. carinii) DHFR and Pneumocystis jirovecii (P. jirovecii) 
 P. carinii DHFR is a small molecule with molecular weight of 26000 Dalton. It 
consists of 206 amino acid residues and is similar to rat liver (rl) DHFR in size. The 
enzyme's optimum pH was 7.0 and its Km for FH2 is four-fold higher (17.6 ± 3.9 μM) 
than rat liver DHFR (4.0 ± 2.2μM). 
The size of the cavity of P. carinii DHFR active site is smaller than that of human  
DHFR (L1210) but larger than that of bacterial (E. coli) DHFR. X-ray crystal structure
121 
have shown that most residues of DHFR involved in catalysis and binding are conserved 
in both human DHFR and P. carinii DHFR, while the polar Asn64 residue in human 
DHFR, located just outside the binding site, and is replaced by nonpolar Phe69 in P. 
carinii DHFR.  
TMP (Figure 6) lacks the glutamic acid side-chain, which is the characteristic 
feature of the nonclassical antifolate. TMP possesses higher selectivity of binding to 
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bacterial DHFR (IC50 = 7 nM for E. coli) than human DHFR (IC50 = 490000 nM) and is 
used for the treatment and prophylaxis of uncomplicated urinary tract infections and 
upper respiratory infections caused by pathogens such as Proteus mirabilis, Escherichia 
coli, and Klebsiella species;
4, 113, 122, 123
 It is also a first line drug for the treatment of P. 
carinii pneumonia (PCP) in combination with sulfamethoxazole,
124
 which blocks the 
conversion of PABA to FH2 through the inhibition of dihydropteroate synthase. The more 
potent P. carinii DHFR inhibitors like PTX (IC50 = 19.3 nM) and TMQ (IC50 = 42 nM) 
lack selectivity (Figure 6).
124-126
  
Recent study showed that P. jirovecii is the real opportunistic pathogen that 
infects human, while P. carinii is the pathogen that is derived from and infects rats.
68
 
According to Cody et al
69
, the recombinant human-derived pneumocystis DHFR (P. 
jirovecii DHFR) differs from rat-derived P. carinii DHFR by 38% in amino acid 
sequences. 
4.2.2 Toxoplasma gondii (T. gondii) DHFR 
 T. gondii is a DHFR-TS bifunctional enzyme with the DHFR domain located at 
the N-terminus and the TS domain is at the C-terminus.
127
 A junction polypeptide 
separates the two domains. The protozoan parasite T. gondii is a ubiquitous organism 
capable of infecting a wide range of vertebrate hosts, including man. Toxoplasmosis is a 
leading opportunistic pathogen associated with AIDS.
128, 129
 Although the crystal 
structures of T. gondii DHFR are not yet available, the primary structure of the DHFR-TS 
gene from T. gondii has been reported by Roos.
130
 
The Km for T. gondii DHFR (IC50 = 4.6 ± 4.3 μM) is similar as that for rat liver 
DHFR (IC50 = 20 μM). Several DHFR inhibitors such as TMQ (IC50 = 10 nM), PTX 
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(IC50 = 4.3 nM) and TMP (IC50 = 2.8 M) (Figure 6) are active against isolated T. gondii 
enzyme and against the growth of T. gondii cells in culture.
129 
4.3 Representative DHFR Inhibitors 
Some of the representative DHFR inhibitors have been reviewed and broadly divided into 
the following categories:  
1. 6-5 Ring Fused Bicyclic Classical Analogues 
2. Tricyclic Classical Analogues 
3. Nonclassical DHFR Inhibitors 
4.3.1. 6-5 Ring Fused Bicyclic Classical Analogues 
 
Figure 23. Pyrrolo [2,3-d]pyrimidine analogues 32 and 33 
Gangjee et al.
151, 152
 reported the pyrrolo[2,3-d]pyrimidine analogues of MTX  (32 
and 33 in Figure 23). Both compounds inhibited the growth of CCRF-CEM human 
leukemia cell lines and showed potent inhibitory activities against P. carinii DHFR with 
IC50 = 38 nM and 44 nM 
respectively
30 
 
 
Figure 24. Pyrrolo [2,3-d]pyrimidine analogues 34-41 
Homologation of the methylene group of 32 and 33 in “bridge region” afforded 34 
and 35 (Figure 24).
153
 Both compounds are sub-micromolar inhibitors of human DHFR 
(IC50 = 0.99 and 0.21 μM respectively). The reduced analogues 36 and 37 are 5-fold more 
potent than their 5,6-unsaturated counterparts (IC50 = 0.20 and 0.049 M).
153
 
The NH in the bridge region of 32 was replaced by a methylene group to afford 
compound 38, which along with its 5,6-dihydro reduced analogue 39 (Figure 30) were 
potent cytotoxic agents in CCRF-CEM culture cell line (IC50 = 1 ng/mL and 8 ng/mL 
respectively).
154-156 
 
Structural modifications of 34 and 36 afforded 40 and 41 (Figure 24).
157 
Both 
compounds inhibited the growth of human epidermal carcinoma KB cells with IC50 
values of 0.27 ng/mL and 0.49 ng/mL, which were 18- and 10-fold lower than that of 
MTX (5.0 ng/mL) respectively. 
 
Figure 25. Pyrrolo[2,3-d]pyrimidine analogue 42  
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As mentioned before, the 2,4-diaminopyrimidine structure is essential for potent 
DHFR inhibitory activity. However, the 4-methyl analogue of 42 (Figure 25) was found 
to be a potent dual TS-DHFR inhibitor.
158
 This observation led to the postulation that 42 
might bind to DHFR in a flipped model so that the pyrrole NH take the place of the 4-
amino group of a regular DHFR inhibitor would have been (Figure 25). 
This hypothesis was later confirmed by X-ray crystal structure of 42 (Figure 25) with 
P. carinii DHFR. Compound 42 binds to P. carinii DHFR in the proposed “2,4-diamino 
mode". On the basis of molecular modeling, the 4- methyl group can increase 
hydrophobic interaction with Phe31 and Leu22 of human DHFR. Analog 42 inhibited the 
growth of CCRF-CEM and FaDu cells in culture with EC50 values of 12.5 nM and 7.0 
nM respectively. Metabolite protection studies indicated that 42 targets both TS and 
DHFR and that FPGS was essential for its activity.
158
 
 
Figure 26. The structures of 43-51 
Gangjee et al.
159
 reported the isosteric replacement of the pyrrole NH in 32, 33 and 
38 with an oxygen to afford classical furo[2,3-d]pyrimidine DHFR inhibitors 43-46 
32 
 
(Figure 26). Compounds 43 and 44 were moderate to good inhibitors of rh DHFR, ec 
DHFR and tg DHFR. The N-methyl analogue 44 was twice as potent as 43. Compound 
45 was much less potent than parent 38. Addition of a methylene group in the bridge 
region of 43 afforded 46 (Figure 26).
160
 This modification abolished the DHFR inhibitory 
activity. 
Taylor et al.
99 
reported the isosteric replacement of the pyrrole NH in 38 with a sulfur 
atom, and the resulting classical thieno[2,3-d]pyrimidine 47 (Figure 26) was inactive 
against tumor cell line growth in culture. Isosteric replacement of the pyrrole NH in 38 
with a carbon atom, and the resulting classical dihydrocyclopenta[d]pyrimidine 
antifolates 48-51 (Figure 26) had bovine liver DHFR inhibitory activities comparable to 
that of MTX. Moreover, variation of the bridge region did not significantly affect the 
activities.
161, 162
 
4.3.4. Tricyclic Classical Analogues 
Table 2. Tricyclic classical analogues 
Compound and Structure Activity Ref. 
 
IC50 =  1.5 μM against 
lcDHFR Bovine DHFR and 
 
 
163 
33 
 
 
IC50 = 39 nM in Human 
leukemia cells  
(MTX:12 nM) 
 
164 
 
Ki = 17 nM against L1210 
DHFR 
(MTX: 4.5 nM) 
165 
4.3.5. Nonclassical DHFR Inhibitors 
Some non-classical DHFR inhibitors show high potencies, which indicate that the 
p-aminobenzoylglutamic acid side chain is not essential for binding to DHFR. The 
discovery of TMQ and pyrimethamine as potential antibacterial and antimalarial agents 
has stimulated the research for new nonclassical antifolates. These agents can be used in 
anti-infective therapy since bacteria and protozoa synthesize folic acid de novo but do not 
utilize preformed folate. Moreover, these analogues are hydrophobic and do not utilize 
the folate active transport systems (such as FR or RFC). They are taken up by passive 
and/or facilitated diffusion and are not substrates for FPGS. Thus they overcome 
resistance encountered with classical inhibitors like PTX, which are associated with a 
defect in transport or FPGS activity. The main drawback of these new potent antifolates 
34 
 
is their lack of selectivity against DHFR derived from pathogens. Unfortunately, almost 
all the recently developed inhibitors follow this trend. 
 
Figure 27. The structures of Pyrimethamine, Methoprin and DAMP 
Pyrimethamine (Figure 27) is a potent selective inhibitor of plasmodia DHFR 
used in the treatment and prophylaxis of malarial.
166-168
 Two small structural changes to 
the pyrimethamine: changing the 6-ethyl group to a methyl group and introducing an 
additional chlorine substitution on the phenyl ring, led to Methoprin (Figure 27),
166 
which 
is a potent vertebrate DHFR inhibitor and was clinically used to treat MTX resistant 
tumors along with the structurally related DAMP (Figure27)
169, 170
 
 
Figure 28. The structures of MZPES and Methylbenzoprim 
   Modifications of pyrimethamine in the 5-phenyl ring resulted in MZPES (Figure 
28), which has completed Phase I clinical trial as an antitumor agent.
171
 Methylbenzoprim 
is one of the tightest binding nonclassical DHFR inhibitor (Ki = 9 pM against rat liver 
DHFR) known to date.
172
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Figure 29. The structures of TMQ and 55-57 
Trimetrexate (TMQ) (Figure 29) is a potent inhibitor of human DHFR, displaying 
better antitumor activity than MTX.
173, 174
 It is also a potent inhibitor of P. carinii DHFR 
but is devoid of selectivity. TMQ (Neutrexin) has been approved for the treatment of P. 
carinii pneumonia. Replacing the nitrogen in the bridge region of TMQ with a carbon 
afford  55
175
 (Figure 29), which is a potent ec DHFR inhibitor. Harris et a.l
175 
reported the 
conformationally restrict analogues 56 and 57. Compound 56 with the Z-configuration 
(cis) had better activity against ec DHFR than the E-isomer 57. 
 
Figure 30. Tetrahydroquinazoline analogues 58-60 
Gangjee et al.
176
 reported a series of 6-substituted tetrahydroquinazolines 
analogues of TMQ. Compounds 58-60 (Figure 30) were nanomolar inhibitors of T. gondii 
DHFR with 5-11 fold selectivity ratios as compared to rl DHFR. 
36 
 
 
Figure 31. The structure of PTX and 61 and 62 
Piritrexim (PTX) is a potent inhibitor of P. carinii DHFR (IC50 = 31 nM)  but is 
devoid of selectivity. It is now used as a second-line therapy in the clinic for moderate to 
severe PCP.
177 
The 5-methyl group of PTX was important for high potency.
178
 The 
removal of the 5-methyl group and/or the 2‟5‟-dimethoxy substituent both resulted in the 
decrease of activity. 
Gangjee et al.
179
 reported 61 and 62 which replaced the methylene bridge of PTX 
with CH2NCH3 (Figure 31). Compound 61 shows extremely potent inhibitory activity 
against T. gondii DHFR (IC50 = 0.58 nM) whereas 62 had excellent antitumor activity. 
A large number of 6-5 bicyclic non-classical DHFR inhibitors including 2,4-
diaminothieno[2,3-d]pyrimidines, 2,4-diaminopyrrolo[2,3-d] pyrimidines, and 2,4-
diaminofuro[2,3-d]pyrimidines and purines have been reported in the literature. 
 
Figure 32. Pyrrolo and thieno[2,3-d]pyrimidine analogues 63-66  
Rosowsky et al.
180
 reported a series of thieno analogs with a carbon atom bridge as 
bioisosteres of pyrido[2,3-d]pyrimidines (63 and 64) (Figure 32) as inhibitors of P. 
37 
 
carinii DHFR, T. gondii DHFR, and rat liver DHFR. Analogue 63 is the most potent in 
this series (IC50 = 0.07M against T. gondii DHFR) and 64 is the most selective for T. 
gondii DHFR (rl/tg = 81). 
Gangjee et al.
181
 also reported a series of pyrrolo[2,3-d]pyrimidine analogues with 
different thiols substitution on the 6-postion. Compounds 65 and 66 (Figure 32) are 
potent inhibitors of DHFR from opportunistic pathogens. It was found that disubstitution 
on the phenyl ring of the side chain was better for inhibiting T. gondii DHFR both in 
terms of potency and selectivity than the monosubstituted or unsubstituted phenyl 
analogues.
181
 
 
Figure 33. Furo[2,3-d]pyrimidine analogues 67-69 
Gangjee et al.
182, 183
 reported 2,4-diaminofuro[2,3-d]pyrimidines 67 and 68 
(Figure 33) as potential DHFR inhibitors with good selectivity for both pcDHFR and 
tgDHFR compared to rat liver DHFR. Different analogues with variations in the bridge 
region indicate that a -CH2-NH- or -CH2-S- bridge connecting the lipophilic side chain 
were conducive for inhibiting P. carinii DHFR both for potency and selectivity. 
Analogue 67 is a potent inhibitor of P. carinii (IC50 = 0.65M). In addition, compounds 
containing bicyclic moieties in the side chains were found to be conducive for P. carinii 
DHFR inhibition over analogues containing monocyclic or tricyclic moieties. 
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Dauzonne et al.
184
 reported furo[2,3-d]pyrimidines 69 (Figure 33), in which the 
lipophilic side chains are attached directly at the 5-position, as inhibitors of DHFR from 
opportunistic pathogens. However, none of the analogs were found to have activity 
against P. carinii DHFR or T.gondii DHFR. Comparing their structures with 67 and 68 
suggests that a direct phenyl substitution at 5-position decreased potency and selectivity 
for T. gondii DHFR. 
 
Figure 34. Tricyclic thieno and furo[2,3-d]pyrimidines 70-73 and74-78 
Rosowsky et al.
180
 reported tricyclic thieno[2,3-d]pyrimidines 70-73 (Figure 34) 
as inhibitors of P. carinii DHFR, T. gondii DHFR and rat liver DHFR. Although these 
analogues displayed potency in the micromolar range, they were non-selective. Gangjee 
et al.
185
 also reported a series of moderately active tricyclic furo[2,3-d]pyrimidine DHFR 
inhibitors 74-78 (Figure 34).  
 
Figure 35. Tricyclic DHFR inhibitors 79-82 
 
A series of 7,8-dialkyl-l,3-diaminopyrrolo[3,2-f]quinazolines 79 and 80 (Figure 
35)
 
were reported by Kuyper et al.
186
 as potential inhibitors of P. carinii DHFR, T. 
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Gondii
 
DHFR and C. albicans DHFR. Compound 79 had a Ki of 0.0071 nM for C. 
albicans DHFR, while compound 80 had a Ki of 0.9 nM against T. gondii DHFR and an 
IC50 of 14 nM against P. carinii DHFR. Although they were extremely potent, they 
lacked selectivity for P. carinii DHFR or T.gondii DHFR. Gangjee et al.
187 
reported a 
novel tricyclic pyrimido[4,5c][2,7] naphthyridone 81 (Figure 35) and the corresponding 
naphthyridines 82 as conformationally restricted inhibitors of DHFR. Although they 
displayed potency in the micromolar range, none of these were selective for P. carinii 
DHFR or T.gondii DHFR. 
5. FOLYL POLY--GLUTAMATE SYNTHETASE (FPGS)  
FPGS is an ATP-dependent enzyme and has both cytosolic and mitochondrial 
forms. It catalyzes the addition of several equivalents of glutamic acid to the γ-carboxyl 
group of folate cofactors and classical antifolates containing the γ-carboxyl group, which 
leads to high intracellular concentration, utilizing ATP and magnesium.
20, 25, 188
 In cases 
of RTX and PMX, the inhibitory activity of the polyglutamylated form are 
 
60-fold 130-
fold more potent than their monoglutamate forms respectively.
191-194
 FPGS has three 
functions in folate homeostasis via polyglutamation: (1) The polyglutamic acid chain is 
hydrophilic and anionic which prevents the efflux of folates and antifolates from the cell; 
(2) maintains high intracellular concentrations in most cases and increases its affinity for 
TS; (3) allows the accumulation of folates in the mitochondria that are required for 
glycine synthesis.
188
 
Tumor cells develop resistance to antifolates that depend on polyglutamylation for 
activation either for retention within tumor cells or to increase inhibitory activity against 
the target folate-dependent enzyme(s), both of which contribute to the antitumor activity 
40 
 
of the analogue.
30, 195-199
 Resistance to the antifolates can be manifested by reduction at 
the level of FPGS activity. Moreover, long retention of polyglutamate forms of 
antifolates within normal cells may cause toxicity, thus limiting the usefulness of such 
antifolates.
72, 196, 200, 202
 
 
Figure 36. Mechanism of polyglutamylation by FPGS 
The proposed catalytic mechanism of FPGS is shown in Figure 36. The 
mechanism involves the binding of the folate or antifolate to the protein followed by 
activation by Mg-ATP, and subsequent attachment of L-glutamate (Figure 36). FPGS 
catalyzes the formation of 84 as a result of an attack by the -COOH of folate or 
antifolates 83 by activation by Mg-ATP.
203-205
 Followed by the nucleophilic nitrogen of 
the L-glutamate 85 attacking the carbonyl group of 84, resulting in a tetrahedral 
intermediate 86 which collapses to form 87 and inorganic phosphate. 
205-207 
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6.Glycinamide-ribonucleotide Formyltransferase (GARFTase) 
6.1 Enzyme description and Catalytic Mechanism 
Glycinamide-ribonucleotide formyltransferase (GARFTase) is a folate-dependent 
enzyme in the de novo purine biosynthetic pathway. It catalyzes the formyl transfer 
reaction that converts GAR to fGAR in the purine biosynthesis pathway, utilizing N
10
-
formyl FH4 as the cofactor. Since purines are crucial components of DNA and RNA, 
inhibition of enzymes in the de novo biosynthesis of purine has been considered an 
effective approach for cancer chemotherapy. 
 
Figure 37. Proposed mechanism of GARFTase 
The catalytic mechanism of GARFTase has been reported by Shim and co-
workers (Figure 37).
208
 Nucleophilic attack by the amino group of GAR upon the formyl 
carbon of N
10
-formyl FH4 leads to the formation of the tetrahedral intermediate 88, which 
converts to fGAR and FH4, with the cleavage of the formyl carbon-N
10
 bond. 
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6.2 The structure of GARFTase 
Human GARFTase is located at the C-terminus of a trifunctional enzyme  human 
GART (HsGART) encoded by purD-purM-purN with a molecular weight of 108 kD 
(1010 amino acids).
209
 The trifunctional polypeptide encodes GAR synthase (GARS, 
PurD, E.C. 6.3.4.13) and aminoimidazole ribonucleotide synthetase (AIRS, PurM, E.C. 
6.3.3.1) activities, in addition to GARFTase activity.
209
  
The E. coli GARFTase structure was considered surrogate for its eukaryotic 
counterpart in the past, because E. coli and human GARFTase share a 38% sequence 
identity. However, recent kinetic and structural studies revealed a number of important 
differences between the human and E. coli enzymes.
210, 211
 The human GARFTase 
domain of the trifunctional enzyme is readily available through cloning and 
overexpression.
210,  212
 In 2005, Smith and coworkers
211
 reported the three-dimensional 
structure of the GARTase domain from the human trifunctional enzyme which is useful 
for chemotherapeutic drug design. The structures of human GARFTase in complex with 
various ligands including β-GAR,210 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-
tetrahydrofolic acid (10-CF3CO-DDACTHF)
213
, and a series of folate inhibitors
214
 at 
different pH have also been reported.   
Welin et al.
209 
recently reported the structures of two functional domains of HsGART: 
GARS and AIRS. Together with the previously reported the structures of the GARTfase 
domain of HsGART,
210, 212
  a complete structural characterization of the individual 
functional units of HsGART was achieved, which allows for a structural understanding of 
substrate specificity and catalytic mechanism, as well as for structure-based drug design. 
Although the construction of full-length HsGART via crystalization of the enzyme in its 
43 
 
intact trifunctional form was not successful, Welin and coworkers
 209 
revealed the overall 
architecture of the trifunctional protein at low-resolution by combining small angle X-ray 
scattering (SAXS) data with the high-resolution crystal structures.  
6.3 Representative GARFTase Inhibitors 
 
Figure 38. The structure of DDATHF 
The discovery of 5,10-dideazatetrahydrofolic acid (DDATHF) (Figure 38), the 
first potent and selective GAFRTase inhibitor and antitumor agent validated GARFTase 
as an anti-cancer drug target. DDATHF exhibits potent, broad-spectrum activity in vivo 
against solid murine and human tumors. As the first GARFTase inhibitor to be brought to 
clinical evaluation, lometrexol, the 6R diastereomer of DDATHF, exhibited promising 
preclinical activity in vivo against solid murine and human tumors. However, its clinical 
development was limited by serious cumulative toxicity, 
213 
which was attributed to 
accumulation of polyglutamate metabolites in normal tissues. 
 
Figure 39. The structure of 89 
Compound 89 was reported by Taylor and coworkers
214
 as an analogue of 
lometrexol. The addition of one methylene unit in the tetrahydropyridine ring of 
lometrexol provided additional conformational mobility in the bicyclic system. 
44 
 
Compound 89 had a Ki of 147 nM against murine trifunctional GARFTase and an IC50 of 
47 nM in vitro cell growth inhibition assay.  
 
Figure 40. The structure of 90 
A novel GARFTase inhibitor 90 (Figure 40) was designed based on the crystal 
structure of rh GARFTase.
 
Compound 90 shows potent inhibitory activity against 
recombinant human GARFTase (Ki = 16 nM). Moreover, in CCRF-CEM cell line, 
compound 90 (IC50 = 16 nM) shows 10-fold increase in potency than lometrexol. It was 
found that FPGS polyglutamylation of 90 caused its higher potency.
215
 
 
Figure 41. The structure of 91 and 92 
To further explore the role of side chain polyglutamation for activity, Demartino and 
coworkers
216
 reported α- and γ-carboxamides 91 and 92 (Scheme 41) as analogues of 90. 
Compound 91 was a potent and selective inhibitor of rhGARFTase (Ki = 56 nM) and 
active in cellular assays (IC50 = 300 nM), which indicated that incorporating the γ-
carboxylic acid as a carboxamide had little effect on the enzyme inhibitory activity. 
45 
 
Moreover, the high potency of 91 suggested that selectivity and efficacy of GARFTase 
do not rely on FPGS polyglutamation. However, compound 92 was much less potent with 
Ki value 4.8 µM and inactive in cellular assays, which indicated that α-carboxylic acid 
was crucial for enzyme binding.  
 
Figure 42. The structure of 93 
    The replacement of  the γ-carboxylic acid in 90 with a tetrazole afforded 93 (Figure 
42),
217
 which is a potent rhGARFTase inhibitor (rh GARFTase Ki = 130 nM) and is 
active in vitro (IC50 = 40 nM, CCRF-CEM). Although Compound 93 was 4-fold less 
potent against rhGARFTase and 2.5-fold less potent in cellular assays compared with 90, 
the activity of 93 does not relied on FPGS polyglutamation and thus allowed its selection 
as a candidate for in vivo examination.  
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II. CHEMICAL REVIEW 
Isosteric replacement of the pyrrolo ring with a thieno ring provides an increase in 
ring size that more closely approximates the pteridine, 6-6 fused ring system of the 
natural folates cofactors. Thus, a series of thieno[2,3-d]pyrimidine derivatives have been 
designed and synthesized. 
The chemistry related to the present work is reviewed and includes synthetic 
approaches to the following systems. 
A. Synthesis of thieno[2,3-d]pyrimidines 
B. Synthesis of thieno[3,2-d]pyrimidines 
C. Seyferth-Gilbert homologation and Bestmann‟s reagent 
D. Cross coupling reactions 
A. Thieno[2,3-d]pyrimidines  
Scheme 1. Retro-synthetic analysis of thieno[2,3-d]pyrimidines 
 
 
 
 The synthetic strategy for the construction of thieno[2,3-d]pyrimidines includes 
two categories (Scheme 1):  
1. From thiophene precursors (Route A) 
2. From pyrimidine precursors (Route B) 
47 
 
1. From thiophene precursors (Route A) 
Scheme 2. Synthesis of thiophene 103 and 104 
 
 The general method (Route A) involves the use of 2-amino thiophenes 103 and 104  
(Scheme 2) has proven to be very fruitful and allowed synthetic entries into several 
thieno pyrimidine analogues with varying substitution patterns. The synthesis of 
derivatives via this general route is discussed below (Scheme 3-16). Reaction of ketones 
or aldehydes 99 with ethyl cyanoactate 101 or malononitrile 102 and sulfur 100 in the 
presence of base (triethylamine or morpholine) under the general procedure of Gewald 
and coworkers
218
 gave the expected 2-amino thiophenes 103 or 104. 
1.1 Condensation to obtain 2-amino-5,6-disubstituted thieno[2,3-d]pyrimidines 
Scheme 3. Synthesis of thieno[2,3-d]pyrimidine 109 
 
2-Amino-5,6-disubstituted thieno[2,3-d]pyrimidines 109 (Scheme 3) were reported to 
be synthesized via cyclocondenation of appropriate thiophenes 105-107 with an amidine 
derivative 108,
219,  220 
which can be guanidine (R = NH2) or chloroformamidine 
48 
 
hydrochloride (R = Cl). The nature of the X substitution in thiophene 105-107 determines 
the substitution pattern at 4-position (Y at the C4-position ) in 109; when X = CN, COOR 
or CHO, the cycliation reaction affords 109 with Y = NH2, OH or H respectively. 
Scheme 4. Synthesis of thieno[2,3-d]pyrimidine 114 
 
Zhang and coworkers
220 
successfully utilized this strategy to synthesize 2-amino-
4,5,6-trisubstituted thieno[2,3-d]pyrimidines 114 (Scheme 4). Thiophene intermediate 
112 was synthesized from ketone 110, sulfur and 111 via the Gewald reaction.
218
 The 
target 2-amino-5,6-disubstituted thieno[2,3-d]pyrimidines 114 were obtained via the 
condensation of 112 with guanidine (R = NH2) or chloroformamidine hydrochloride (R = 
Cl). 
Scheme 5. Synthesis of thieno[2,3-d]pyrimidine 117 
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In 1980, a novel synthesis of 2-amino-4-phenyl substituted thieno[2,3-d]-
pyrimidines 117 was reported by Ishikawa and coworkers.
221
 Urea 116 was utilized for 
condensation with aminocarbonyl thiophenes 115 to afford 117.  
1.2 Condensation to obtain 2-methyl-5,6-disubstituted thieno[2,3-d]pyrimidines  
Scheme 6. Synthesis of thieno[2,3-d]pyrimidine 120 
 
A novel facile method was reported by Dave and coworkers.
222
 Substituted 
nitriles 119 as cyclization reagents reacted with 2-amino-4-carboxylate thiophenes 118 in 
the presence of HCl to afford thieno[2,3-d]pyrimidines 120 (Scheme 6). Different 
substitutions can be introduced in the 2-postion depending on the substitution groups of 
the carbonitrile in 119. For example, when acetonitrile was used in the reaction, 2-
methyl-5,6-disubstituted thieno[2,3-d]pyrimidines was obtained. When the carboxylate 
substitution R of 118 is a good leaving group such as OR or NH2, the cylication product 
has an OH group at the 4-position. 
Scheme 7. Synthesis of thieno[2,3-d]pyrimidine 123 
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    A novel approach for the synthesis of 2-substituted thieno[2,3-d]pyrimidines was 
reported by Cruceyra and coworkers.
223
 The 2-substituted-4-oxo- thieno[2,3-
d]pyrimidines 123 (Scheme 7) were synthesized by the condensation of thiophene 121 
and aldehyde 122. The R group of 122 can be an alkyl or aromatic substitution. 2-
Methyl-5,6-disubstituted thieno[2,3-d]pyrimidines 123 were obtained when the R group 
is a methyl group.  
Scheme 8. Synthesis of thieno[2,3-d]pyrimidine 127 
 
A modified approach was reported by Corral and coworkers
224
 for the synthsis of 
thieno[2,3-d]pyrimidine in 1978, using acid chlorides as the cyclization reagent instead of 
an aldehyde (Scheme 8). The amino group of the thiophene 124 attacked the carbonyl 
group of acid chloride 125 to form the intermediate amide 126, which cyclized with NH3 
to afford thieno[2,3-d]pyrimidines 127. Good leaving groups, such as OCH3, at R3 
position in 124 resulted in OH substitutions at the X position in 127. When acetyl 
choloride was used as the reactant, 2-methyl-5,6-disubstituted thieno[2,3-d]pyrimidines 
127 was obtained after cycliation. 
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Scheme 9. Synthesis of thieno[2,3-d]pyrimidine 131 
 
 
  Konno and coworkers
225
 reported the synthesis of 131, 2-methyl-4-oxo-6-
phenylthieno[2,3-d]pyrimidine, via the condensation of thiophene 128 with acetic 
anhydride 129, followed by cyclization with NH3 (Scheme 9). 
1.3 Condensation to obtain 2-unsubstituted-5,6-bisubstituted thieno[2,3-
d]pyrimidines  
Scheme 10. Synthesis of thieno[2,3-d]pyrimidine 134 
 
  
Hesse and coworkers
226 
reported the synthesis of thieno[2,3-d]pyrimidine 134. 
The reaction of thiophene 132 and formic acid gave 133, which cyclized with formamide 
to afford 134 (Scheme 10). Compound 134 was also obtained via the reaction of 
thiophene 4-carbonitrile 135 and formic acid in the presence of a catalytic amount of 
H2SO4 under microwave irradiation condition (Scheme 10). 
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Scheme 11. Synthesis of thieno[2,3-d]pyrimidine 134 
 
 
 
Recently, Horiuchi and coworkers
227 
reported the one-pot synthesis of 134. 
Thiophene 138 reacted with formamide afforded 134 in good yield (Scheme 11).  
1.4 Condensation to obtain other 2-substituted thieno[2,3-d]pyrimidines  
Scheme 12. Synthesis of thieno[2,3-d]pyrimidine 142 
 
Cyclocondensation of 140 with various substituted aldehydes provided 
thieno[2,3-d]pyrimidines 142 with different substitutions at 2-position (Scheme 12). 
Depending on the nature of 141, the R groups in 142 can be an alkyl or an aryl group.  
Scheme 13. Synthesis of thieno[2,3-d]pyrimidine 146 
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An acid chloride 144 was used instead of an aldehyde as the cyclization reagent in 
the cyclocondensation with 143 to  afford various 2-substitued thieno[2,3-d] pyrimidines 
146 (Scheme 13).  
Scheme 14. Synthesis of thieno[2,3-d]pyrimidine 149 
 
In 1998, Briel and coworkers
228
 reported the synthesis of 2-phenyl substituted 
thieno[2,3-d]pyrimidine 149 via the condensation of thiophene 147 with benzamidine 
hydrochloride 
148 (Scheme 14). 
Scheme 15. Synthesis of thieno[2,3-d]pyrimidine 155 
 
 
 
 
Scheme 15 shows the synthesis of 2-benzyl-4-oxo-6-substituted thieno[2,3-
d]pyrimidine 155, employing the same method as shown in scheme 6.
 222
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Scheme 16. Synthesis of thieno[2,3-d]pyrimidine 158 
 
 
 
Changing the thiophene 4-carboylate 153 to the thiophene 4-carbonitrile 156 and 
condensation with trichloro-acetonitrile 157 affords 2-trichloromethyl-4-aminio 
thieno[2,3-d]pyrimidine 158 (Scheme 16).
222 
 
2. From pyrimidine precursors (Route B) 
Scheme 17. Synthesis of thieno[2,3-d]pyrimidine 162 
 
 
 
Taylor and coworkers
229
 reported the synthesis of the classical TS inhibitor 162 as 
an analogue of pemetrexed. Condensation of 2-substituted-4-hydroxy-6-
mercaptopyrimidine 159 with the α-chloroketone gave pyrimidine sulfide 161, which 
cyclized to give 162, in the presence of p-toluenesulfonic acid. 
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Scheme 18. Synthesis of thieno[2,3-d]pyrimidine 166 
 
 
 
A novel approach for the synthesis of thieno[2,3-d]pyrimidine 166 was reported 
by  Sakamoto and coworkers
230
 in 1986 (Scheme 18). The intermediate 165 was 
synthesized by Sonogashira coupling between iodopyrimidines 163 and ethynyl-
trimethyl-silane 164. Compound 165 then cyclized to give 166 in the presence of NaSH. 
Scheme 19. Synthesis of thieno[2,3-d]pyrimidine 170 
 
 
In 1988, a novel approach for the synthesis of the thieno[2,3-d]pyrimidine 170 
via a cyclization reaction of 5-carbonitrile-6-mercaptopyrimidnes 167 and chloroacetone 
168 (Scheme 19) was reported by Ried and coworkers.231 Compound 169 was the key 
intermediate in the reaction, which was further cyclized in the presence of NaSH to 
give 17 
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Scheme 20. Synthesis of thieno[2,3-d]pyrimidine 173 
 
Similarly, El-Dean and coworkers
232
 utilized chloro-acetonitrile 172, instead of 
chloro-acetone 168, with 171 to afford 5-amino-4-methyl-2-phenyl-thieno[2,3-
d]pyrimidine-6-carbonitrile 173 (Scheme 20).  
Scheme 21. Synthesis of thieno[2,3-d]pyrimidine 176 
 
As shown in Scheme 21, Briel and coworkers
233
 reported a modified strategy to 
synthesize 176. 5-Ethylester-6-mercaptopyrimidnes 174 cyclized with chloroacetic acid 
methyl ester 175 to afforded the thieno[2,3-d]pyrimidine 176 with a 5-hydoxy group 
instead of a 5-amino (Scheme 21).  
Scheme 22. Synthesis of thieno[2,3-d]pyrimidine 180  
 
Based on the cyclization reaction shown in Scheme 19, a modified method was 
developed by Ried and coworkers (Scheme 22).
234
 5-Carbonitrile-6-chloropyrimidine 
177 reacted with ethyl 2-mercaptoacetate 178 to form intermediate 179, which was 
further cyclized to afford 180. 
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Scheme 23. Synthesis of thieno[2,3-d]pyrimidine 188 
 
  
Similarly, Van Straten and coworkers
235
 reported the synthesis of 188 (Scheme 
22). Condensation of 181 with aldehyde 182 and ethyl cyanoacetate 183 in the presence 
of K2CO3 gave pyrimidone 184, which was then treated with POCl3 followed by base-
mediated nucleophilic substitution and cyclization to afford 188 (Scheme 23).  
 Scheme 24. Synthesis of thieno[2,3-d]pyrimidine 196 
   
Van Straten and coworkers
235 
also reported the synthesis of 196 by the procedure 
depicted in Scheme 24. α, β-Unsaturated ketones, obtained by aldol condensations, 
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reacted with 2-cyanothioacetamide 192 to afford thiopyridones 193, which underwent 
nucleophilic substitution and cyclization to afford 196 (Scheme 24).  
B. Thieno[3,2-d]pyrimidines 
Scheme 25. Retro-synthetic analysis of thieno[3,2-d]pyrimidines 
 
 
 
The synthetic strategy for the construction of thieno[3,2-d]pyrimidines includes 
two categories (Scheme 25):  
1. From thiophene precursors (Route A) 
2. From pyrimidine precursors (Route B) 
1. From thiophene precursors (Route A)  
Scheme 26. General routes for the synthesis of thieno[3,2-d]pyrimidines from key 
thiophene intermediate 202 
  
59 
 
Route A: 3-amino-2-carboxyl-5,6-disubstituted thiophenes 202 (Scheme26) are 
the key intermediates for the synthesis of thieno[3,2-d]pyrimidines 203 with varying 
substitution patterns. 
Scheme 27. Synthesis of key thiophene intermediate 207 
 
 
 
Migianu and Kirsch
236
 reported the synthesis of 207 from -methylene ketones 
204 by the procedure depicted in Scheme 27. -Methylene ketones 204 were converted 
to β-chloroacroleins 205 via Vilsmeier-Haack-Arnold reaction. β-Chloroacrylonitriles 
206 were prepared via the reaction of 205 and  hydroxylamine and subsequent  
dehydration in acetic anhydride. Condensation of 206 with methyl or ethyl thioglycolate 
in base gave the key intermediate 207 (Scheme 27).  
Scheme 28. Synthesis of key thiophene intermediate 210  
 
Recently, a similar method was reported by Thomae and coworkers.
237 β-Chloro-
acrylonitriles 208 was synthesized by a previously described method (Scheme 27). 
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Condensation of 208 with Na2S and β-chloroacrylonitrile afforded the key intermediate 
210 (Scheme 28).  
Scheme 29. Synthesis of key thiophene intermediate 215 
 
A novel approach to synthesize thiophenes 215 was reported by Ried and 
coworkers.
238 
The starting material 211 was reduced to 212, which was treated with tosyl 
chloride to afford 213. The tosyl group was displaced by methyl thioglycolate in 
methanol to give a mixture of 214 and 215 (Scheme 29). Cyclization of 215 simiar to 207 
afforded thieno[3,2-d]pyrimidines.  
Scheme 30. Synthesis of thieno[3,2-d]pyrimidine 220 
  
Ren and coworkers
239
 introduced an improved synthesis of 220 (Scheme 30).  The 
in situ generated sodium mercaptoacetonitrile reacted with 216 to give thiophene 218, 
which in turn reacted with guanidine carbonate to afford 220. It is a general approach to  
convert o-aminonitriles to 2,4-diaminopyrimidines via the cyclization with guanidine.  
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Scheme 31. Synthesis of thieno[3,2-d]pyrimidine 224 
 
Peng and coworkers
240
 reported the synthesis of 224.  Cyclization of formamide 
and 223, synthesized according to a literature procedure
241
, afforded thieno[3,2-
d]pyrimidine 224 (Scheme 31). 
Scheme 32. Synthesis of thieno[3,2-d]pyrimidine 229 
 
  
 
Artyomov and coworkers
242
 used N-cyanochloroacetamidine 226 to synthesize 
fused pyrimidines.  Regioselective alkylation of thiolate 225 at the S-atom afforded 
intermediate 227, which then underwent a Thorpe cyclization to give aminothiophene 
228. Compouond 228 under acid catalysis condition was converted to diaminopyrimidine 
229 (Scheme 32). 
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2. From pyrimidine precursors (Route B) 
Scheme 33. Synthesis of pyrimidothieno[3,2-d]pyrimidine 234   
 N-cyanochloroacetamidine 231 was also used in the synthesis of a variety of 
substituted pyrimidines.
242
 As shown in Scheme 33, 231 reacted with 230 to form 232, 
which was cyclized to give the bicyclic thienopyrimidine 233 and then further cyclized to 
tricyclic pyrimidothienopyrimidine 234 (Scheme 33). 
C. Seyferth-Gilbert homologation and Bestmann’s reagent 
Scheme 34.  Corey-Fuchs reacton and Seyferth-Gilbert reaction 
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Terminal alkynes are extremely useful in organic transformations including 
Sonogashira couplings,
243 
Favorskii reaction,
244 
azide alkyne Huisgen cycloaddition to 
give triazoles.
245 
The Corey-Fuchs reaction
246
 and Seyferth-Gilbert reaction
247, 248
 have 
been employed in the conversion of aldehydes or ketones to alkynes that have one 
additional carbon than the starting material. However, the Corey-Fuchs reaction requires 
strong base for dehydrohalogenation of the intermediate 237 (Scheme 34) at low 
temperature, which limits its use. Seyferth-Gilbert reaction of a ketone or aldehyde with 
dimethyl (diazomethyl)phosphonate 239 in base affords alkynes (Scheme 34) in one step. 
Reagent 239 is often called the Seyferth-Gilbert reagent. It should be prepared freshly 
and isolated just prior to metalation. 
Scheme 35.  Bestmann-Ohira modification 
 
Recently, Bestmann
249
 and Ohira
250
 reported a modification to the Seyferth-
Gilbert reaction. They utilized dimethyl 1-diazo-2-oxopropylphosphonate 242, which is 
also called the Bestmann-Ohira reagent, instead of 239. Under this mild reaction 
condition, reagent 242 in situ generated the anion of  239 by acyl cleavage and the 
aldehyde is converted to alkyne without the use of strong base. 
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Scheme 36. proposed mechanism for Seyferth-Gilbert reaction  
 
Under base condition, the methoxy group attacks the carbonyl of the Bestmann-
Ohira reagent 244 to form intermediate 245, which cleaves to form methyl acetate and 
246. Anion 246 then reacts with aldehyde through a mechanism similar to the Witting 
reaction to form oxaphosphatane 248. Elimination of the phosphate anion gave the vinyl 
diazo-intermediate 249 and 250. Elimination of nitrogen gas afforded the vinyl carbene 
251, which on rearrangement forms the desired alkyne 252 (Scheme 36).
251
 
Scheme 37. Preparation of the Bestmann-Ohira reagent  
  
Tosyl azide 254 is the most frequently used reagent for diazo transfer. Callant and 
coworkers
252
 reported the synthesis of 255 via tosyl azide (Scheme 37). However, tosyl 
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azide was found to be most hazardous, of highest sensitivity and largest heat of 
decomposition.
253 
Recently, p-acetamidobenzenesulfonyl azide (p-ABSA) 255 (Scheme 
37) has been used for the preparation of the diazo compounds.
254 
It is cheap, safe and ease 
of removal of the byproduct p-acetamidobenzenesulfonamide 258 through filtration. p-
ABSA 257 reacted with 253 to afforded the Bestmann-Ohira Reagent in good yield. 
Scheme 38. Proposed mechanism for the Bestmann-Ohira reagent preparation 
 
 
 
The proposed mechanism for Bestmann-Ohira reagent preparation reaction is 
listed in Scheme 38. The base picks up a proton from 253 to form an enolate 257, which 
attacks the azide 254. With the leaving of the sulfonyl amide 256, the desired Bestmann-
Ohira reagent is obtained. 
Roth and coworkers,
255 
and Meffre and coworkers
256 
reported an improved one-
pot reaction, which uses the in situ generation of the Bestmann-Ohira reagent for the 
reaction with the aldehyde. 
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Scheme 39. Improved one-pot reaction  
 
 
Commercially available 253 and tosyl azide or p-ABSA are mixed in a suspension 
of K2CO3 in CH3CN. After stirring for 2 h, the aldehyde, dissolved in methanol, was 
added to the above solution to afford the desired alkynes (Scheme 39).
255 
Meffre and 
coworkers applied this one-pot reaction to the compounds with stereogenic centers 261 
without loss of optical purity in the resulting alkynes 262 (Scheme 39).
256
  
D. Cross coupling 
Metal-catalyzed cross coupling reactions have been widely used in reactions involving C-
C, C-H, C-N, C-S and C-P bonds formation.
257-259
 Various metal-catalyzed cross 
coupling reactions have been developed including Sonogashira coupling, Buchwald-
Hartwig coupling, Suzuki coupling, Stille coupling, Ullmann coupling and others. 
Among the transition metals, palladium and copper are frequently used metal for organic 
synthesis. 
1. Ullmann coupling 
2. Sonogashira coupling 
3. Buchwald type coupling 
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1. Ullmann coupling 
Scheme 40. A general model for the Ullmann coupling 
 
Ullmann coupling is a coupling reaction between aryl halides with copper 
(Scheme 40). The Ullmann coupling involves the formation of a C-O, C-N and C-S 
bond by the reaction between the aryl halide and phenol, aniline or thiophenol.
260
 The 
Ullmann coupling requires harsh reacation conditions, including high temperature (> 
200
 o
C), strong bases, long reaction times. Cu (I) salts have been typically used as the 
metal source in Ullmann coupling.
260
 The bases used for this reaction can be K2CO3, 
Cs2CO3, NaOtBu.  
Scheme 41. Ullmann coupling 
 
 
In 2003, Wu
261
 and Miljanic
262
 reported the formation of the C-S bond via 
Ullmann coupling (Scheme 41) at lower temperature (80-110
 o
C) with high yield. 
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Scheme 42. Ullmann coupling 
 
Recently, Sperotto and coworkers
263
 reported a ligand free condition in Ullmann 
coupling (Scheme 42). Aryl iodides 267 reacted with aryl thiols using DMF or NMP as 
solvent, CuI (1.2 eq) and K2CO3 (1.3 eq) to afford 269 in high yield. 
Scheme 43. Microwave assisted Ullmann coupling 
 
            Microwave assisted organic synthesis has been widely used in organic synthesis, 
resulting in faster and cleaner reactions. In 2002, Cherng and coworkers
264
 reported 
microwave assisted Ullmann coupling (Scheme 43). Substituted aryl bromides and 
iodides 267 reacted with aryl thiols in the presence of CuI, K2CO3 and NMP under 
microwave irradiation at 195 
o
C to afford 269 in 67-89% yield. 
2. Sonogashira cross-coupling 
Scheme 44. A general model for Sonogashira coupling 
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In 1975, Sonogashira et al.
265 
reported palladium catalyzed terminal alkynes in 
coupling reactions with aryl iodides or vinyl bromides (Scheme 44). The process of 
coupling involves oxidative addition, transmetallation and reductive elimination. Two 
catalysts, palladium (0) complex and copper (I) halide salt are required for this reaction, 
such as Pd(PPh3)4, Pd2(dba)3, Pd(OAc)2. Base is necessary in this coupling reaction to 
neutralize the byproduct of this reaction. Base such as K2CO3, NEt3, Cs2CO3 are 
generally used. The reactivity order aryl and vinyl halides is I ≈ OTf > Br >> Cl.266 
Scheme 45. Example of Sonogashira coupling. 
 
In 2007, Gangjee and coworkers
267
 reported the Sonogashira coupling of 273 with 
phenyl acetylene in the presence of Pd(PPh3)4 and CuI at room temperature over 12 h to 
afford 275 (Scheme 45).  
Scheme 46. Example of Sonogashira coupling 
 
In a similar trend, compound 278 was reported by Gangjee and coworkers
268
 and 
synthesized via a Sonogashira coupling of 276 with substituted aryl iodides (Scheme 46). 
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Scheme 47. Microwave assisted Sonogashira coupling 
 
In 2002, Eedelyi and coworkers
269
 reported microwave assisted Sonogashira 
couplings between aryl iodides, bromides and chlorides with TMSA (trimethyl silyl 
alkyne). The reaction was carried out in the presence of DMF, DIEA, PdCl2(PPh3)2 and 
CuI under microwave irradiation at 120 
o
C for 5 min (Scheme 47). 
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III. STATEMENT OF THE PROBLEM 
1. Synthesis of nonclassical analogues 5-methyl-6-substituted arylthio-thieno[2,3-
d]pyrimidine-2,4-diamines 2-13 as DHFR inhibitors. 
Figure 43. Structures of antifolates 
Folate metabolism has long been recognized as an attractive target for cancer 
chemotherapy due to its indispensable role in the biosynthesis of nucleic acid precursors. 
Within folate metabolism, the synthesis of 2‟-deoxythymidine-5‟-monophosphate 
72 
 
(dTMP) from 2‟-deoxyuridine-5‟-monophosphate (dUMP) is catalyzed by thymidylate 
synthase (TS). During this reductive methylation process, 5,10-methylenetetrahydrofolate 
is converted to dihydrofolate (DHF), which in turn is reduced to tetrahydrofolate (THF) 
via the enzyme DHFR. DHFR carries out the first step in the regeneration of 5,10-
methylenetetrahydrofolate (5,10-MTHF) utilizing NADPH as the reductant. Thus, TS and 
DHFR are crucial for the synthesis of dTMP in DNA biosynthesis and cell proliferation. 
Inhibition of either enzyme leads to “thymineless death”. Because of this, both TS and 
DHFR represent attractive targets for developing antitumor agents, antibacterial, 
antifungal and antiopportunistic infection agents.
1-5
 
Several TS and DHFR inhibitors, as separate entities, have found clinical utility as 
antitumor agents. Figure 43 illustrates important examples of clinically used TS inhibitors 
such as raltitrexed and pemetrexed. Similarly, the DHFR inhibitor methotrexate (MTX) 
(Figure 43) has been used clinically for more than 50 years. Several TS and DHFR 
inhibitors which are analogues of folate have also shown antitumor activities in vitro and 
in vivo with some currently in clinical trials. 
It has been observed, both in clinically available agents as well as in experimental 
agents, that TS inhibitors and DHFR inhibitors when used separately or in combination 
with other agents can provide successful antitumor therapy. In addition, synergism of two 
separate antifolates which inhibit TS and DHFR has been demonstrated in growth 
inhibitory studies against Lactobacillus casei, rat hepatoma cells, and human lymphoma 
cells. Thus it is of interesting to design a single agent with dual TS and DHFR inhibitory 
activity. Such dual inhibitors could act at two different sites (TS and DHFR) and might 
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be capable of providing “combination therapy” in a single agent without the 
pharmacokinetic disadvantages of two separate agents.
270
 
As part of a continuing effort to develop novel classical antifolates as antitumor 
agents, Gangjee et al.
271
 reported the synthesis of N-{4-[(2,4-diamino-5-methyl-7H-
pyrrolo[2,3-d]-pyrimidin-6-yl)sulfanyl]benzoyl}-L-glutamic acid (281; Figure 43) as a 
potent dual inhibitor of DHFR and TS with IC50 values in the 10
-7
 M range in its 
monoglutamate form, thus providing dual inhibition of human TS and human DHFR. 
Molecular modeling using SYBYL 7.0 indicated that 281 binds to human DHFR in the 
normal 2,4-diamino mode with the 5-methyl group interacting with Val115, while it 
could also bind to human TS in the flipped mode with the 5-methyl group forming 
hydrophobic interaction with Try109. Compound 281 also demonstrated potent inhibitory 
activity against the growth of several human tumor cell lines in the National Cancer 
Institute (NCI) preclinical in vitro screen, with GI50 values of 10
-7
 to 10
-8
 M or lower. The 
DHFR inhibitory potency and tumor cell inhibitory activities of 281 were in part 
attributed to its C5-methyl group. Thus 281 is a promising lead compound which can be 
further structurally modified to optimize human TS, DHFR and tumor cells inhibitory 
activities.  
 
Figure 44. Superimposition of a 6-5 thieno[2,3-d]pyrimidine ring system (red) on to a 6-
5 pyrrolo[2,3-d]pyrimidine ring system (gray) 
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In the course of structure-based drug design,  the thieno[2,3-d]pyrimidine 
scaffold, which could be considered an isostere of the pyrrolo[2,3-d]pyrimidine system, 
was investigated to develop potential dual TS and DHFR inhibitors. Molecular modeling 
(Figure 44) using MOE indicated that the C5-methyl of thieno[2,3-d]pyrimidine (red) 
could mimic the C5-methyl of pyrrolo[2,3-d]pyrimidine (gray) in which the 5-methyl 
group was reported to have a conducive hydrophobic interaction with Val115 in human 
DHFR binding pocket. Thus, compound 284 (Figure 43) was designed as an isostere of 
281 to determine the importance of the pyrrole 7-NH in 281 for binding to human TS and 
DHFR. The replacement of the NH of a pyrrolo[2,3-d]pyrimidine with a S to afford the 
thieno[2,3-d]pyrimidine was also anticipated to evaluate the importance of a hydrogen 
bond donor (NH) versus a hydrogen bond acceptor (S). In addition the larger size of the 
sulfur atom compared to the nitrogen allows the thieno[2,3-d]pyrimidines to more closely 
mimic the size of the 6-6 pteridine system of folates such as 5-methyl-5-deaza 
methotrexate or 5-methyl-5-deaza aminopterin, in which the 5-methyl group was reported 
previously to have a hydrophobic interaction with human DHFR.
283 
In addition to the 
classical analogue 284, it was also of interest to synthesize nonclassical analogues 285-
295 (Figure 43) with the thieno[2,3-d]pyrimidine scaffold as potential antitumor agents. 
An additional aspect of our interest in nonclassical dual TS-DHFR inhibitors lies in the 
treatment of opportunistic infections in immunocompromised patients such as those with 
acquired immunodeficiency syndrome (AIDS).
272
 The principal cause of death in patients 
with AIDS is opportunistic infections caused by Pneumocystis jirovecii (P. jirovecii)
273 
and Toxoplasma gondii (T. gondii).
274
 Mycobacterium avium (ma) Complex can also 
adversely influence the quality of life of AIDS patients. Trimethoprim (TMP) and 
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pyrimethamine, which are nonclassical, lipophilic DHFR inhibitors, are currently used to 
treat P. jirovecii and T. gondii infections. However, both are weak inhibitors of pj DHFR 
and tg DHFR and must be used with sulfonamides to provide a synergistic effect.
275 
Unfortunately, combination therapy produce severe side effects in several cases. Gangjee 
et al.
271
 have recently discovered the potent and selective DHFR inhibitory activity of a 
series of 2, 4-diamino-5-methyl-6-substituted pyrrolo[2,3-d]pyrimidines 282 and 283 in 
particular against tg DHFR. These are non-classical 6-5 bicyclic antifolates with 6-aryl 
substitutions. X-ray crystal structure,
276, 277 
multiple sequence alignment
278
 and molecular 
modeling (SYBYL 6.810) indicate that the 5-methyl group interacts with Ile123 in pc 
DHFR, Val151 in tg DHFR, and Ile102 in ma DHFR. The 5-methyl group in these 
compounds also influences the conformations of the 6- aryl side chain and could 
contribute to the potency of these compounds. Molecular modeling suggests that a 5-
methyl group of a 6-5 bicyclic antifolate has similar interaction and conformational 
effects as a 5-methyl in a 6-6 ring system antifolate.
276
 Substituted thieno[2,3-
d]pyrimidines 284-295 as sulfur isosteres of the lead pyrrolo[2,3-d]pyrimidines 282 and 
283 were designed. It should be noted that the thieno[2,3-d]pyrimidine scaffold has been 
examined previously for antibacterial and antimalarial activity.
279–283
 Several noncalssical 
thieno[2,3-d]pyrimidine analogues have also been evaluated as inhibitors of P. carinii 
DHFR and T. gondii DHFR.
280–283
 Some of these analogues have been found to be 
selective for DHFR from these pathogens.
281, 283
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2. 6,5,6-tricyclic Benzo[4,5]thieno[2,3-d]pyrimidines as Dual Thymidylate Synthase 
and Dihydrofolate Reductase Inhibitors  
 The TS reaction requires 5,10-methylenetetrahydrofolate (5,10-CH2THF) as a 
cofactor for one carbon unit transfer and represents the only de novo pathway for 
intracellular dTMP synthesis. DHFR catalyzes the reduction of dihydrofolate to 
tetrahydrofolate, and is indirectly responsible for dTMP synthesis by maintaining the 
reduced folate pool.
284
 
 Raltitrexed (RTX),
285
 pemetrexed (PMX)
286
 and methotrexate (MTX)
287
 (Figure 43) 
are examples of TS and/or DHFR inhibitors used in the clinic. RTX, approved in several 
European countries, Australia, Canada, and Japan for the treatment of advanced 
colorectal cancer. RTX is a TS inhibitor that undergoes rapid polyglutamylation by the 
enzyme folylpolyglutamate synthetase (FPGS).
288, 289
 PMX, in combination with 
cisplatin, was approved for the treatment of malignant pleural mesothelioma and also for 
non-small cell lung cancer. With TS inhibition as the primary mechanism of action, PMX 
was reported to inhibit several other folate-dependent enzymes including DHFR, 
glycinamide ribonucleotide formyltransferase (GARFTase), and aminoimidazole 
carboxamideribonucleotide formyltransferase (AICARFTase).
286
 Similar to RTX, 
polyglutamyltion by FPGS is essential for the cytotoxicity of PMX. 
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Figure 45.   Antifolates 
 Classical antifolates, such as RTX and PMX, that have a N-benzoyl-L-glutamic 
acid side chain usually function as substrates for FPGS, which leads to high intracellular 
concentrations of these antitumor agents and increases TS inhibitory activity for some 
antifolates (RTX, 60-fold and PMX 130-fold) compared to their monoglutamate 
forms.
290-293
 Although polyglutamylation of certain antifolates (such as RTX and PMX) is 
necessary for their cytotoxic activity, it has also been implicated in toxicity to host cells, 
because of the longer cellular retention time of such polyanionic poly-glutamate 
metabolites.
294
 In addition, reduced expression of FPGS in tumor cells can lead to 
resistance to FPGS dependent classical antifolates such as PMX.
295-297
 
 
To circumvent the potential tumor resistance problems associated with FPGS, 
classical antifolates should have high folate enzyme inhibitory potency as their 
monoglutamate forms and not require polyglutamylation by FPGS to exert their 
antitumor activity.
298, 299 
Typically, antifolates that contain a 2-methyl-4-oxo substitution 
in the pyrimidine ring (such as RTX) are TS inhibitors, while 2-amino-4-oxo substitution 
in the pyrimidine ring (such as PMX) may provide affinity for both TS and DHFR. 2,4-
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Diamino substitutions on the pyrimidine ring of antifolates is usually associated with 
DHFR inhibitory activity.     
 In an attempt to prevent or minimize the potential problems associated with 
FPGS, including tumor resistance, and to develop dual TS and DHFR inhibitors, Gangjee 
et al.
298 
reported the synthesis of a classical antifolate N-{4-[(2-amino-6-methyl-4-oxo-
4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)thio]benzoyl}-L-glutamic acid, 297 (Figure 
45), as a potent inhibitor of isolated human (h) TS (IC50 = 42 nM) with moderate 
inhibition against human recombinant DHFR (IC50 = 2.2 M) in its monoglutamate form 
thus providing dual inhibitory activity of TS and DHFR.  
 Compound 297 was equipotent with 296 (Figure 45), a potent TS inhibitor, 
against hTS and was more potent than the clinically used RTX and PMX against isolated 
hTS in their monoglutamate forms. Molecular modeling (SYBYL 6.91)
300
 suggested that 
the 6-methyl group in 297 makes important hydrophobic contacts with Trp109 in hTS 
and also serves to lock the 5-position side chain into favorable, low energy conformations 
(Figure 46). Both these factors probably contribute to the high inhibitory activity of 297 
in its monoglutamate form against hTS.  
 A potential advantage of compound 297 over RTX and PMX is that it is not a 
substrate for hFPGS, from CCRF-CEM cells, at concentrations up to 1045 M.298 The 
lack of hFPGS substrate activity of 297 was attributed, in part, to the presence of the 6-
methyl group on the pyrrolo[2,3-d]pyrimidine of 297. The 6-methyl group of 297 
probably creates steric hindrance in its binding to the active site of hFPGS. Alternatively, 
the 6-methyl group of 297 may force the 5-position side chain into a conformation that is 
not conducive for binding to hFPGS. The fact that PMX, a pyrrolo[2,3-d]pyrimidine, 
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much like 297, lacks a 6-methyl group and is a substrate for FPGS lends credence to the 
involvement of the 6-methyl moiety in preventing FPGS substrate activity in 297. 
 
 
Figure 46. Stereoview compound 297 superimposed on pemetrexed (not shown) in 
human TS (PDB1JU6395), indicating the interaction of the 6-CH3 with Trp109 
  
Tricyclic 296 (Figure 45) is a classical TS inhibitor with Ki = 0.09 nM.
298 
Although 
this compound is an excellent substrate for FPGS, it is subject to the addition of only one 
additional glutamic acid. Moreover, the high potency of 296 does not rely on 
polyglutamation. The monoglutamate form is equi-potent with the diglutamate form.
301
 
Compound 296 is a noncompetitive TS inhibitor and its activity is not affected by the 
concentration of 5,10-CH2THF.
302, 303
 In addition, it has been demonstrated that 
overexpression of the multidrug resistance proteins, MRP1 and MRP2, can confer tumor 
resistance to short term (4 h), but not long term (72 h), exposure of 296.
304
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Figure 47.   Target classical antifolates with the tricyclic benzo[4,5]thieno[2,3-
d]pyrimidine scaffold. 
In the course of our structure-based drug design program, it was of interest to 
synthesize classical antifolates 298-301 with a benzo[4,5]thieno[2,3-d]pyrimidine 
scaffold (Figure 47),  as structural hybrids of 296 and 297. Compounds 298 and 299, 
similar to 296, have a 2-methyl-4-oxo pyrimidine ring which is generally associated with 
TS inhibition. In contrast, 300 and 301 have a 2-amino-4-oxo substituent, which could 
afford dual TS and DHFR inhibition, as observed for 297 and PMX. 
    The 2-substitutions on 298-301 would access the importance of hydrogen-
bonding at this position (300, 301) versus hydrophobic binding (298, 299) to biological 
activity. The size of a sulfur atom in 298-301 is larger than a nitrogen atom and smaller 
than two carbon atoms, thus the thiophene B-ring in benzo[4,5]thieno[2,3-d]pyrimidines 
298-301 mimics both the smaller pyrrolo B-ring in 297 and the larger quinazoline B-ring 
in 298 (Figure 48). 
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Figure 48. Superimposition of benzo[4,5]thieno[2,3-d]pyrimidine (red), pyrolo[2,3-
d]pyrimidine (green) and benzo[f]quinazoline (cyan) 
 
 Similar to the C-ring in 296 and the 6-methyl group in 297, the benzo C-ring in 
398-301 makes hydrophobic contacts with Trp109 in hTS and restricts the side chain to a 
conformation conducive for potent TS activity but perhaps not for FPGS substrate 
activity.  
 To explore the effects of side chain flexibility on biological activity, compounds 
298 and 300 have the same benzoylglutamate side chain as 297, while 299 and 301 have 
a more conformationally restricted 2-isoindolinyl-L-glutamate side chain like 296. Unlike 
other classical TS inhibitors, the glutamate side chain in 296 is part of  an isoindolinone 
system, which restricts the side chain conformation. The crystal structure of the ternary 
complex TS-dUMP-296 (PDB: 1SYN) 
305
 revealed that the binding of 296 and the dUMP 
nucleotide induced a closed conformation of the TS protein, similar to other antifolates. 
Surprisingly, however, the binding surface of 296 includes a hydrophobic patch from Val 
77 that is normally buried and not on the surface.
305 
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Figure 49. Stereoview of compound 298 (blue) superimposed on 296 (purple) in ecTS 
(green). Figure prepared with MOE 2008.10
 300
 
 As shown in Figure 49, molecular modeling using MOE 2008.10
300
 revealed that 
when the central ring in 296 is truncated to a 5-member ring in the benzo[4,5]thieno[2,3-
d]pyrimidine 298, and the side chain substitution is moved from the 6-position to the 5-
position, the resulting compound binds to TS in a manner similar to 296. 
Molecular modeling suggested that although 2-methyl substituted compounds 298 
and 299 can not form a salt bridge with Glu30 of hDHFR at the N1 and 2NH2, like MTX, 
the 2-amino compounds 300 and 301 (Figure 47) can bind just like folate (PDB: 1U72) in 
which the 2-amino-4-oxo group binds to the enzyme with hydrogen bonding and the 
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heterocycle and the benzoyl moieties bind to Phe31, Phe34 and Ile 60. The -carboxylic 
acid of the glutamate makes ionic contact with Arg70. 
 
 
Figure 50. Proposed binding mode with DHFR. The “Normal mode” is defined as the 
binding mode of folic acid (a 2-amino-4-oxo pyrimidine system) to human DHFR. The 
“flipped” mode is defined as the binding mode when the molecule is rotated about the C2-
NH2 bond by 180
o
 
 According to molecular modeling, a second mode of binding would involve a 
180 rotation about the C-2, NH2 bond (Figure 50), whereby the sulfur of the thiophene 
ring is now superimposed on the 4-oxo group of folate, with all other interactions being 
preserved. It is important to note that binding of 300 and 301 in the flipped mode (Figure 
50) also allows the sulfur of the thiophene ring to mimic the 4-amino of MTX. To 
determine which of these two modes of binding the molecule adopts to bind hDHFR, 300 
and 301 were each cocrystalized with isolated hDHFR (Dr. Vivian Cody).     
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3. Classical and Nonclassical 2-Amino-4-oxo-5-arylthio-substituted-6-isopropyl 
thieno[2,3-d]pyrimidines as Dual Thymidylate Synthase and Dihydrofolate 
Reductase Inhibitors and Potential Agent for Toxoplasma gondii Infection  
The problem of resistance in tumors, due to low or defective FPGS, has placed 
limitations on the use of classical antifolates, which depend on polyglutamylation for 
their cytotoxicity. Classical antifolates also require carrier systems such as reduced folate 
carrier (RFC) to gain entry into the target cells. A decreased expression in folate 
transporter systems represents another mechanism for drug resistance.  
 
 
Figure 51. The structure of Nolatrexed 
Lipophilic nonclassical antifolates were designed to overcome the problem of 
tumor drug resistance associated with classical antifolates. These lipophilic nonclassical 
antifolates lack the polar glutamate side chain found in classical antifolates and hence do 
not depend on FPGS for their inhibitory activity of the target enzymes. Additionally, they 
also do not require the RFC system for active uptake into the cell since they are lipophilic 
and are passively transported into cells. Nolatrexed (Figure 51) is the first nonclassical 
TS inhibitor in clinical trials as an antitumor agents.
306, 307
 
Selective nonclassical dual TS and DHFR inhibitors have the potential to treat 
opportunistic infections in immunocompromised patients such as those with acquired 
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immunodeficiency syndrome (AIDS). The principal cause of death in patients with AIDS 
is opportunistic infections caused by Pneumocystis jirovecii (P. jiroveciii) and 
Toxoplasma gondii (T. gondii).
308-310
 Due to the limits of current therapies,
311-313
 it is of 
considerable interest to incorporate selectivity and potency into single nonclassical 
antifolates that can be used alone to treat these infections. 
 
 
 
Figure 52. The structure of thieno[2,3-d]pyrimidine antifolates 302-313 
 
Gangjee et al. 
314
 discovered the potent TS inhibitory activity of a series of 2-
amino-4-oxo-5-arylthio-substituted-6-ethylthieno[2,3-d]pyrimidine analogues. 
Compound 303 (Figure 52) is a potent dual inhibitor of human TS (IC50 = 54 nM) and 
human DHFR (IC50 = 19 nM).
 
Molecular modeling using (SYBYL 8.0)
300 
indicated that 
the 6-methyl group in 302 and the 6-ethyl group in 303 make important hydrophobic 
contacts with Trp109 in human TS and also sterically restrict the rotation of the 5-
position side chain so that it adopts a favorable conformation for binding to human TS.  
Gangjee et al.
314
 previously reported the crystal structure of 302 and 303 bound to 
natural and mutant human DHFR (PDB: 3GHW and 3GHC). In both crystal structures, 
thieno[2,3-d]pyrimidine inhibitors were shown to bind with DHFR in the “normal” folate 
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orientation. The crystal structures also indicated that the 6-substitutent interacted with a 
small hydrophobic pocket composed of Ile7, Thr56 and Val115. 
To determine the optimum size of the 6-alkyl group for TS and DHFR inhibitory 
activity, classical 6-isopropyl substituted thieno[2,3-d]pyrimidines 304 (Figure 52) and 
nonclassical  analogues 305-313 were also designed. The introduction of the bulky 
isopropyl substitution at 6-position was anticipated to further restrict the conformation of 
5-position substitution thus affect the biolocial activities of the compounds. In addition, 
the hydrophobic interaction between the 6-isopropyl substitution and Trp 109 may be 
further enhenced compared to methyl and ethyl groups.  
Gangjee et al. have previously shown that nonclassical analogues of 302 (Figure 
52) with electron withdrawing groups in the phenyl ring of the side chain also enhance 
human TS inhibitory activity. SAR studies indicated that analogues with electron 
withdrawing groups at the 3- and/or 4-positions of the phenyl side chain provide 
optimum inhibitory potency against human TS. Some nonclassical analogues with 
electron withdrawing substitutions on the phenyl ring demonstrated greater potency 
against human TS than the clinically used RTX and PMX. In contrast to the requirements 
for human TS inhibition, electron donating substituents such as methoxy, methyl, and 
bulky substituents such as naphthyl are conducive for DHFR inhibition; hence 
nonclassical analogues containing these substituents were also designed in the 2-amino-4-
oxo-5-arylthio-substituted-6-isopropyl thieno[2,3-d]pyrimidine series. 
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4. Classical and Nonclassical 2-Amino-4-oxo-5-arylthio-substituted-6-propyl 
thieno[2,3-d]pyrimidines as Dual Thymidylate Synthase and Dihydrofolate 
Reductase  Inhibitors and Potential Agent for Toxoplasma gondii Infection  
As introduced previously, Gangjee et al. 
314
 discovered the potent TS inhibitory 
activity of a series of 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-
d]pyrimidine analogues. The 6-methyl group in 302 makes important hydrophobic 
contacts with Trp109 in human TS and also sterically restrict the rotation of the 5-
position side chain so that it adopts a favorable conformation for binding to human TS.  
 
Figure 53. Stereoview: Docking structure of 304 (gray) in the X-ray crystal 
structure of 302 with double mutant human DHFR (PDB : 3GHC), generated by MOE 
2008.10
315
 
In the crystal structures, 302 was shown to bind with DHFR in the “normal” 
folate orientation. The crystal structures also indicated that the 6-substitutent interacted 
with a small hydrophobic pocket composed of Ile7, Thr56 and Val115 (Figure 53).  
As mentioned above, to determine the optimum size of the 6-alkyl group for TS 
and DHFR inhibitory activity, classical 6-isopropyl substituted thieno[2,3-d]pyrimidines 
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304 (Figure 52) and nonclassical analogues 305-313 were also synthesized and evaluated. 
However,  compound 304 showed poor DHFR inhibitory activity (fifty fold less potent 
than the methyl analog). 
 
Figure 54. Stereoview: docking structure of 304 (isopropyl) bound to human DHFR in 
“normal” mode (violet), in “flipped” mode (green) (PDB :3GHW), generated by MOE 
2008.10.
315
 
Molecular modeling revealed that compound 304 could not bind to human DHFR 
in the “normal” mode, because of the steric clash between the bulky 6-isopropyl group 
and the narrow hydrophobic pocket (Ile 7, Thr 56 and Val 115) (Figure 54). Instead, 
compound 304 adopts a “flipped” mode to bind with human DHFR compared to folic 
acid. Docking of 304 into the crystal structure of 302 (blue) in human DHFR (PDB : 
3GHW) shows the sulfur atom of the thieno ring to be close to the 4-oxo group of 302 
(Figure 53). In this binding mode, the Glu30 residue also interacts with the 2-NH2 and N1 
moieties of 304. The p-aminobenzoyl ring along with thieno[2,3-d]pyrimidine ring makes 
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hydrophobic interactions with Phe31, Phe34, and Ile60, and the -COOH forms an ionic 
bond with Arg70 just as compound 302 does with human DHFR in the “normal” binding 
mode. The flipped mode of 304 resulted in a 50-fold decrease in its activity compared 
with compounds (302, 303) having a straight chain substitution at 6-position. 
 
Figure 55. The structure of thieno[2,3-d]pyrimidine antifolates 314-323 
Thus it is proposed that a staight chain substition at 6-position is more favorable 
for DHFR inhibition. To further explore the optimal substitution at the 6-position, 
classical and nonclassical 6-n-propyl straight chain substituted thieno[2,3-d]pyrimidines 
314-323 (Figure 55) were designed.  
 
Figure 56. Stereoview: compound 314 bound to human DHFR in “normal” mode (PDB : 
3GHW), generated by MOE 2008.10.
315
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Molecular modeling also revealed that when the 6-substitution was a straight 
chain propyl group, the compounds retain the ability to bind the human DHFR in the 
“normal” binding mode and restore human DHFR inhibitory activity. In the “normal” 
binding mode (Figure 56), compound 314 binds just like folic acid (PDB : 1DRF), 302 
(PDB : 3GHW) and 303 (PDB : 3GHC). In this binding mode, the 2-NH2 and the N3 
moieties form hydrogen bonds with Glu30. The -carboxyl group of 314 interacts with 
Arg70 in an ionic bond and the thieno[2,3-d]pyrimidine and the phenyl ring make 
hydrophobic contacts with Phe31, Phe34, and Ile60 (Figure 56) in the binding pocket. 
The 6-propyl substitution contacts with Ile7 and Val115 in the hydrophobic pocket. 
As mentioned above, Gangjee et al. have previously shown that nonclassical 
analogues of 302 (Figure 52) with electron withdrawing groups in the phenyl ring of the 
side chain also enhance human TS inhibitory activity. SAR studies indicated that 
analogues with electron withdrawing groups at the 3- and/or 4-positions of the phenyl 
side chain provide optimum inhibitory potency against human TS. Certain analogues with 
electron withdrawing substitutions on the phenyl ring demonstrated greater potency 
against human TS than the clinically used RTX and PMX. In contrast to the requirements 
for human TS inhibition, electron donating substituents such as methoxy, methyl, and 
bulky substituents such as naphthyl are conducive for DHFR inhibition; hence 
nonclassical analogues containing these substituents were also synthesized in the 2-
amino-4-oxo-5-arylthio-substituted-6-propyl thieno[2,3-d]pyrimidine series. As indicated 
above for the classical analogue 314, it was anticipated that the nonclassical analogues 
315-323 would also provide dual inhibitory activity against human TS and human DHFR. 
91 
 
5. A novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of 
purine biosynthesis with selectivity for high affinity folate receptors over reduced 
folate carrier for cellular entry 
          The biological importance of reduced folates derives from their essential roles in 
one-carbon transfer leading to thymidylate, purine nucleotides, serine, and methionine, 
and in biological methylation reactions from S-adenosylmethionine.
316
 Antifolates, 
typified by MTX, PMX and RTX (Figure 43) are structurally similar to folic acid and 
typically bind to folate-dependent enzymes to inhibit folate-dependent pathways.
317
 MTX 
continues to be an integral component of the chemotherapeutic arsenal for several cancers 
including pediatric acute lymphoblastic leukemia, osteogenic sarcoma, lymphoma, and 
breast cancer.
317 
RTX is used throughout much of the world cxcept USA for advanced 
colorectal cancer.
318
 PMX was approved in 2004 for pleural mesothelioma in the US,
319
 
and subsequently, as a second line treatment for non-small cell lung cancer.
320 
MTX is a potent inhibitor of dihydrofolate reductase (DHFR), whereas PMX and 
RTX derive their primary cytotoxic effects by inhibiting thymidylate synthase (TS). 
Lometrexol (LMX) (Figure 43) was introduced in 1985
321
 as a targeted antipurine 
antifolate. The notion of selectively targeting de novo purine nucleotide biosynthesis has 
roots in early studies of azaserine
322
 or thiopurines
323
 and is based on the assumption that 
depletion of purine nucleotide pools can limit nucleotides for DNA synthesis and repair, 
while also impacting ATP and GTP stores important for cellular energetics.
324
 This effect 
could be even more acute in several cancer cells that lack enzymes involved in purine 
salvage.
325
 Although there have been reports that antipurine antifolates such as LMX 
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were cytostatic rather than cytotoxic,
326
 in other reports, antipurine antifolates were 
distinctly cytotoxic.
327, 328
   
While PMX, RTX, LMX and MTX the aforementioned antifolates are often 
considered to possess limited selectivity for tumor cells over normal proliferative tissues 
such as bone marrow and gastrointestinal mucosa, interest in the development of 
antifolates remains particularly high for agents that target high affinity folate receptors 
(FRs).
329
 This reflects the restricted patterns of tissue expression for FRs, including the 
vast majority of ovarian and endometrial cancers for FRα and myeloid leukemias for 
FRβ.330 There are other factors that account for tumor selectivity of FR-targeted 
therapies, including the apical localization for FRα in normal epithelia such as renal 
tubules or choroid plexus where it is inaccessible to the circulation, and synthesis of non-
functional FRβ in normal hematopoietic cells.331   
Ample literature documents applications of FRs for tumor targeting with folic 
acid as the targeting agent. For instance, cytotoxins (e.g., mitomycin C), liposome-
encapsulated drugs (e.g., doxorubicin), or radionuclides have been conjugated to folic 
acid for targeting FR-expressing tumors.
332-334
 There are at least two potential 
complications of this approach. These include: (i) instability in plasma versus that within 
tumor cells such that the folate conjugate may be prematurely cleaved and release the 
cytotoxic agent prior to reaching the tumor resulting in toxicity to normal cells, thus 
precluding selectivity; and (ii) the possibility that free folic acid released upon cleavage 
within the tumor could provide a growth-sustaining nutrient detrimental to tumor 
inhibition. Another approach involves a targeting ligand which itself is cytotoxic. 
Unfortunately, most folate-based therapeutics such as classical antifolates (including 
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RTX, PMX, and LMX) that are substrates for FRs are also substrates for the ubiquitously 
expressed reduced folate carrier (RFC) such that there is no tumor selectivity with these 
agents.
335
 Indeed, the discontinuation of continued clinical development of LMX can be 
directly traced to the severe myelosuppression encountered in a Phase 1 clinical trial,
336 
at 
least partly due to its excellent substrate activity for RFC uptake and polyglutamylation 
by normal tissues. Clearly, a specific FR-targeted agent that also possesses cytotoxic 
activity would circumvent the drawbacks of folic acid-conjugated cytotoxic agents and 
the lack of selectivity associated with clinically used antifolates MTX, PMX and RTX. 
Indeed, FR selective cytotoxic agents can be envisaged to provide highly selective 
antitumor agents against tumors expressing FR with little or no host toxicity. 
 
Figure 57. The structure of antifolates 324-330  
Deng et al.
328
 described a novel series of 6-substituted classical pyrrolo[2,3-
d]pyrimidine antifolates, differing only in the lengths of the carbon bridge (3- to 6-
carbons), characterized by potent and selective substrate activities for FRα and FRβ, and 
negligible substrate activity for RFC. The intracellular enzyme target of the 6-substituted 
pyrrolo[2,3-d]pyrimidines was identified as glycinamide ribonucleotide formyltransferase 
(GARFTase), the first folate-dependent reaction in the de novo purine synthesis pathway.  
In this study, the focus was extended to a novel isosteric series of 6-substituted 
thieno[2,3-d]pyrimidine antifolates 324-330  (Figure 57), with a 2- to 8-carbon bridge 
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between the thieno[2,3-d]pyrimidine and the benzoyl moiety, respectively. Isosteric 
replacement of the pyrrolo ring with a thieno ring for this series provides an increase in 
ring size that more closely approximates the pteridine, 6-6 fused ring system of the 
natural cofactor. In addition, replacement of the NH of the pyrrole with a S also allows 
for comparison of the relative importance of a hydrogen bond donor (NH) with a 
hydrogen bond acceptor(s).   
6. Importance of the Side Chain Aryl Group for Folate Receptor Targeting and 
GARFTase Inhibitory Activity in Classical Thieno[2,3-d]pyrimidine Antifolates  
6-Substituted thieno[2,3-d]pyrimidine antifolates 324-330 were found to be potent 
and selective inhibitors of cells that express FRα and FRβ. The thieno[2,3-d]pyrimidines 
324-330 are unique and distinct from all other clinically used classical antifolates, 
including the pyrrolo[2,3-d]pyrimidine (PMX), quinazoline (RTX), and pteridine (MTX) 
antifolates, in that they are neither substrates for RFC nor PCFT. In this series, 326 with a 
four carbon bridge is the most potent inhibitor of cells expressing FRs α and β, and this 
activity is directly related to intracellular GARFTase inhibition.
337
 
 
Figure 58. The structure of antifolates 331-334 
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To further investigate the structural requirements of the thieno[2,3-d]pyrimidine 
antifolates for FR transport and GARFTase inhibition, particularly the importance of the 
aromatic ring in the side-chain, a series of compounds 331-334 (Figure 58) with 
positional isomer phenyl different aryl substitutions were designed, synthesized and 
evaluated. The aryl group in side-chain is believed not only to allow the appropriate 
relative orientation of the thieno[2,3-d]pyrimidine scaffold (part A) and the glutamate 
portion (part B), but also provides important interactions with the transporter and the 
target enzyme.  
Table 3. The angle of aryl disubstitutions 
 
Compound  Ar angle 
326 
 
180
o
 
331 
 
180
o
 
332 
 
120
o
 
333 
 
147.4
o
 
96 
 
334 
 
125.5
o
 
 
As shown in Table 3, the angle between part A and part B is a measurement of the 
relative spatial orientation of A and B. For 331, although A and B substitutions have the 
same angle (180
o
) as the parent 326, the existence of an extra CH3 in 331 ortho to the 
alkyl chain in part A may restrict the free rotation of the otherwise flexible alkyl linker. 
Moreover, this methyl group could provide extra hydrophobic binding with the 
transporter FR and/or the enzyme GARFTase. 
Depending on the angle, the overall distance between A and B in 332, 333 and 
334 are slightly different (measured as the distance from the 6-CH2 on the thieno[2,3-
d]pyrimidine and the carbonyl on the aryl side chain), which may also affect the binding 
affinity of the compounds with the transporter and/or target enzyme. 
 
 
                          A                                                                                   B       
Figure 59. A: Structural alignment between 2,5-disubstituted thiophene (purple) and  
para-disubstituted benzene (green), B: tructural alignment between 2,5-disubstituted 
furan (purple) and 1,3-meta-disubstituted benzene (green)generated by MOE 2008.10. 
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  In 332, a meta substitution pattern was adopted such that the angle between the 
two parts A and B is 120
o
. 2,5-Disubstuted thiophene can mimic para-substituted 
benzene (Figure 59), while 2,5-disubstituted furan can mimic meta-substituted benzene 
(Figure 59). Thus, the benzoyl ring in 326 was bioisoterically replaced by a thienoyl ring 
or a furoyl ring, the resulting compounds 333 and 334 have different 147.4
o
 and 125.5
o
 
angles respectively (Table 3) as well as the potential interactions between the hetero 
atoms in the aryl ring and the transporter and/or enzyme. 
7. Importance of the Glutamate Moiety for Folate Receptor Targeting and 
GARFTase Inhibitory Activity in Classical Thieno[2,3-d]pyrimidine Antifolates 
As mentioned above, a series of thieno[2,3-d]pyrimidines 324-330 (Figure 57)  
were prepared as potent and selective inhibitors of tumor cells that express FRs α and 
β.337 This series of thieno[2,3-d]pyrimidine antifolates 324-330 are neither substrates for 
RFC nor PCFT, which is unique from all the other clinically used classical antifolates 
evaluated, including the pyrrolo[2,3-d]pyrimidine PMX, the quinazoline RTX, and the 
pteridine MTX antifolates. In this series, compounds 325 and 326 with a 3- or 4-
methylene bridge were consistently the most potent inhibitors of cells expressing FRs α 
and β, and this was associated with potent inhibition of GARFTase.  
 
 
Figure 60. The structure of antifolates 335-339 
98 
 
To further investigate the structural requirements of the thieno[2,3-d]pyrimidine 
antifolates for GARFTase inhibition and selective FR binding, particularly the 
importance of the carboxylic acid moieties in the glutamate, a series of analogues 335-
339 (Figure 60) with variation in the carboxylic acids of the L-glutamate moiety were 
designed, synthesized and evaluated. Compounds 335 and 336 have a CH3 or  H at the α-
position instead of a carboxylic acid group to explore the importance of glutamate α-
carboxylic acid. Compounds 337-339 maintain the α-carboxylic acid but have variations 
(CH3 in 337, H in 338 and SH in 339) at the γ-carboxylic acid position.  
8. The synthesis of substituted thieno[3,2-d]pyrimidin-4-amine as antimitotic 
anticancer agents. 
 Tubulin binding agents belong to a very important class of antitumor agents and 
are widely used in the clinic for cancer chemotherapy.
338
 Based on their binding sites on 
tubulin, most antimicrotubule agents can be divided into three classes, taxoids, the vinca 
alkaloids and colchicine site inhibitors.
339, 340
    
The first group includes paclitaxel (Taxol) and docetaxel (Taxotere), as well as the 
epothilones (Figure 61). Paclitaxel and other taxoids (and the epothilones) bind to the 
interior of the microtubule,
341, 342
 and the tubulin β-subunit. Unlike the other two classes 
of antimicrotubule agents, the taxoids stimulate tubulin polymerization and are 
designated microtubule-stabilizing agents. They are useful in the treatment of breast, lung, 
ovarian, head and neck and prostate carcinomas among others. 
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Figure 61. The structures of microtubule targeting agents  
 The second class are the vinca alkaloids including vincristine, vinblastine, 
vindesine and vinorelbine (Figure 61). The vinca alkaloids also bind at the β-tubulin  but 
is distinct from that of taxoids. The vinca alkaloids are important in the treatment of 
leukemias, lymphomas, non-small cell lung cancer and other cancers. A diverse 
collection of small molecules, including cochicine and combrestatatins, bind to the 
colchicine site  on  β-tubulin at its interface with α-tubulin, distinct from the vinca site.  
Similar to the vinca alkaloids, colchicine site agents inhibit tubulin polymerization. 
Colchicine itself is not used as an antitumor agent but is used in the treatment of gout and 
familial Mediteranean fever. Although there are no clinically approved antitumor agents 
that bind to the colchicine site, several of these agents are currrently in clinical trials.
343, 
344
 Combretastatins, as exemplified by combretastatin A-4 (CA4) and its phosphorylated 
100 
 
prodrug combretastatin A-4 phosphate (CA4P) are currently in  clinical trials,
345
 which 
demonstrates the importance of developing colchicine site agents as antitumor agents.  
  Multidrug resistance (MDR) is a major limitation of cancer chemotherapy, and 
MDR tumors are usually resistant microtubule disrupting agents. Overexpression of P-
glycoprotein (Pgp) represents one of the major mechanism of tumor resistance. An 
elevated Pgp level has been reported in the clinical setting in a number of tumor types, 
particularly after patients have received chemotherapy.
346, 347
 In addition, Pgp expression 
has also been reported to be a prognostic indicator in certain cancers and is associated 
with poor response to chemotherapy. 
348, 349
 Due to the overwhelming lack of success of 
Pgp inhibitors in the clinic,  new microtubule targeting agents not susceptible to Pgp-
mediated resistance  are desired.
347, 350 
Such agents will fill an unmet need in the clinic for 
patients that develop resistance due to Pgp overexpression. The expression of  βIII-
tubulin is involved in clinical resistance to taxoids and vinca alkaloids in multiple tumor 
types including non small cell lung,
351-353
 breast,
354
 and ovarian cancers.
355, 356
 Stengel et 
al.
357
 and Lee et al.
358
 showed that colchicine  site agents circumvent βIII-tubulin 
resistance, which indicated the critical importance of developing new agents that bind to 
the colchicine site as an alternative to the taxoids for the treatment of refractory cancers.    
 Poor water solubility is an additional problem associated with several of the 
currently used antitubulin agents,  particularly the taxoids. It is necessary to formulate 
such drugs in Cremophor or polysorbate, which can cause hypersensitivity reactions and 
require long administration times.  Thus  the development of water soluble microtubule 
targeted agents are highly coveted, and have attracted enormous  research effort.  
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Figure 62. The structures of antimitotic agent 340-344 
 Gangjee recently discovered that furo[2,3-d]pyrimidine 340 showed 
antiproliferative activity against the NCI-60 panel of tumor cells at low nanomolar levels 
and was active in taxol resistant tumor cell lines that over express Pgp. Compound 340 
has additional advantages over clinical antimitotic agents, such as taxol, in that it is easily 
synthesized and is readily converted to the water soluble HCl salt form. Microtubule 
depolymerization through the binding at the colchicine site was determined to be the 
primary mechanism of action for 340. 
Compared to the 4-NH analogue, the 4-N-methylated compound 340 showed 
spectacular antimitotic antitumor activity, which could be attributed, in part, to 
conformational restriction. A structure-activity relationship study revealed that the 
conformationally restricted analogue 341 (Figure 62) showed potent antiproliferative 
activity against the NCI-60 tumor cells. Compound 341 was equipotent with CA4P  and 
twice as potent as 340 as an inhibitor of tubulin assembly in a quantitative study. 
Compound 341 also inhibited the binding of [
3
H]colchicine  to tubulin as potently as 
CA4P. The quantitative study suggested that 341 is a more potent inhibitor than 340. 
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The thieno[3,2-d]pyrimidine scaffold in this study was of interest to further 
explore the SAR of lead compounds 340 and 341. This scaffold can be explored to 
determine the importance of the furan oxygen in the furo[2,3-d]pyrimidine for binding to 
tubulin. The larger size of the sulfur atom compared to the oxygen allows the thieno[3,2-
d]pyrimidines to more closely mimic the size of a 6-6-ring system, which may influence 
the conformation of the 4‟-methoxy aniline substitution. In addition, the replacement of 
the O of a furo[2,3-d]pyrimidine with a C in  the thieno[3,2-d]pyrimidine was also 
anticipated to evaluate the importance of electron distribution in the ring system as well 
as the importance of hydrogen bonding abilities of O in the furo[2,3-d]pyrimidine 
scaffold. 
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IV. CHEMICAL DISCUSSION 
1. Synthesis of nonclassical analogues 5-methyl-6-substituted arylthio-thieno[2,3-
d]pyrimidine-2,4-diamines 285-295 as DHFR inhibitors. 
Scheme 48. The synthesis of nonclassical analogues 285-295 
 
The synthesis of 285-295 were accomplished as shown in Scheme 48. The key 
intermediate 347 was synthesized following a 2-step procedure (Scheme 48). Reaction of 
acetone with malononitrile and sulfur in the presence of morpholine was carried out 
according to the general procedure of Gewald and coworkers
359
 to afford the expected 
thiophene aminonitrile 346. Different solvents and bases were attempted for this reaction. 
Ethanol as solvent and morpholine as base was found to be the best conditions with 63% 
yield of the target. Compound 346 was then condensed with guanidine hydrochloride in 
DMSO to give 347 in 64% yield.
360
 
Compounds 285-294 were synthesized from 347 with a slightly modified 
oxidative thiolation procedure initially reported by Gangjee et al.
361
 The original 
procedure required protection of the 2,4-diamino groups, which significantly lowered the 
overall yield (25% on average). In addition, the original procedure required 16 h of 
reaction time to afford both thiolation and deprotection.  
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After several attempts of varing the reaction time, temperature and the amount of 
the iodine in bench-top reactions and microwave irradiation, it was discovered that the 
best procedure for the reaction was to suspend one equivalent of 347, two equivalents of 
the appropriately substituted thiophenols and one equivalent of iodine in ethanol-water 
(2:1) in a microwave reaction vial and irradiated at 180 °C for 10-20 min. After the 
reaction mixture was cooled to ambient temperature, the mixture was washed with 
saturated sodium thiosulfate solution and then concentrated under reduced pressure. The 
residue was loaded on a silica gel column and eluted with 5% MeOH in CHCl3. It was 
determined that the byproduct in this reaction was  the disulfide, obtained on oxidation 
from the thiophenol. Compounds 285-294 were obtained in yields ranging from 40% to 
78%. This modified synthetic procedure afforded the target compounds 285-294 with an 
improvement in the overall yield to 50% on average.  
The structures of 285-294 were established by 1H NMR where the disappearance 
of C6 proton at 6.49 ppm (compound 347) and the presence of the requisite protons of the 
6-substituted thiols at 6.30-7.30 ppm. The 2,4-diamino protons were deshielded, due to 
the deshielding zone created by the substitutions at 6-position. Compounds 285-294 
were also characterized by elemental analysis or high resolution MS (HRMS). 
2. 6,5,6-Tricyclic Benzo[4,5]thieno[2,3-d]pyrimidines as Dual Thymidylate Synthase 
and Dihydrofolate Reductase Inhibitors  
Based on retro-synthetic analysis, it was anticipated that target compound 301 
could be divided into two parts: the central tricyclic scaffold 349 and the isoindolinone 
side chain 355. N-alkylation reaction of 349 with 355 followed by saponification would 
afford 301. 
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Scheme 49. Retro synthetic analysis to classical analogue (2S)-2-(5-{[(2-amino-
4-oxo-3,4-dihydro[1]benzothieno[2,3-d]pyrimidin-5-yl)methyl]amino}-1-oxo-1,3-
dihydro-2H-isoindol-2-yl)pentanedioic acid 301 
 
The side chain 355 could be obtained from 358 through esterification, 
bromination, cyclization and reduction (Scheme 49). The central tricyclic 349 could be 
derived from 350, which in turn could be synthesized from commercially available 2-
methylcyclohexanone through the Gewald reaction, cyclization, aromatization and 
bromination. 
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Scheme 50. Synthesis of tricyclic thieno[2,3-d]pyrimidine 362 
 
The synthesis of tricylic intermediate 362 is presented in Scheme 50. Aromatic 
intermediate 360 was obtained from 359. Numerous attempts were made and detailed 
discussion is provided below (Table 4). The 
1
H NMR of compound 360 showed the 
disappearance of alicylic protons at 1.54 - 3.17 ppm and appearance of three phenyl 
protons at 6.98-7.43 ppm. Tricyclic thieno[2,3-d]pyrimidine 350 was obtained directly 
from 360 under similar condensation condition discussed in Scheme 48. Compound 350 
showed poor solubility in most organic solvents without 2-amino group protection. It 
could not be brominated at the 5-methyl group. Hence, the 2-amino group of 350 was 
protected with pivaloyl anhydride at reflux (71% yield). The pivaloyl protected 
compound 361 showed good solubility in 1,2-dichloromethane and radical bromination 
with NBS and a catalytic amount of benzoyl peroxide
362
 afforded the key intermediate 
362 in 42% yield. The 
1
H NMR of 362 showed the appearance of a singlet peak at 5.71 
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ppm, which corresponded to the benzylic protons, and disapperance of the peak at 3.05 
ppm, which corresponded to the 5-CH3 protons 
Scheme 51. Attempted synthesis of key intermediate 350 
 
            The key intermediate in the synthesis of 349 was the  aromatic tricyclic 
thieno[2,3-d]pyrimidine 350, which could be brominated to 349. Theoretically, there 
were two strategies to obtain target compound 350. Strategy I was to synthesize tricyclic 
thieno[2,3-d]pyrimidine 351 first, which can be aromatized to 350. Strategy II was to 
aromatize bicyclic intermediate 360 first followed by condensation to give 350. Since 
351 was a versatile intermediate with general applicability, strategy I was attempted first. 
The conditions that are attempted was summaried in Table 4. 
Table 4. Strategy I: Aromatization of tricyclic thieno[2,3-d]pyrimidine 351 
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Entry Oxidant Solvent Temperature Time Yield 
1 SeO2 HOAc Reflux 24 h No reaction 
2 MnO2 Dioxane Reflux 12 h, 24 h No reaction 
3 DDQ Dioxane Reflux 12 h, 24 h No reaction 
4 DDQ Toluene Reflux 12 h No reaction 
5 DDQ DMSO Reflux 4 h  trace amount 
6 DDQ DMSO 120 
o
C (microwave) 30 min  trace amount 
7 DDQ DMF 130 
o
C (microwave) 10 min No reaction 
8 DDQ DMF 150 
o
C (microwave) 20 min No reaction 
9 DDQ Dioxane 
/DMSO 
120 
o
C (microwave) 20 min No reaction 
10 DDQ Toluene 
/DMSO 
120 
o
C (microwave) 20 min No reaction 
 
Rosowsky et. al.
363 
previously reported the synthesis of  aromatic tetracyclic 
thieno[2,3-d]pyrimidine via SeO2 in HOAc at reflux. SeO2 oxidation was attempted first 
(entry 1 in Table 4). However, there was no new spot on TLC. Gangjee et. al.
364 
reported 
the oxidation of dihydropyrrolo[2,3-d]pyrimidine to aromatic analogues via MnO2. MnO2 
and 351 in dioxane at reflux for 12 h and 24 h (entry 2) were attempted. No new spot was 
observed on TLC. DDQ had been reported
14 
as a dehydrogenation agent. Compound 351 
treated with DDQ in dioxane for 12 h at reflux afforded no new spot on TLC. Extending 
the reaction time to 24 h or using DDQ in toluene did not afford any products (entry 3). 
High boiling point solvents like DMSO were also tired. Compound 351 and DDQ in 
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DMSO at reflux for 4 h afforded a light new spot on TLC and some decomposed starting 
material 351 (entry 5). This sparked our interest in DDQ as aromatization agent.  
Microwave irradiation was also evaluated for this reaction. DDQ and 351 in 
DMSO under microwave irradiation at 120 
o
C for 30 min (entry 6) gave a trace amount 
of a new spot on TLC. However, it was difficult to purify this new spot due to its close Rf 
value with starting material 351 and small quantity of the product. DMF as solvent was 
also attempted. DDQ and 351 in DMF under microwave irradiation at 130 
o
C for 10 min 
(entry 7) and 150 
o
C for 20 min (entry 8) afforded no new spot on TLC. Mixed solvent 
system such as DDQ and 351 in dioxane / DMSO (1:1) under microwave irradiation at 
120 
o
C for 20 min (entry 9) and toluene / DMSO (1:1) at 120 
o
C for 20 min (entry 10) did 
not afford any new spot on TLC. 
The poor solubility of 351 in organic solvent was perhaps responsible for the 
failure of aromatization. The 2-amino group of 351 was protected with a pivaloyl group 
and the resulting compound 363 showed good solubility in most organic solvents. 
Table 5. Strategy I: Aromatization of tricyclic thieno[2,3-d]pyrimidine 363       
 
Entry Oxidant Solvent Temperature Time Yield 
1 DDQ Dioxane Reflux 4 h, 8 h, 12 h  No reaction 
2 DDQ Toluene Reflux 12 h No reaction 
3 DDQ Benzene Reflux 12 h No reaction 
4 DDQ Dioxane 
/Toluene 
Reflux 12 h No reaction 
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5 DDQ DMSO Reflux 8 h No reaction 
6 DDQ DMSO 100 oC (microwave) 30 min No reaction 
7 DDQ DMSO 180 oC (microwave) 30 min No reaction 
8 DDQ Toluene 100 oC (microwave) 60 min unisolatable 
9 DDQ Toluene 120 oC (microwave) 30 min unisolatable 
 
Protected tricyclic thieno[2,3-d]pyrimidine 363 and DDQ in dioxane, toluene, 
benzene, DMSO, dioxane/toluene (1:1) (entries 1-5 in Table 5) at reflux for 4-12 h 
afforded no new spot on TLC. DDQ and 363 was also attempted under microwave 
irradiation in DMSO at 100 oC for 30 min (entry 6) and 180 oC for 30 min (entry 7). 
Neither of them afforded any product. Similarly, DDQ and 363 under microwave 
irradiation in toluene at 100 oC for 60 min (entry 8) and at 120 oC for 30 min (entry 9) 
afforded no new spot on TLC. 
Table 6. Strategy II: Aromatization of bicyclic intermediate 359 
 
Entry Oxidant Solvent Temperature Time Yield 
1 MnO2 Toluene Reflux 24 h No reaction 
2 SeO2 Toluene Reflux 24 h No reaction 
3 DDQ  Toluene Reflux 5 h No reaction 
4 DDQ Dioxane 140 oC (microwave) 20 min No reaction 
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Failure of Strategy I led to the alternate Strategy II, where the bicylic scaffold was 
aromatized first. Bicyclic intermediate 359 showed good solubility in most organic 
solvents. Toluene was chosen as the solvent and MnO2, SeO2 and DDQ were chosen as 
oxidants. Under bench-top condition and microwave irradiation (entries 1-4 in Table 6), 
none of them gave the target aromatic compound 360. 
After a literature survey, a Pd-C dehydrogenation reaction was found.
365, 366
 
Bicyclic intermediate 365, 10% Pd-C, methylcinnamate and piperidine in refluxing 
toluene
366  
did not afford any new spot on TLC, following the reported procedure (entry 1 
in Table 7). Since 365 showed good solubility in most organic solvent, CH2Cl2 was 
selected as the solvent (entry 2). After treating 365 with 10% Pd-C in CH2Cl2 at reflux for 
12 h, a new spot was observed on TLC. When the reaction time was extended to 24 h, the 
starting material 365 could be still be detected as reacted. In order to characterize the 
structure of the new spot, the reaction was stopped and the aromatic intermediate 366 was 
obtained in 30% yield after column chromatography. 
Table 7. Strategy II: Aromatization of bicyclic intermediate 365 
 
Entry Oxidant Solvent Temperature Time Yield 
1 Pd/C Toluene,  
piperidine 
methylcinnamate 
Reflux 24 h No reaction 
2 Pd/C CH2Cl2 Reflux 24 h  30.1 % 
 
3 Pd/C Toluene Reflux 24 h 51.6% 
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4 Pd/C Toluene Reflux 36 h 88% 
 
5 DDQ Toluene Reflux 5 h  trace amount 
6 DDQ Toluene 150 oC 
(microwave) 
30 min  trace amount 
 
The spectroscopic data (
1
H NMR) and elemental analysis were consistent with the 
structure of 366. The 
1
H NMR of 366 showed the disappearance of peaks at 1.65-2.61 
ppm and the appearance of four phenyl protons at 7.05-7.97 ppm.  
In order to increase the conversion rate of this reaction, a higher boiling solvent 
toluene, was tried (entry 3). However, after 24 h reaction in toluene at reflux, starting 
material 365 could be still detected on TLC and 366 was obtained in 51.6% yield by 
column chromatography. These two reaction conditions indicated that a higher reaction 
temperature may be beneficial (comparing the boiling points of CH2Cl2 and toluene). 
Next the reaction time was extended to  36 h (entry 4) and the TLC showed the formation 
of one major spot identified as 366 and small amount of by-product. Compound 366 was 
obtained in 88% yield after column chromatography.  
It was important to know whether the 4-CH3 moiety hampered oxidation, since 
DDQ did not afforded the oxidation of the 4-CH3 substituted bicyclic intermediate 359. 
Intermediate 365 was also treated with DDQ in toluene at reflux and under microwave 
irradiation (entries 5-6). Both conditions afforded trace amounts of target compound 366, 
which suggested that DDQ was probably incapable of aromatizing bicyclic analogues 
359 or 365. 
 
 
113 
 
 
Table 8. Strategy II: Aromatization of bicyclic intermediate 359 
 
Entry Oxidant Solvent Temperature Time Yield 
1 Pd/C Toluene Reflux 24 h 25.1% 
2 Pd/C Toluene Reflux 36 h 30.2% 
3 Pd/C Mesitylene Reflux 48 h 52.1%  
 
 
The success in the aromatization of 365 generated encouragement for the 
synthesis of the aromatic intermediate 360. Compound 359 and 10% Pd-C in toluene at 
reflux for 4 h afforded a new spot on TLC. When the reaction time was extended to 24 h, 
some by-products were observed on TLC. Compound 360 was obtained in 25% yield by 
column chromatography  
(entry 1 in Table 8). 
 The 
1
H NMR of compound 360 showed the disappearance of allicyclic 
methylene peaks at 1.54-3.17 ppm and the appearance of three phenyl protons at 6.98-
7.43 ppm. To increase the yield of this reaction, the reaction time was extended to 36 h 
(entry 2). However, the reaction was found to be incomplete even after 36 h and longer 
reaction times resulted in the decomposition of 359 (TLC) and further complicated the 
purification. Compound 360 was obtained in 30.2% yield by column chromatography. 
Since a higher reaction temperature could be beneficial to this reaction, high boiling 
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solvent like mesitylene were also tried (entry 3). Compound 359 and 10% Pd-C in 
mesitylene at reflux for 48 h afforded 360 in 52% yield after column chromatography. 
The reaction, however, was still found to be incomplete (TLC). The low yield of this 
reaction might also be due to the steric hindrance of the 4-CH3 group.  
 
Figure 63. Proposed mechanism of aromatization of 359 and 365 
Grossman et al 
367
 discussed the mechanism of Pd-C as a dehydrogenation agent. 
The mechanism of aromatization of 359 and 365 was proposed as shown in Figure 63. 
Through an oxidative insertion process, Pd 
0
 (Pd-C) is inserted between carbon and 
hydrogen to form a Pd 
II
 species, which then undergo a β-hydride elimination to cleave 
the Pd 
II
 species with the formation of a double bond. The same process is repeated for a 
second round to give the aromatized target compounds 360 and 366. In this reaction, 
stoichiometric amount of Pd-C is necessary, since Pd 
0
 can not be regenerated from the 
Pd 
II
 species. The steric hindrance of the 4- methyl group in 359 might hamper the initial 
step of Pd 
0
 insertion. 
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Table 9. Application of Pd-C in aromatization of tricyclic thieno[2,3-d]pyrimidines 351 
and 363 
 
Entry Oxidant Solvent Temperature Time Yield 
1 Pd/C Toluene reflux 48 h No reaction 
2 Pd/C Mesitylene reflux 48 h No reaction  
 
Pd-C as a dehydrogenation agent was applied to the aromatization of 351 and 363 
in toluene and mesitylene (Table 6) at reflux. After 24 h, there was no new spot observed 
on TLC, which indicated that this method was not applicable to the tricyclic thieno[2,3-
d]pyrimidine scaffold. 
Table 10. Application of Pd-C condition in aromatization of bicyclic thieno[2,3-
d]pyrimidines 364 and 365    
 
Entry Oxidant Solvent Temperature Time Yield 
1 Pd/C Toluene reflux 24 h No reaction 
2 Pd/C Mesitylene reflux 24 h No reaction  
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Pd-C as a dehydrogenation agent was also applied to the bicyclic intermediates 
367. Surprisingly, after reaction in toluene and mesitylene at reflux for 24 h, neither gave 
the target compound (Table 10). Comparing 359 and 365 with 367, the only difference 
was the 3-substitution. When the substitution was an ester group, Pd-C worked. However, 
the reaction did not work when the substitution was a nitrile group. The reason behind 
this is still not clear.  
Scheme 52. Synthesis of side-chain of 355 
 
 
Following a literature procedure,
368 
amine 355 was synthesized as shown in 
Scheme 52. Esterification of 369 with SOCl2/MeOH afforded 358 in 91% yield and 
radical bromination with N-bromosuccinimide and a catalytic amount of benzoyl 
peroxide afforded 357 in 48% yield (Scheme 52). The 
1
H NMR of 357 showed the 
disappearance of protons at 2.69 ppm (CH3) and appearance of protons at 4.86 ppm 
(CH2Br). Treatment with excess diethyl L-glutamate hydrochloride and K2CO3 in DMF 
at room temperature afforded isoindoline 356 as orange oil in 56% yield. The 
1
H NMR of 
356 showed the appearance of protons at 4.51-4.83 ppm (isoindoline CH2) and 5.09-5.14 
ppm (Gluα-CH). Reduction of the nitro group in 356 afforded the amine 355 in 92% 
yield.  
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Scheme 53. Synthesis of classical analogue 301 
 
With central tricyclic building block 362 and side chain 355 in hand, a N- 
alkylation reaction
369
 was carried out to give intermediate 370 in 38% yield. Hydrolysis 
of the ethyl ester and removal of pivaloyl protecting group of 370 with 1 N NaOH 
followed by acid workup gave target compound 301 in 34% yield (Scheme 53). The 
1
H 
NMR of 301 showed six aromatic protons at 6.64-7.72 ppm and two benzylic protons at 
5.13-5.14 ppm as doublet. The expected NH at 6.74 ppm exchanged with D2O indicated 
the success of the condensation reaction. The presence of the requisite protons of the side 
chain also confirmed the structure of 301. The structure of 301 was further confirmed by 
HRMS. 
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3. N-{4-[(2-amino-6-isopropyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-
yl)sulfanyl]benzoy-L-glutamic acid 4 and nonclassical analogues 304-313 
Scheme 54. Synthesis of thieno[2,3-d]pyrimidine 373 
  
Commercially available isovaleraldehyde 371 reacted with sulfur, ethyl 
cyanoactetate and morpholine in EtOH for 24 h at room temperature under Gewald 
reaction conditions to afford 372 in 78% yield. Cyclization of 372 with 
chloroformamidine hydrochloride afforded the thieno[2,3-d]pyrimidine 373 in 87% yield 
(Scheme 54). 
Scheme 55. Synthesis of thieno[2,3-d]pyrimidine 305 
 
With the intermediate 373 in hand, oxidative thiolation at C5-position was 
attempted to afford target compound 305. However, following previously reported 
procedure, the reaction of 373 with benzenethiol and I2 in a mixture of ethanol/water (2:1) 
under microwave irradiation at 180 °C for 30 min did not afford 305 (Scheme 55). One 
possible reason of this reaction might be the steric hindrance of the 6-isopropyl group, 
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which hampers the addition of the thiol to the 5- position. Due to the failure of the one-
step oxidative thiolation, it became necessary to explore an alternative strategy to afford 
the target compounds. 
Scheme 56. Attempted synthesis of key intermediates 374 or 375 
 
A two-step reaction to introduce thiols to the C5-postion was attempted. The 5-
halogen substituted thieno[2,3-d]pyrimidines 374 or 375 could undergo coupling 
reactions to afford the 5-thiol substituted thieno[2,3-d]pyrimidines. Thus compound 374 
or 375 were the key intermediates for the transformation. The first approach for the 
synthesis of 374 was to utilize NBS in DMF at room temperature and at reflux for 24 h 
(Scheme 56). All these attempts failed. Halogenation at 5-position using NIS did not 
afford the desired intermediate either. Recently, Gangjee et al.
 370
 reported a convenient 
C5-bromination reaction of 2-amino-4-oxo-6-methylthieno[2,3-d]pyrimidin with bromine 
under microwave irradiation. So bromine in acetic acid at reflux and microwave 
irradiation at 150 
o
C for 30 min were also attempted (Scheme 56) but was unsuccessful.  
To our surprise, all efforts to introduce the halogen into the 5-position were 
unsuccessful. The possible reason might be the steric hindrance of the 6- isopropyl group, 
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which hampered the addition of the halogen to the 5- position. Thus, an alternative 
halogenation method had to been considered.  
Scheme 57. Synthesis of key intermediate 375 
 
 
After a literature survey, a two-step reaction for iodine introduction at the 5- or 6- 
position was found.
371
 Compound 373 (Scheme 57) was reacted with mercuric acetate at 
150 
o
C and then treated with brine. The resulting solid 376 was collected through 
filtration and was used for the iodination reaction without further purification. Iodine was 
added to a solution of 376 in CH2Cl2 and 375 was obtained in 68% yield (two-step 
reaction). The 
1
H NMR of 375 showed the disappearance of the C5-proton at 6.78 ppm. 
Compound 375 was also characterized by elemental analysis. 
Scheme 58. The synthesis of thio ester 381 
  
121 
 
The synthesis of the classical analogue 304 required the thio ester 379 or 381, 
which were not commercially available. As previously reported,
370 
compound 379 was 
synthesized from the commercially available disulfide 377, which was esterified to 378 
via ethyl iodide. Reduction of 378 to the corresponding sodium salt of ethyl 4-
mercaptobenzoate 379 was achieved using sodium borohydride in ethanol (Method I in 
Scheme 58). Another method
 
was developed and is also described in Scheme 58 (Method 
II). Thionyl chloride was added dropwise to a stirred solution of commercially available 
4-mercaptobenzoic acid in MeOH. When the addition was complete the mixture was left 
to stand at room temperature for 12 h to obtain a yellow solid. The filtrate was 
concentrated under reduced pressure to afford a yellow solid 381 in 94% yield. This 
method had the advantage over the previously reported Method I of having a shorten 
sequence and higher yield. The 
1
H NMR spectrum showed the presence of a singlet at 3.6 
ppm which exchanged on addition of D2O indicating the presence of SH group. 
 
Scheme 59. Synthesis of classical analogue 304 via Buchward coupling 
 
 
 
With intermediate 375 in hand, two different coupling conditions were attempted, 
including the Buchward coupling of 375 with methyl 4-mercaptobenzoate in the presence 
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of i-Pr2NEt, Pd2dba3, Xantphos
372 
under microwave irradiation at 190 
o
C, which afforded 
382 in 64% yield (Scheme 59), and the Ullmann coupling
373
 of 375 and appropriate 
arylthiols in the presence of CuI and K2CO3 in DMF under microwave irradiation at 100 
o
C for 60-120 min, which afforded 305-313 in 75-91% yield (Scheme 60).  
For the synthesis of the classical compound 304, the required intermediate 382 
was prepared through the Buchward coupling in 64 % yield (Scheme 59). The 
1
H NMR 
spectrum of 382 showed the presence of two doublets at 7.06 ppm and 7.78 ppm, which 
confirmed the structure of 382. Hydrolysis of the ethyl ester of 382 with 1 N NaOH in 
ethanol followed by acid workup gave the corresponding acid 383 in 98% yield. With 2-
Cl-4,6-dimethoxy-1,3,5-triazine and 4-methylmorpholine as the coupling reagents, acid 
383 were coupled with diethyl-L-glutamate hydrochloride to afford compound 384 in 
95% yield.  
The 
1
H NMR spectrum of 384 revealed the expected peptide NH doublet at 8.60 
ppm and 8.62 ppm, which exchanged with D2O. The splitting pattern of Gluα-CH was 
simplified to a singlet on the addition of D2O since the exchange of the NH proton 
prevented the coupling. Hydrolysis of 384 in 1 N NaOH followed by acid workup gave 
target compound 304 in 83% yield. Compound 304 was also characterized by 
1
H NMR 
and elemental analysis. 
Comparing these two coupling reactions, the Ullmann coupling had the advantage 
over Buchward coupling of both higher yield and easier handling since the later required 
evacuation and backfilling with nitrogen (3 cycles). Compounds 305-311 were 
synthesized via Ullmann coupling (Scheme 60) in good yields. The structures of 305-
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311 were established by 1H NMR (the presence of the protons of the aryl side chain at 
6.76-8.22 ppm) and elemental analysis or HRMS. 
Scheme 60. Synthesis of nonclassical analogues 305-311 via Ullmann coupling 
 
4. Synthesis of nonclassical analogues 2-amino-6-propyl-5- substituted arylthio-
thieno[2,3-d]pyrimidin-4(3H)-one 317-319 and 323. 
Scheme 61. Synthesis of nonclassical analogues 317-319 and 323 
 
 
Commercially available valeraldehyde 385 was reacted with sulfur, ethyl 
cyanoactetate and morpholine in EtOH for 24 h at room temperature under Gewald 
reaction conditions to afford 386 (Scheme 61) in 78% yield. Cyclization of 386 with 
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chloroformamidine hydrochloride afforded the thieno[2,3-d]pyrimidine 387 in 80% yield. 
Compound 387 was reacted with mercuric acetate at 150 
o
C and then treated with brine. 
The resulting solid 388 was collected by filtration and was used for the iodination 
reaction without further purification. Iodine was added to a solution of 388 in CH2Cl2 and 
389 was obtained in 68% yield (two-step reaction).  
Compounds 317-319 and 323 were obtained using Ullmann coupling reported 
previously, which entailed the treatment of 389 with substituted thiophenols in the 
presence of CuI and K2CO3 in DMF under microwave irradiation at 100 
o
C for 60-120 
min. The structures of 317-319 and 323 were established by 1H NMR (the presence of 
the protons of the aryl side chain at 6.77-8.22 ppm) and HRMS. 
7. Synthesis of 2-amino-4-oxo-6-substituted thieno[2,3-d]pyrimidines with 2 to 8 
carbon bridge length analogues 324-330. 
Scheme 62. Synthesis of thieno[2,3-d]pyrimidines 324-330 
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Target compounds 324-330 were synthesized as shown in Scheme 62. The 
appropriate allyl alcohols 390-396 were treated with palladium diacetate, ethyl 4-
iodobenzoate, LiCl, LiOAc and Bu4NCl in DMF to afford the aldehydes 397-403 (80-
85% yield).
374 
A modified reaction temperature of 80
 o
C from that reported in the 
literature improved the yield. Aldehydes 397-403 were then reacted with sulfur, ethyl 
cyanoactetate and morpholine in EtOH for 24 h at room temperature under Gewald 
reaction conditions to afford 404-410. Cyclization of 404-410 with chloroformamidine 
hydrochloride afforded the thieno[2,3-d]pyrimidines 411-417 in 55-80% yield. 
Hydrolysis of the ethyl esters of 411-417 with 1 N NaOH in ethanol followed by acid 
workup gave the corresponding acids 418-424. With 2-Cl-4,6-dimethoxy-1,3,5-triazine 
and 4-methylmorpholine as the coupling reagents, acids 418-424 were coupled with 
diethyl-L-glutamate hydrochloride to afford compounds 425-431 (69-77%). Hydrolysis 
of 425-431 in 1 N NaOH, followed by acid workup gave target compounds 324-330 in 
96-98% yield (Scheme 62).  The 
1
H NMR spectrum of 324-330 revealed the expected 
peptide NH doublet at 8.50- 8.60 ppm, which exchanged on addition of D2O. The 
splitting pattern of Gluα-CH was reduced to a singlet on addition of D2O following the 
exchange of NH proton. Compounds 324-330 were also confirmed by elemental analysis. 
12. Synthesis of N-({5-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-
yl)but-1-yn-1-yl]thiophen-2-yl}carbonyl)-L-glutamic acid 333. 
The one-step palladium-catalyzed coupling of allylic alcohols with aryl halides (I, 
Br) with the previously reported reaction condition (Scheme 62) could afford the 
aldehydes in high yield. However, when starting material 439, obtained via esterification 
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from 438, was attempted under these conditions, the desired aldehyde 440 was not 
obtained (Scheme 63). 
Scheme 63. Attempted synthesis of key intermediate 44 
  
Intermediate 441 was synthesized using previously reported procedures. Coupling 
of 438 with diethyl-L-glutamate hydrochloride afforded 441 in 83% yield. Compound 
441 was then reacted with allylic alcohol in the presence of palladium catalyst,  however 
no desired aldehyde 442 was obtained. 
Scheme 64. Proposed synthesis of key intermediate 448 
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Compound 444 (Scheme 64) was synthesized by microwave assisted Sonogashira 
coupling of 441 with hex-5-yn-1-ol in 71% yield. The reaction was attempted using 
CH3CN as solvent, triethylamine as base, PdCl2 as catalyst and Cu2I as an additive under 
microwave irradiation at 100 
o
C for 10 min. Based on the retro-synthetic analysis, it was 
predicted that target compound 448 could be obtained, after several functional group 
conversion steps from 444. With 444 in hand, the reduction of the triple bond, followed 
by a Swern oxidation could afforded aldehyde 446, a key intermediate for target 448. 
However, the subsequent harsh reaction condtions, including reflux and high temperature 
could racemize the chiral center on the glutamate side-chain. Thus, an alternate synthetic 
strategy for the target compound 448 was explored. 
Scheme 65. Synthesis of intermediate 451 
 
Reaction of alcohol 449 (Scheme 65) and 438 was carried out in CH3CN at 100 
o
C for 10 min under microwave irradiation following previously reported Sonogashira 
coupling conditions with low yield of 27% (Scheme 65).
375
 The reaction was found to be 
incomplete (TLC). Protection of the carboxlic aid 438 as methyl ester 439 increased the 
yield to 85% (Scheme 65). The 
1
H NMR of 451 showed eight protons at 1.54-3.43 ppm 
revealing the success of the Sonogashira coupling/ 
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Table 11. Attempted synthesis of aldehyde 452 
 
 
 
 Conditions Temperature Reagent 1 Reagent 
2 
Reagent 3 Yield 
1 0 
o
C--r. t. 
         
DMSO NEt3 No 
reaction 
2 0 
o
C--r. t.     
 
DMSO NEt3 No 
reaction 
3 -78 
o
C--r. t. 
          
DMSO NEt3 87% 
 
The aldehyde 452 was obtained by oxidation of 451 (Table 11). Three different 
Swern oxidation conditions were attempted, including modified conditions (entries 1-2 in 
Table 11) and normal condition (entry 3). Neither of modified conditions worked for 451 
while a normal Swern oxidation afforded 452 in 87% yield. 
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Scheme 66. Synthesis of thieno[2,3-d]pyrimidine 457 
 
Aldehyde 452 (Scheme 66) reacted with sulfur, ethyl cyanoactetate and 
morpholine in EtOH for 24 h at room temperature under Gewald reaction conditions to 
afford 453 in 40% yield. Cyclization of 453 with chloroformamidine hydrochloride 
afforded the thieno[2,3-d] pyrimidine 454 in 52% yield. Hydrolysis of the ethyl ester 454 
with 1 N NaOH in ethanol followed by acid workup gave the acid 455 in 94% yield. 
Compound 456 was synthesized using the procedure previously reported. Coupling of 
455 with diethyl-L-glutamate hydrochloride afforded 456 in 78% yield. Hydrolysis of 
456 in 1 N NaOH, followed by acid workup gave target compound 457 in 92% yield 
(Scheme 66).  
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The 
1
H NMR spectrum of 457 revealed the expected peptide NH doublet at 8.62 
ppm and 8.71 ppm, which exchanged on the addition of D2O. The splitting pattern of 
Gluα-CH was simplified on the addition of D2O. Compound 457 was also confirmed by 
HRMS. 
 
Table 12.  Comparison of hydrogenation with different intermediates* 
Substrate Reaction 
time 
Description Yield 
 
8 h TLC:  only one spot 
NMR: no reduction 
No reaction 
 
8h, 16h, 
24h, 48h 
TLC:  two spots but 
difficult to separate 
70% 
reduction 
(NMR) 
 
24 h, 48h TLC: Only one spot 
 
30% 
reduction 
(NMR) 
 
24 h TLC : a complete 
reduction 
confirmed by NMR 
Quantitative 
*10% Pd/C as the catalyst and H2 pressure is 55psi. 
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Different hydrogenation conditions and substrates are compared for the synthesis 
of 448. Initial attempts to reduce the triple bond derived from the Sonogashira reaction 
was hydrogenation with 10% Pd-C in a mixture of methanol and 5 drops of acetic acid.           
Intermediate 456 was attempted first and no desired product spot was detected on 
TLC after 8 h of reaction. Since the reduced compound may have the same Rf value on 
TLC as 456, 
1
H NMR was carried out to characterize the spot obtained after its isolation. 
It was found that there was no reduced product. 
Intermediate 454 was also attempted and a new spot was visible on TLC after 8 h 
of reaction (Table 12). However, the two spots on TLC had very close Rf values and were 
not separable via column chromatography. The reaction time was increased to 16 h and 
454 could be detected on TLC. The reaction was found to be incomplete (TLC) even after 
48 h. The 
1
H NMR of the mixture showed that about 70% of 454 had been reduced.  
Intermediate 453 was also attempted and no new spot was found on TLC after 24 
h and 48 h. The 
1
H NMR of crude product suggested 30% of 453 was reduced.  
To our surprise, it was difficult to reduce these triple bond intermediates using 
catalytic hydrogenation. The possible reason might be that trace amount of sulfur from 
the Gewald reaction could poison Pd-C catalyst. Although sulfur was removed by 
filtration after reaction, there might be trace amount of residual sulfur even after several 
column chromatography purification. To overcome the possible poisioning effect of 
sulfur, intermediate 451, the intermediate prior to Gewald reaction, was used for the 
catalytic reduction. The reaction was complete (TLC) after 24 h reaction with quatitive 
yield (Table 12). The 
1
H NMR of the reduced compound 458 (Scheme 66) showed the 
appearance of a triplet that integrated for two protons at 2.79-2.83 ppm and multiple 
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peaks integrated for two protons at 1.38-1.67 ppm corresponding to two methylene 
groups. Thus it was decided to carry out the reduction prior to the Gewald reaction. 
Scheme 67. Synthesis of thieno[2,3-d]pyrimidine 333 
         
  Compound 458 (Scheme 67) was synthesized by catalytic hydrogenation of 451 
in 92% yield and the key intermediate aldehyde 459 was obtained by oxidation of 458 via 
Swern Oxidation in 83% yield (Scheme 67). With key aldehyde 459 in hand, thiophene 
intermediate 460 was obtained in 63% yield following the previously reported procedures 
for the Gewald reaction. Cyclization of 460 with chloroformamidine hydrochloride 
afforded the thieno[2,3-d]pyrimidine 461 in 85% yield. Hydrolysis of 461 with 1 N 
NaOH in ethanol followed by acid workup gave acid 462. Compound 463 was 
synthesized using procedure previously reported. Coupling of 462 with diethyl-L-
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glutamate hydrochloride afforded 463 in 75% yield. Hydrolysis of 463 in 1 N NaOH, 
followed by acid workup gave target compound 333 in 94% yield (Scheme 67).  
The 
1
H NMR spectrum of 333 revealed the expected peptide NH doublet at 8.47 
ppm and 8.49 ppm, which exchanged on the addition of D2O. The splitting pattern of 
Gluα-CH was simplified on addition of D2O since the exchange of NH protone destoried 
the coupling. Compound 333 was also confirmed by elemental analysis. 
9. Synthesis of classical thieno[2,3-d]pyrimidines 335-338 with different amino acid 
in place of the glutamate. 
Acid 464 (Scheme 68) was synthesized using procedures previously reported. 
Following a previously reported procedure, coupling of 464 with appropriate 
commercially available amines afforded the desired compounds 335-338.  
Schme 68. Synthesis of thieno[2,3-d]pyrimidines 335-338 
  
The 
1
H NMR spectrum of 335 revealed the expected peptide NH doublet at 8.46 
ppm and 8.48 ppm, which exchanged on addition of D2O. Additionally, the presence of 
multiple peaks at 4.25-4.31 ppm (α-CH) and the presence of a triplet at 0.93-0.97 ppm (γ-
CH3) integrating for three protons confirmed the structure of 335.  
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The 
1
H NMR spectrum of 336 revealed the expected peptide NH doublet at 
8.47ppm and 8.49 ppm, which exchanged on addition of D2O, and the presence of the 
requisite protons of the amino acid side chain confirmed the structure of 336.  
The 
1
H NMR spectrum of 337 revealed the expected peptide NH doublet at 8.20 
ppm and 8.22 ppm, which exchanged on addition of D2O. Additionally, the presence of 
multiple peaks at 4.29-4.36 ppm (α-CH) and the presence of doublet peaks at 1.16-1.18 
ppm (α-CH3) confirmed the structure of 337.  
The 
1
H NMR spectrum of 338 revealed the expected peptide NH doublet at 8.38 
ppm and 8.41 ppm, which exchanged on addition of D2O, and the presence of the 
requisite protons of the amino acid side chain confirmed the structure of 338. Compounds 
335-338 were also confirmed by elemental analysis. 
15. Synthesis of N
4
-aryl-2-methyl-thieno[3,2-d]pyrimidines 342-344. 
 Scheme 69. Synthesis of thieno[3,2-d]pyrimidines 342-344 
   
The conversion of ethyl 2-amino-thiophene-3-carboxylate to 2-methyl thieno[2,3-
d]pyrimidin-4(3H)-one is reported in the literature. Using a similar method, commercially 
available 466 (Scheme 69) was dissolved in CH3CN and HCl gas was bubbled through 
the solution to afford 467 as a white solid in 50% yield. Chlorination at the 4-position 
reacted on treatment with POCl3 at reflux to afford the key intermediate 468 in 76% 
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yield. The displacement of the 4-chloro moiety of 468 with appropriate anilines  and 
tetrahydroquinolines afforded the target compounds 342-344 in yields that ranged from 
65% to 79%.  
The 
1
H NMR of the 342 showed the appearance of  two new peaks at 3.49-3.84 
ppm, which corresponded to OCH3 and N-CH3, supporting the structure of 342. 
Moreover, the 
1
H NMR of 342 showed the appearance of two new doublets at 7.04-7.39 
ppm, which corresponded to the 4-substituted aromatic aniline.  
The 
1
H NMR of 343 showed the appearance of a new singlet peak at 3.78 ppm, 
which corresponded to OCH3. Similarly, it showed the appearance of two new doublets at 
6.95-7.62 ppm, which corresponded to the 4-substituted aromatic aniline. The appearance 
of a new singlet at 9.52 ppm, which exchanged with D2O and corresponded to the 4-NH, 
also supported the structure of 343. 
 The 
1
H NMR of 344 showed appearance of a new singlet at 3.78 ppm, which 
corresponded to the OCH3. It also showed the appearance of peaks at 1.89-4.02 ppm with 
integration value of six protons, which corresponded to the three methylene groups of the 
tetrahydroquinoline, supporting the structure of 344. Compounds 342-344 were also 
confirmed by elemental analysis. 
16. Synthesis of N-(4-methoxyphenyl)-N-methylthieno[3,2-d]pyrimidin-4-amine 474. 
Compound 470 (Scheme 70) was synthesized according to literature 
procedures.
376
 Commercially available 466 was reacted with acetic anhydride to give 469 
in 93% yield, which was used for the next step without further purification. Cyclization 
of 469 with ammonium formate in fomamide provided thieo[3,2-d]pyrimidin-4(3H)- one 
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470 in 80% yield. Although it was a 2-step reaction, the overall yield (74%) was 
acceptable. 
Scheme 70. Synthesis of thieno[3,2-d]pyrimidine 471 
   
Interestingly, following previously reported procedures, chlorination at the 4-
position with POCl3 at reflux afforded 471 instead of 472. The 
1
H NMR of the 471 
showed appearance of  a singlet at 4.13 ppm with an integration of three protons, which 
corresponded to OCH3. Moreover, the 3-NH peak at 12.48 ppm for 470 disappeared. The 
structure of compound 471 was also confirmed by elemental analysis.  
This reaction was repeated for three times and each time 471 was obtained instead 
of 472. It is of interest to determine where the methoxy group come from. A search of the 
literature
20
 revealed that 471 had been synthesized from 472 with sodium methoxide 
(Scheme II in Scheme 70). However, sodium methoxide was never used in the present 
work. The possible resource of this methyoxy group might be methanol that was used for 
preparing the silica gel plug for column chromatography. 
137 
 
Scheme 71. Synthesis of thieno[3,2-d]pyrimidine 472 
 
Following previously reported chlorination procedure and avoiding the use of 
methanol, thieno[3,2-d]pyrimidine 470 was reacted with POCl3 to afford 472 in 89% 
yield (Scheme 71), which verified that the methanol was the source of 4-methyoxyl group 
in the previously isolated 471 (Scheme 70). 
Scheme 72. Synthesis of thieno[3,2-d]pyrimidine 474 
 
The displacement of the 4-chloro moiety of 472 with 4-methoxy-N-methylaniline 
afforded target compound 474 (Scheme 72). The 
1
H NMR of the 474 showed the 
appearance of  two new peaks at 3.49 ppm and 3.84 ppm, which corresponded to the 
OCH3 and N-CH3 respectively, supporting the structure of 474. The 
1
H NMR of the 474 
also showed the appearance of two new doublets at 7.05-7.41 ppm, which corresponded 
to the 4-substituted aniline. Compound 474 was also confirmed by elemental analysis. 
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V. SUMMARY 
A total of one hundred and ninteen compounds were synthesized. Among them thirty-
nine new final target compounds were designed, synthesized characterized and evaluated 
from these projects. These compounds are as follows 
 
1. 5-Methyl-6-(phenylsulfanyl)thieno[2,3-d]pyrimidine-2,4-diamine (285).  
2. 6-[(4-Methoxyphenyl)sulfanyl]-5-methylthieno[2,3-d]pyrimidine-2,4-diamine 
(286).   
3. 6-[(2,6-Dimethylphenyl)sulfanyl]-5-methylthieno[2,3-d]pyrimidine-2,4-
diamine (287).   
4. 6-[(3,4-Dimethylphenyl)sulfanyl]-5-methylthieno[2,3-d]pyrimidine-2,4-
diamine (288).   
5. 6-[(2,5-Dimethoxyphenyl)sulfanyl]-5-methylthieno[2,3-d]pyrimidine-2,4-
diamine (289).   
6. 6-[(3,4-Dimethoxyphenyl)sulfanyl]-5-methylthieno[2,3-d]pyrimidine-2,4-
diamine (290).  
7. 5-Methyl-6-[(3,4,5-trimethoxyphenyl)sulfanyl]thieno[2,3-d]pyrimidine-2,4-
diamine (291).   
8. 5-Methyl-6-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidine-2,4-diamine 
(292).   
9. 6-[(3,4-Dichlorophenyl)sulfanyl]-5-methylthieno[2,3-d]pyrimidine-2,4-
diamine (293).   
10.  5-Methyl-6-(1-naphthylsulfanyl)thieno[2,3-d]pyrimidine-2,4-diamine (294).  
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11. (2S)-2-(5-{[(2-amino-4-oxo-3,4-dihydro[1]benzothieno[2,3-d]pyrimidin-5-
yl)methyl]amino}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)pentanedioic acid 
(301).  
12. 2-Amino-4-oxo-6-isopropyl-5-phenylsulfanylthieno[2,3-d]pyrimidine (305).  
13. 2-Amino-6-isopropyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-
4(3H)-one (306).  
14. 2-Amino-5-[(3,4-dichlorophenyl)sulfanyl]-6-isopropylthieno[2,3-d]pyrimidin-
4(3H)-one (307). Using the general procedure above compound 307  
15. 2-Amino-6-isopropyl-5-(1-naphthylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-
one (308).  
16. 2-Amino-6-isopropyl-5-(2-naphthylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-
one (309).  
17. 2-Amino-5-[(4-fluorophenyl)sulfanyl]-6-isopropylthieno[2,3-d]pyrimidin-
4(3H)-one (310).  
18. 2-Amino-5-[(4-methoxyphenyl)sulfanyl]-6-isopropylthieno[2,3-d]pyrimidin-
4(3H)-one (311).  
19. N-{4-[(2-amino-6-isopropyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-
yl)sulfanyl]benzoyl}-L-glutamic acid (304). 
20.  2-Amino-6-propyl-5-(1-naphthylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one 
(317).  
21. 2-Amino-6-propyl-5-(2-naphthylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one 
(318).  
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22. 2-Amino-6-propyl-5-(4-bromophenyl sulfanyl)thieno[2,3-d]pyrimidin-4(3H)-
one (319).  
23. 2-Amino-6-propyl-5-[(2,5-dimethoxyphenyl)sulfanyl]-thieno[2,3-d]pyrimidin-
4(3H)-one (323).  
24. N-{4-[2- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-
yl)ethyl]benzoyl}-L-glutamic acid (324).  
25. N-{4-[3- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-
yl)propyl]benzoyl}-L-glutamic acid  (325).  
26. N-{4-[4- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-
yl)butyl]benzoyl}-L-glutamic acid  (326).   
27. N-{4-[5- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-
yl)pentyl]benzoyl}-L-glutamic acid  (327).   
28. N-{4-[6- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-
yl)hexyl]benzoyl}-L-glutamic acid (328).  
29. N-{4-[7- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-
yl)heptyl]benzoyl}-L-glutamic acid (329). 
30.  N-{4-[8- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-
yl)octyl]benzoyl}-L-glutamic acid (330).  
31. N-({5-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-
yl)butyl]thiophen-2-yl}carbonyl)-L-glutamic acid (333).  
32. (2S)-2-({4-[4-(2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-
yl)butyl]benzoyl}amino)butanoic acid (335).  
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33. N-{4-[4-(2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-
yl)butyl]benzoyl}norvaline (336).  
34. 3-({4-[4-(2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-
yl)butyl]benzoyl}amino)butanoic acid (337).  
35. 4-({4-[4-(2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-
yl)butyl]benzoyl}amino)butanoic acid (338).  
36. N-(4-Methoxyphenyl)-N,2-dimethylthieno[3,2-d]pyrimidin-4-amine (342)  
37. N-(4-Methoxyphenyl)-2-methylthieno[3,2-d]pyrimidin-4-amine (343)  
38. 6-Methoxy-1-(2-methylthieno[3,2-d]pyrimidin-4-yl)-
1,2,3,4tetrahydroquinoline (344)  
39. N-(4-Methoxyphenyl)-N-methylthieno[3,2-d]pyrimidin-4-amine (474).   
Among them twenty one thieno[2,3-d]pyrimidines were designed and synthesized as 
dual TS and DHFR inhibitors. One benzo[4,5]thieno[2,3-d]pyrimidines was designed and 
synthesized as dual TS and DHFR inhibitor. Thirteen thieno[2,3-d]pyrimidines were 
designed and synthesized as GARFTase inhibitors with folate receptor (FR) specificity 
and antitumor activity. Four thieno[3,2-d]pyrimidines were designed and synthesized as 
RTK inhibitors with antimitotic antitumor activity.  
Compound 285-294 were designed as sulfur isosteres of lead pyrrolo[2,3-
d]pyrimidines and  showed potent and selective dual TS and DHFR inhibitory activity.  
Compound 301 with a tricyclic benzo[4,5]thieno[2,3-d]pyrimidine scaffold and a 
flexible and rigid benzoylglutamate were synthesized as dual thymidylate synthase (TS) 
and dihydrofolate reductase (DHFR) inhibitors. Compared to the 2-methyl analog, 
compounds with a 2-NH2 group increases hTS inhibition by more than 10-fold and also 
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afford excellent hDHFR inhibition (IC50 = 0.09-0.1 μM). The X-ray crystal structures of 
301 with hDHFR reveal, for the first time, the binding mode of tricyclics 
benzo[4,5]thieno[2,3-d]pyrimidine with human DHFR. 
Classical analogues 304 and nine nonclassical analogues 305-311 were synthesized as 
potential dual thymidylate synthase (TS) and dihydrofolate reductase (DHFR) inhibitors. 
The classical compound 304 showed potent human TS (IC50 = 80 nM) inhibition 
Compared to the 6-methyl and 6-ethyl analogs, the 6-isopopyl compound was 47-fold 
less potent as human DHFR inhibitor, which indicated that the bulk of the 6-substitution 
pattern determines the binding of 2-amino-4-oxo-6-substituted lthieno[2,3-d]pyrimidine 
with human DHFR. 
To further explore the substitution effects at 6-position, a series of nonclassical 2-
amino-6-propy-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidines 317-319 and 323 were 
designed and synthesized. These series of compounds restored  DHFR inhibitory 
activities and showed remarkable selectivities among DHFRs from different species. 
Compound 317 in this series showed an remarkable 1000-fold selectivity against T. 
gondii DHFR over human DHFR, which is better than any compound known in the 
literature.   
A series of seven 2-amino-4-oxo-6-substituted thieno[2,3-d]pyrimidines 324-330 (n = 
2-8) were synthesized as selective folate receptor (FR) α and β substrates and as 
antitumor agents. This series of compounds revealed for the first time that transport of 
classical compounds by FRs can be independent from RFC or PCFT. To further 
investigate the structural requirements of antifolates with respect to FR substrate activity 
and antitumor activity, 335-338 with variations in the glutamate moiety and 333 with 
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variations in side chain aryl group in thieno[2,3-d]pyrimidine antifolates were designed 
and synthesized.  
 In addition, bicyclic substituted thieno[2,3-d]- and theino[3,2-d]pyrimidines 342-
344 and 474 were synthesized as antimitotic agents. These compounds showed potent 
inhibition of tumor cells in culture and extended the structure-activity relationship for the 
bicyclic scaffolds in the antimitotic area. 
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VI. EXPERIMENTAL SECTION 
General Methods for Synthesis:                   
All evaporations were carried out in vacuo with a rotary evaporator. Analytical 
samples were dried in vacuo (0.2 mm Hg) in an Abderhalden drying apparatus over P2O5. 
Thin-layer chromatography (TLC) was performed on silica gel plates with fluorescent 
indicator. Spots were visualized by UV light (254 and 365 nm). All analytical samples 
were homogeneous on TLC in at least two different solvent systems. Purification by 
column and flash chromatography was carried out using Merck silica gel 60 (200-400 
mesh). The amount (weight) of silica gel for column chromatography was in the range of 
50-100 times the amount (weight) of the crude compounds being separated. Columns 
were dry packed unless specified otherwise. Solvent systems are reported as volume 
percent mixture. Melting points were determined on a Mel-Temp II melting point 
apparatus and are uncorrected. Proton nuclear magnetic resonance (
1
H NMR) spectra 
were recorded on a Bruker WH-300 (300MHz) spectrometer. The chemical shift () 
values are reported as parts per million (ppm) relative to tetramethylsilane as internal 
standard; s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br s = broad 
singlet, exch = protons exchangeable by addition of D2O. Elemental analyses were 
performed by Atlantic Microlab, Inc., Norcross, GA. Elemental compositions were 
within ± 0.4% of the calculated values. Fractional moles of water or organic solvents 
frequently found in some analytic samples could not be removed despite 24 h of drying in 
vacuo and were confirmed, where possible, by their presence in the 
1
H NMR spectrum. 
All solvents and chemicals were purchased from Aldrich Chemical Co. or Fisher 
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Scientific and were used as received except anhydrous solvents which were freshly dried 
in the laboratory.  
2-Amino-4-methylthiophene-3-carbonitrile (346). A mixture of sulfur (3.2 g, 0.1 mol), 
acetone (5.8 g, 0.1 mol), malononitrile (6.6 g, 0.1 mol) and EtOH (100 mL) were placed 
in a round bottom flask and warmed to 45 
o
C and treated dropwise with morpholine (8.7 
g, 0.1 mol) over 15 min. The mixture was stirred for 4 h at 45 
o
C and 24 h at room 
temperature. Unreacted sulfur was removed by filtration, and the filtrate was 
concentrated under reduced pressure to afford a brown oil. The residue was loaded on a 
silica gel column packed with silica gel and eluted with 10% ethyl acetate in hexane to 
afford 346 (8.6 g, 63%) as a brown solid; Rf 0.52 (hexane/EtOAc 3:1); 
1
H NMR (CDCl3) 
 2.19 (s, 3 H, 4-CH3), 4.79 (s, 2 H, NH2 exch), 5.97 (s, 1 H, 5-CH).  
5-Methylthieno[2,3-d]pyrimidine-2,4-diamine (347).
 
 A mixture of 346 (0.55 g, 4 
mmol) and guanidine (1.8 g, 20 mmol) in DMSO (7 mL) was heated at 190 
o
C for 2 h. 
The reaction solution was evaporated in vacuo to dryness, and the residue was purified by 
column chromatography on silica gel with 5% MeOH in CHCl3 as the eluent to afford 
346 (0.46 g, 64%) as a brown solid; mp 205.2-205.6 
o
C, (lit.
10
 mp 210-212 
o
C); Rf 0.49 
(MeOH/CHCl3, 1:6); 
1
H NMR (DMSO-d6)  2.41 (s, 3 H, 5-CH3), 5.99 (s, 2 H, NH2 
exch), 6.39 (s, 2 H, NH2 exch), 6.49 (s, 1 H, 6-CH). This compound was used directly for 
next step of reaction without further characterization.  
General Procedure for the Synthesis of Compounds 285-294. 
Compounds 285-294 were synthesized from 347, appropriately substituted thiophenols 
and iodine. To a microwave reaction vial was added 347 (0.09 g, 0.5 mmol), benzenethiol 
(0.11 g, 1 mmol) and iodine (0.127 g, 0.5 mmol), and a mixture of ethanol/water (2:1, 5 
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mL). The reaction mixture was irradiated in a microwave apparatus at 180 
o
C for 20 min. 
After the reaction mixture was cooled to ambient temperature, the mixture was washed 
with saturated sodium thiosulfate solution (15 mL) and the mixture was concentrated 
under reduced pressure. The residue was loaded on a silica gel column packed with silica 
gel and eluted with 5% MeOH in CHCl3. The fractions containing the desired product 
(TLC) were pooled and evaporated to afford the product. 
5-Methyl-6-(phenylsulfanyl)thieno[2,3-d]pyrimidine-2,4-diamine (285). Compound 
285 (0.093 g, 64.9%) was obtained from 347 (0.09 g, 0.5 mmol), benzenethiol (0.11 g, 1 
mmol) and iodine (0.127 g, 0.5 mmol) as yellow solid; mp 238.6-239.1 
o
C; Rf 0.45 
(CHCl3/MeOH, 6: 1); 
1
H NMR (DMSO-d6)  2.51 (s, 3 H, 5-CH3), 6.25 (s, 2 H, NH2 
exch), 6.65 (s, 2 H, NH2 exch), 7.11-7.17 (d, 2 H, C6H5), 7.18, 7.19 (d, 1 H, C6H5), 7.27-
7.30 (d, 2 H, C6H5); Anal. calcd. for (C13H12N4S2): C, 54.14; H, 4.19; N, 19.43; S, 22.24; 
found: C, 53.93; H, 4.41; N, 19.09; S, 21.85. 
6-[(4-Methoxyphenyl)sulfanyl]-5-methylthieno[2,3-d]pyrimidine-2,4-diamine (286).   
Compound 286 (0.122 g, 77%) was obtained from 347 (0.09 g, 0.5 mmol), 4-methoxy- 
benzenethiol (0.14 g, 1 mmol) and iodine (0.127 g, 0.5 mmol) as yellow solid; mp 208.2-
208.5 
o
C, Rf 0.51 (CHCl3/MeOH, 6: 1); 
1
H NMR (DMSO-d6)  2.51(s, 3 H, 5-CH3), 3.68 
(s, 3 H, OCH3), 6.19 (s, 2 H, NH2 exch), 6.59 (s, 2 H, NH2 exch), 6.87-6.89 (d, 2 H, 
C6H4), 7.12-7.14 (d, 2 H, C6H4); Anal. calcd. for (C14H14N4OS2. 0.7 CH3OH): C, 51.79; 
H, 4.97; N, 16.44; S, 18.81; found: C, 52.0293; H, 4.62; N, 16.34; S, 18.49. 
6-[(2,6-Dimethylphenyl)sulfanyl]-5-methylthieno[2,3-d]pyrimidine-2,4-diamine 
(287).   
Compound 287 (0.063 g, 40%) was obtained from 347 (0.09 g, 0.5 mmol), 2,6-dimethyl- 
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benzenethiol (0.138 g, 1 mmol) and iodine (0.127 g, 0.5 mmol) as yellow solid; mp 
213.5-214.4 
o
C;  Rf 0.48 (CHCl3/MeOH, 6: 1); 
1
H NMR (DMSO-d6)  2.43 (s, 6 H, 2 
CH3), 2.54 (s, 3 H, CH3), 6.19 (s, 2 H, NH2 exch), 6.63 (s, 2 H, NH2 exch), 7.17 (br s, 3 
H, C6H3); Anal. calcd. for (C15H16N4S2 . 0.5 CH3OH): C, 55.99; H, 5.46; N, 16.85; S, 
19.29; found: C, 56.09; H, 5.25; N, 17.05; S, 19.19. 
6-[(3,4-Dimethylphenyl)sulfanyl]-5-methylthieno[2,3-d]pyrimidine-2,4-diamine 
(288).   
Compound 288 (0.093 g, 59%) was obtained from 347 (0.09 g, 0.5 mmol), 3,4-dimethyl- 
benzenethiol (0.138 g, 1 mmol) and iodine (0.127 g, 0.5 mmol) as yellow solid; mp 
223.8-224.6 
o
C; Rf 0.48 (CHCl3/MeOH, 6: 1); 
1
H NMR (DMSO-d6)  2.11 (s, 9 H, 3 
CH3), 6.19 (s, 2 H, NH2 exch), 6.58 (s, 2 H, NH2 exch), 6.57, 6.59 (d, 1 H, C6H3), 6.78 (s, 
1 H, C6H3), 7.03, 7.05 (d, 1 H, C6H3); Anal. calcd. for (C15H16N4S2. 0.4 CH3OH): C, 
56.17; H, 5.39; N, 17.01; S, 19.48; found: C, 56.48; H, 5.20; N, 16.82; S, 19.32. 
6-[(2,5-Dimethoxyphenyl)sulfanyl]-5-methylthieno[2,3-d]pyrimidine-2,4-diamine 
(289).   
Compound 289 (0.085 g, 49.1%) was obtained from 347 (0.09 g, 0.5 mmol), 2,5-
dimethoxybenzenethiol (0.17 g, 1 mmol) and iodine (0.127 g, 0.5 mmol) as yellow solid; 
mp 213.8-214.0 
o
C; Rf 0.51 (CHCl3/MeOH, 6: 1); 
1
H NMR (DMSO-d6)  2.45 (s, 3 H, 5-
CH3), 3.57 (s, 3 H, OCH3), 3.80 (s, 3 H,OCH3), 6.10 (s, 1 H, C6H3), 6.26 (s, 2 H, NH2 
exch), 6.66 (s, 2 H, NH2 exch), 6.70-6.72 (d, 1 H, C6H3), 6.93-6.94 (d, 1 H, C6H3); HRMS 
(EI) calcd for C15H16N4O2S2 348.0756, found 348.0754. 
6-[(3,4-Dimethoxyphenyl)sulfanyl]-5-methylthieno[2,3-d]pyrimidine-2,4-diamine 
(290).   
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Compound 290 (0.101 g, 58 %) was obtained from 347 (0.09 g, 0.5 mmol), 3,4-
dimethoxy-benzenethiol (0.17 g, 1 mmol) and iodine (0.127 g, 0.5 mmol) as yellow solid; 
mp182.8-183.6 
o
C; Rf 0.48 (CHCl3/MeOH, 6: 1); 
1
H NMR (DMSO-d6)  2.45 (s, 3 H, 5-
CH3), 3.68 (s, 6 H, 2 CH3), 6.19 (s, 2 H, NH2 exch), 6.62 (s, 2 H, NH2 exch), 6.66, 6.68 
(d, 1 H, C6H3), 6.80 (s, 1 H, C6H3), 6.89, 6.91 (d, 1 H, C6H3); Anal. calcd. for 
(C15H16N4O2S2. 0.5 CH3OH): C, 51.08; H, 4.98; N, 15.37; S, 17.59; found: C, 51.18; H, 
4.75; N, 15.44; S, 17.45. 
5-Methyl-6-[(3,4,5-trimethoxyphenyl)sulfanyl]thieno[2,3-d]pyrimidine-2,4-diamine 
(291).  Compound 291 (0.184 g, 69.3 %) was obtained from 347 (0.126 g, 0.7 mmol), 
3,4,5-trimethoxybenzenethiol (0.28 g, 1.4 mmol) and iodine (0.177 g, 0.7 mmol) as white 
solid; mp 245.8-246.5 
o
C; Rf 0.53 (CHCl3/MeOH, 6: 1); 
1
H NMR (DMSO-d6)  2.47 (s, 3 
H, 5-CH3), 3.58 (s, 3 H, OCH3), 3.70 (s, 6 H, 2 OCH3), 6.19 (s, 2 H, NH2 exch), 6.38 (s, 2 
H, C6H2), 6.61 (s, 2 H, NH2 exch); Anal. calcd. for (C16H18N4O3S2): C, 50.78; H, 4.79; N, 
14.80; S, 16.94; found: C, 50.69; H, 4.95; N, 14.59; S, 16.75. 
5-Methyl-6-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidine-2,4-diamine (292).  
Compound 292 (0.087 g, 57.3%) was obtained from 347 (0.1  g, 0.55 mmol), 4-nitro-
benzenethiol (0.17 g, 1.1 mmol) and iodine (0.14 g, 0.55 mmol) as yellow solid; mp  292-
293 
o
C; Rf 0.50 (CHCl3/MeOH, 6: 1); 
1
H NMR (DMSO-d6)  2.45 (s, 3 H, 5-CH3), 6.36 
(s, 2 H, NH2 exch), 6.74 (s, 2 H, NH2 exch),  7.32, 7.34 (d, 2 H, C6H4), 8.17, 8.19 (d, 2 H, 
C6H4); Anal. calcd. for (C13H11N5O2S2 . 0.2 CH3OH): C, 46.66; H, 3.50; N, 20.61; S, 
18.87; found: C, 46.49; H, 3.54; N, 20.55; S, 18.70. 
6-[(3,4-Dichlorophenyl)sulfanyl]-5-methylthieno[2,3-d]pyrimidine-2,4-diamine 
(293).  Compound 293 (0.196 g, 78.5 %) was obtained from 347 (0.126  g, 0.7 mmol), 
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3,4-dichlorobenzenethiol (0.25 g, 1.4 mmol) and iodine (0.177 g, 0.7 mmol) as yellow 
solid; mp 238.6-238.9 
o
C; Rf 0.51 (CHCl3/MeOH, 6: 1); 
1
H NMR (DMSO-d6)  2.41 (s, 3 
H, 5-CH3), 6.21 (s, 2 H, NH2 exch), 6.61 (s, 2 H, NH2 exch ),  6.93 (s, 1 H C6H3), 7.24 (s, 
1 H, C6H3), 7.43 (s, 1 H, C6H3); Anal. calcd. for (C13H10Cl2N4S2): C, 43.70; H, 2.82; N, 
15.68; S, 17.95;Cl, 19.84; found: C, 43.64; H, 2.93; N, 15.48; S, 17.68; Cl, 20.01. 
 5-Methyl-6-(1-naphthylsulfanyl)thieno[2,3-d]pyrimidine-2,4-diamine (294). 
Compound 294 (0.055 g, 74 %) was obtained from 347 (0.04 g, 0.22 mmol), 
naphthalene-1-thiol (0.07 g, 0.44 mmol) and iodine (0.056 g, 0.22 mmol) as yellow solid; 
mp 233.8-234.4 
o
C; Rf 0.54 (CHCl3/MeOH, 5: 1); 
1
H NMR (DMSO-d6)  2.54 (s, 3 H, 5-
CH3), 6.26 (s, 2 H, NH2 exch), 6.67 (s, 2 H, NH2 exch), 7.05, 7.07 (d, 1 H, C10H7), 7.41-
7.45 (t, 1 H, C10H7), 7.59-7.67 (m, 2 H, C10H7), 7.78, 7.80 (d, 1 H, C10H7), 7.96, 7.99 (d, 
1 H, C10H7), 8.23, 8.26 (d, 1 H, C10H7); HRMS (EI) calcd for C17H14N4S2 338.0659, 
found 338.0658. 
General Procedure for the Synthesis of Compounds 359, 365. 
 
A mixture of sulfur (1 mmol), the appropriate ketone (1 mmol), ethyl cyanoactetate (1 
mmol) and EtOH (5 mL) were placed in a round bottom flask and warmed to 45 
o
C and 
treated dropwise with morpholine (1 mmol) over 15 min. The mixture was stirred for 5 h 
at 45 
o
C and 24 h at room temperature. Unreacted sulfur was removed by filtration, and 
the filtrate was concentrated under reduced pressure to afford an orange oil. The residue 
was loaded on a silica gel column packed with silica gel and eluted with 10% ethyl 
acetate in hexane. The fractions containing the desired product (TLC) were pooled and 
evaporated to afford the products. 
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Ethyl 2-amino-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate (365). Compound 
365 (10.12 g, 89.8 %) was obtained as an yellow solid by reacting cyclohexanone (5.6 g, 
50 mmol) with sulfur (1.6 g, 50 mmol) and ethyl cyanoactetate (5.65 g, 50 mmol) as 
described in the General Procedure above; mp 111.6-111.9 
o
C; Rf 0.43 (hexane/EtOAc 
3:1);
 1
H NMR (DMSO-d6): δ 1.23-1.26 (t, 3 H, COOCH2CH3), 1.67-1.71 (m, 4 H), 2.41-
2.43 (t, 2 H), 2.58-2.61 (t, 2 H), 4.12-4.17 (q, 2 H, COOCH2CH3), 7.20 (s, 2 H, NH2 
exch). This compound was used directly for next step of reaction without further 
characterization. 
Ethyl 2-amino-4-methyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate (359). 
Compound 359 (6.97 g, 80.9 %) was obtained as an orange solid by reacting 2-
methylcyclohexanone (4.04 g, 36 mmol) with sulfur (1.1 g, 36 mmol) and ethyl 
cyanoactetate (4.07 g, 36 mmol) as described in the General Procedure above; mp 69.9-
71 
o
C; Rf 0.44 (hexane/EtOAc 3:1);
 1
H NMR (DMSO-d6): δ 1.08-1.10 (d, 3 H, 2-CH3), 
1.25-1.28 (t, 3 H, COOCH2CH3), 1.57-1.78 (m, 4 H), 2.39-2.43 (m, 2 H), 3.15-3.17 (m, 1 
H), 4.10-4.24 (q, 2 H, COOCH2CH3), 7.23 (s, 2 H, NH2 exch). 
General Procedure for the Synthesis of Compounds 360 and 366. 
 
A mixture of 359 or 365 (1 g), 10 % Pd-C (1 g) and toluene (30 mL) were placed in a 
round bottom flask and refluxed for 1-2 days. The mixture was cooled to room 
temperature and Pd-C was removed by filtration, and the filtrate was concentrated under 
reduced pressure to afford an brown oil. The residue was loaded on a silica gel column 
packed with silica gel and eluted with 10% ethyl acetate in hexane. The fractions 
containing the desired product (TLC) were pooled and evaporated to afford the products. 
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Ethyl 2-amino-1-benzothiophene-3-carboxylate (366). Compound 366 (1.84 g, 82.3 %) 
was obtained as an light yellow solid by reacting 365 (2.25 g, 9.98 mmol) with 10 % Pd-
C (2.25 g) as described in the General Procedure above; mp 107.5-108.2 
o
C; Rf 0.37 
(hexane/EtOAc 3:1);
 1
H NMR (DMSO-d6): δ 1.34-1.37 (t, 3 H, COOCH2CH3), 4.29-4.33 
(q, 2 H, COOCH2CH3), 7.05- 7.08 (m, 1 H, C6H4), 7.24- 7.27 (m, 1 H, C6H4), 7.60, 7.62 
(d, 1 H, C6H4), 7.97, 7.98 (d, 1 H, C6H4), 7.97 (s, 2 H, NH2 exch); Anal. calcd. for 
(C11H11NO2S): C, 59.71; H, 5.01; N, 6.33; S, 14.49; found: C, 59.60; H, 5.01; N, 6.25; S, 
14.40 
Ethyl 2-amino-4-methyl-1-benzothiophene-3-carboxylate (360). Compound 360 
(0.123 g, 52.1%) was obtained as an orange semi solid by reacting 359 (0.239 g, 1 mmol) 
with 10 % Pd-C (0.239 g) as described in the General Procedure above (use mesitylene as 
solvent); Rf 0.38 (hexane/EtOAc 3:1);
 1
H NMR (DMSO-d6): δ 1.29-1.32 (t, 3 H, 
COOCH2CH3), 2.38 (s, 3 H, CH3), 4.25-4.30 (q, 2 H, COOCH2CH3), 6.98-7.04 (m, 2 H, 
C6H3), 7.44, 7.45 (d, 1 H, C6H3), 7.43 (s, 2 H, NH2 exch). 
General Procedure for the Synthesis of Compounds 351 and 350. 
A mixture of appropriate thiophene and chloroformamidine hydrochloride (1:4) in 
DMSO2 was heated at 140 C for 4 h.   The mixture was cooled to room temperature and 
water (15 mL) was added and ammonium hydroxide was used to neutralize the 
suspension. The brown solid, obtained by filtration, was washed with water and dried 
over P2O5 vacuum. The solid was dissolved in methanol and silica gel was added. A dry 
silica gel plug was obtained after evaporation of the solvent. The plug was loaded on to a 
silica gel column and eluted with 5% methanol in chloroform. The fractions containing 
the desired product (TLC) were pooled and evaporated to afford the products. 
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2-Amino-5-methyl-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one 
(351). Compound 351 (0.46 g, 59.7%) was obtained as a light yellow solid by reacting 
359 (0.74 g, 3.28 mmol) with chloroformamidine hydrochloride (1.51 g, 13.12 mmol) in 
DMSO2 (4 g) as described in the General Procedure above.mp > 299.3-300 °C; Rf 0.5 
(MeOH/CHCl3, 1:6); 
1
H NMR (DMSO-d6)  1.18-1.20 (d, 3 H, CH3), 1.59-1.61 (m, 1 H), 
1.71-1.83 (m, 3 H), 2.54-2.64 (m, 2 H), 3.15-3.18 (m, 1 H), 6.39 (s, 2 H, 2-NH2 exch), 
10.73 (s, 1 H, 3-NH exch); Anal. calcd. for (C11H13N3SO · 0.2 H2O): C, 55.30; H, 5.65; 
N, 17.59; S, 13.42; found: C, 55.19; H, 5.65; N, 17.33; S, 13.17. 
2-Amino-5-methyl[1]benzothieno[2,3-d]pyrimidin-4(3H)-one (350). Compound 350 
(0.29 g, 60.7 %) was obtained as a yellow solid by reacting 360 (0.49 g, 2.07 mmol) with 
chloroformamidine hydrochloride (1.19 g, 10.37 mmol) in DMSO2 (2 g) as described in 
the General Procedure above.mp > 300 °C; Rf 0.41 (MeOH/CHCl3, 1:6); 
1
H NMR 
(DMSO-d6)  2.87 (s, 3 H, CH3), 6.82 (s, 2 H, 2-NH2 exch), 7.13- 7.17 (m, 2 H, C6H3), 
7.57, 7.59 (d, 1 H, C6H3), 10.92 (s, 1 H, 3-NH exch).  
2,2-Dimethyl-N-(5-methyl-4-oxo-3,4-dihydro[1]benzothieno[2,3-d]pyrimidin-2-
yl)propanamide (364). To a 100 mL round-bottomed flask was added 350 (1.34 g, 5.8 
mmol) and excess Piv2O (4 eq). The mixture was refluxed for 2 h. The silica gel plug 
obtained was loaded onto a silica gel column and eluted with 1:8 ethyl acetate/n-hexane 
to afford 364 (1.299 g, 70.9 %) as a white solid, mp 178.3-179.5 °C; Rf 0.35 
(hexane/EtOAc 3:1); 
1
H NMR (CDCl3) δ 1.35 (s, 9 H, 3 CH3 of Piv), 3.05 (s, 3 H, 5-
CH3), 7.28 (m, 2 H, C6H3), 7.56, 7.59 (d, 1 H, C6H3), 8.14 (s, 1 H, NH exch), 11.86 (s, 1 
H, NH exch). 
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2,2-Dimethyl-N-(5-methyl-4-oxo-3,4-dihydro[1]benzothieno[2,3-d]pyrimidin-2-
yl)propanamide (362) A solution of  364 (1.1 g, 3.49 mmol) in 1,2- dichloroethane (50 
mL) was treated with N-bromosuccinimide (0.62 g, 3.49 mmol) and benzoyl peroxide (50 
mg), and the mixture was refluxed for 1 day. The mixture was cooled to room 
temperature and washed with water, and evaporated to an orange solid. The solid was 
dissolved in methanol and silica gel was added. A dry silica gel plug was obtained after 
evaporation of the solvent. The plug was loaded on to a silica gel column and eluted with 
6 % ethyl acetate in hexane to afford 362 (0.577 g, 41.9 %) as a orange solid; mp 217.8-
219.1 °C;  Rf 0.3 (hexane/EtOAc 3:1); 
1
H NMR (CDCl3)  1.27 (s, 9 H, 3 CH3 of Piv), 
5.71 (s, 2 H, CH2Br), 7.30, 7.33 (d, 1 H, C6H3), 7.43, 7.46 (d, 1 H, C6H3), 7.64, 7.66 (d, 1 
H, C6H3), 8.07 (s, 1 H,  NH exch), 11.99 (s, 1 H,  NH exch). This compound was used 
directly for next step of reaction without further characterization. 
Methyl 2-methyl-4-nitrobenzoate (358). Thionyl chloride (4.3 g, 36.45 mmol) was 
added dropwise to a stirred solution of 369 (3 g, 16.57 mmol) in MeOH (25 mL) while 
maintaining the internal temperature below 12 
o
C. When addition was complete the mixture 
was left to stand at room temperature for 12h to obtain white solid. And the filtrate was 
concentrated under reduced pressure to afford white solid. The solid was   washed with 
hexane and ethyl ether to afford 358 (2.95 g, 91.3 %); mp 153.7-154.4 °C (lit.
39
 mp 153-
154 °C); Rf 0.43 (hexane/EtOAc 3:1); 
1
H NMR (CDCl3)  2.69 (s, 3 H, CH3), 3.95 (s, 3 H, 
COOCH3), 8.02-8.11 (m, 3 H, C6H3). 
Methyl 2-(bromomethyl)-4-nitrobenzoate (357). A solution of 358 (2.57 g, 13.19 
mmol) in 1,2-dichloroethane (100 mL) was treated with N-bromosuccinimide (2.3 g, 
13.19 mmol) and benzoyl peroxide (0.26 g), and the mixture was refluxed for 2 days, 
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then cooled, washed with water, and evaporated to an yellow oil (3.52 g). The oil was 
dissolved in acetone and silica gel was added. A dry silica gel plug was obtained after 
evaporation of the solvent. The plug was loaded on to a silica gel column and eluted with 
10 % ethyl acetate in hexane to afford 357 (1.73 g, 48.2 %) as a yellow oil; Rf 0.53 
(hexane/EtOAc 3:1); 
1
H NMR (CDCl3)  3.89 (s, 3 H, COOCH3), 4.86 (s, 2 H, CH2Br), 
7.98-8.23 (m, 3 H, C6H3). This compound was used directly for next step of reaction 
without further characterization. 
Diethyl (2S)-2-(5-nitro-1-oxo-1,3-dihydro-2H-isoindol-2-yl)pentanedioate (356). The 
oil 357 (0.85 g, 3.1 mmol) was stirred for 16 h with diethyl glutamate hydrochloride 
(1.54 g, 6.4 mmol) and powdered K2CO3 (1.7 g, 12 mmol) in DMA (3 mL) under argon. 
The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3 X 20 
mL). The combined EtOAc solutions were washed twice with brine, dried, and 
evaporated to an orange oil. The oil was dissolved in methanol and silica gel was added. 
A dry silica gel plug was obtained after evaporation of the solvent. The plug was loaded 
on to a silica gel column and eluted with 25 % ethyl acetate in hexane to afford to afford 
356 (0.63 g, 55.7 %) as a orange oil; Rf 0.44 (hexane/EtOAc 1:1); 
1
H NMR (CDCl3)  
1.17-1.22 (t, 3 H, COOCH2CH3), 1.26-1.31 (t, 3 H, COOCH2CH3), 2.19-2.49 (m, 4 H, 
CHCH2CH2COOEt), 4.02-4.23 (2q, 4 H, COOCH2CH3),  4.51-4.83 (dd, 2 H, -CH2-), 
5.09-5.14 (m, 1 H, CHCH2CH2COOEt), 8.00-8.03 (d, 1 H, C6H3), 8.36 (br s, 2 H, C6H3). 
This compound was used directly for next step of reaction without further 
characterization. 
Diethyl (2S)-2-(5-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)pentanedioate (355). To 
a Parr hydrogenation bottle was added 356 (0.55 g, 1.51 mmol), 10% Pd/C (0.09 g) and 
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EtOAc (30 mL). Hydrogenation was carried out at 55 psi for 12 h. After filtration, the 
organic phase was evaporated at vacuum to afford 355 (0.467 g, 92.5 %) as a orange oil; 
Rf 0.19 (hexane/EtOAc 1:1); 
1
H NMR (CDCl3)  1.17-1.19 (t, 3 H, COOCH2CH3), 1.20-
1.25 (t, 3 H, COOCH2CH3), 2.20-2.51 (m, 4 H, CHCH2CH2COOEt), 4.02-4.28 (m, 6 H, 2 
COOCH2CH3, NH2 exch),  4.22-4.51 (dd, 2 H, -CH2-), 5.03-5.07 (m, 1 H, 
CHCH2CH2COOEt), 6.69-6.73 (m, 2 H, C6H3), 7.60, 7.63 (d, 1 H, C6H3). This compound 
was used directly for next step of reaction without further characterization. 
Diethyl (2S)-2-{5-[({2-[(2,2-dimethylpropanoyl)amino]-4-oxo-3,4dihydro[1] 
benzothieno[2,3-d]pyrimidin-5-yl}methyl)amino]-1-oxo-1,3-dihydro-2H-isoindol-2-
yl}pentanedioate (370). A stirred solution of 362 (0.18 g, 0.46 mmol) in dry DMF (5 
mL) was treated with 355 (0.31 g, 0.91 mmol) and K2CO3 (0.095 g, 0.69 mmol) was 
stirred for 1 h at 80 °C under argon. The cooled reaction mixture was filtered and the 
filtrate was evaporated to obtain orange solid. The solid was dissolved in methanol and 
silica gel was added. A dry silica gel plug was obtained after evaporation of the solvent. 
The plug was loaded on to a silica gel column and eluted with ethyl acetate: hexane (1: 1) 
to afford 370 (0.112 g, 37.7 %) as a yellow solid; Rf 0.19 (hexane/EtOAc 1:1). It was 
used directly in the next step. 
(2S)-2-(5-{[(2-amino-4-oxo-3,4-dihydro[1]benzothieno[2,3-d]pyrimidin-5-yl)methyl 
]amino}-1-oxo-1,3-dihydro-2H-isoindol-2-yl)pentanedioic acid (301). To a 50 mL 
round flask was added s 370 (0.112 g, 0.173 mmol), aqueous 1 N NaOH (3 mL) and 
methanol (12 mL). The mixture was refluxed for 12 h. The methanol was evaporated 
under reduced pressure and the residue was dissolved in water (5 mL). The solution was 
cooled to 0
 o
C and carefully acidified to pH 3 with drop wise addition of 1 N HCl. The 
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resulting suspension was left at 0
 o
C for 2 h and the residue was collected by filtration. 
Washed with water (5 mL) and dried over P2O5/vacuum at 50
 o
C to afford 301 (0.03 g, 34 
%) as a orang solid; Rf 0.33 (MeOH/CHCl3, 1:6 + 1 drop of gl. HOAc);
 1
H NMR 
(DMSO-d6): δ 1.97-2.20 (m, 4 H, Gluβ-CH2, Gluγ-CH2), 4.21-4.25 (m, 2 H, isoindolinyl 
CH2), 4.68-4.71 (m, 1 H, Gluα-CH), 5.13, 5.14 (d, 2 H, Benzylic CH2), 6.64 (br s, 2 H, 
C6H3), 6.74 (s, 1 H, NH exch), 6.89 (s, 2 H, 2-NH2 exch), 7.20-7.26 (t, 1 H, C6H3), 7.30-
7.33 (d, 1 H, C6H3), 7.39-7.42 (dd, 1 H, C6H3), 7.69-7.72 (d, 1 H, C6H3), 11.11 (s, 1 H, 3-
NH exch), 12.78 (s, 2 H, 2COOH exch). HRMS (ESI, pos mode) m/z [M + H]
+
 calcd for 
C24H21N5O6S, 508.1285; found, 508.1321. 
Ethyl 2-amino-5-isopropylthiophene-3-carboxylate (372). A mixture of sulfur (1.92 g, 
60 mmol), isovaleraldehyde (5.17 g, 60 mmol), ethyl cyanoactetate (6.78 g, 60 mmol) 
and EtOH (100 mL) were placed in a round bottom flask and warmed to 45 
o
C and 
treated dropwise with morpholine (5.23 g, 60 mmol) over 15 min. The mixture was 
stirred for 4 h at 45 
o
C and 24 h at room temperature. Unreacted sulfur was removed by 
filtration, and the filtrate was concentrated under reduced pressure to afford an orange oil. 
The residue was loaded on a silica gel column packed with silica gel and eluted with 10 
% ethyl acetate in hexane to afford 372 (9.97 g, 78%) as a orange solid; Rf 0.66 
(hexane/EtOAc 3:1); 
1
H NMR (CDCl3)  1.24-1.25 (d, 6 H, CH (CH3)2), 1.32-1.35 (t, 3 
H, COOCH2CH3), 2.86-2.97 (m, 1 H, CH (CH3)2), 4.23-4.28 (q, 2 H, COOCH2CH3), 5.78 
(s, 2 H, NH2 exch), 6.63 (s, 1 H, 4-H); HRMS (EI) calcd for C10H15NO2S m/z = 213.0823, 
found m/z = 213.0828. 
2-Amino-6-isopropylthieno[2,3-d]pyrimidin-4(3H)-one (373). A mixture of 372 (2.2 g, 
10.3 mmol) and chloroformamidine hydrochloride (4.7 g, 41 mmol) in DMSO2 (15 g, 
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153 mmol) was heated at 150 
o
C for 2 h. The mixture was cooled to room temperature 
and water (30 mL) was added and ammonium hydroxide was used to neutralize the 
suspension. The brown solid, obtained by filtration, was washed with water and dried 
over P2O5 vacuum. The solid was dissolved in methanol and silica gel was added. The 
plug was loaded on to a silica gel column and eluted with 5% methanol in chloroform to 
afford 373 (1.88 g, 87%) as a yellow solid; mp > 300 
o
C; Rf 0.25 (MeOH/CHCl3, 1:6); 
1
H 
NMR (DMSO-d6)  1.23-1.25 (d, 6 H, CH (CH3)2), 2.99-3.06 (m, 1 H, CH (CH3)2). 6.46 
(s, 2 H, 2-NH2 exch), 6.78 (s, 1 H, 5-H), 10.81 (s, 1 H, 3-NH exch); Anal. (C9H11N3SO) 
C, H, N, S 
Methyl 4-sulfanylbenzoate (381). Thionyl chloride (2.64 g, 22 mmol) was added 
dropwise to a stirred solution of 4-mercaptobenzoic acid (1.54 g, 10 mmol) in MeOH (20 
mL) while maintaining the internal temperature below 12 
o
C. When addition was 
complete the mixture was left to stand at room temperature for 12 h to obtain yellow 
solid. And the filtrate was concentrated under reduced pressure to afford yellow solid. 
The solid was washed with hexane and ethyl ether to afford 381 (1.577 g, 93.7%) as light 
yellow solid; mp 99.7-101.5 
o
C; Rf 0.58 (hexane/EtOAc 3:1); 
1
H NMR (CDCl3)  3.60 (s, 
1 H, SH, exch ), 3.89 (s, 3 H, COOCH3), 7.27, 7.30 (d, 2 H, C6H4 ), 7.87, 7.90 (d, 2 H, 
C6H4).  
2-Amino-5-iodo-6-isopropylthieno[2,3-d]pyrimidin-4(3H)-one (375). To a mixture of 
373 (2.5 g, 11.9 mmol) in glacial acetic acid (60 mL) was added mercuric acetate (5.69 g, 
17.93 mmol) at room temperature. The mixture was heated at 100 
o
C for 3 h. Then the 
mixture was poured into a brine solution (60 mL) and stirred for 30 min. The yellow solid 
376 (4.2 g, 78.9%) obtained by filtration was washed with water and hexane and dried 
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over P2O5 vacuum; mp 252.7 
o
C. Compound 376 (3.5 g, 7.8 mmol) was dissolved in 
CH2Cl2 (100 mL) and I2 (3.85 g, 15.2 mmol) was added. The reaulting mixture attired for 
5 h at room temperature. The mixture was washed with 2 N NaS2O3 and dried via 
MgSO4. The plug was loaded on to a silica gel column and eluted with 3% methanol in 
chloroform to afford 375 (2.25g, 86%) as a yellow solid; mp 252.7 
o
C; Rf 0.26 
(MeOH/CHCl3, 1:10); 
1
H NMR (DMSO-d6)  1.20-1.22 (d, 6 H, CH (CH3)2), 3.23-3.30 
(m, 1 H, CH (CH3)2). 6.57 (s, 2 H, 2-NH2 exch), 10.90 (s, 1 H, 3-NH exch); Anal. calcd. 
for (C9H10IN3SO): C, 32.25; H, 3.01; N, 12.54; S, 9.57; I, 37.86; found: C, 32.35; H, 
2.97; N, 12.37; S, 9.48; I, 37.69. 
General procedure for the synthesis of compounds 305-311 and 382. 
A mixture of appropriate arylthiols (1.5 eq), K2CO3 (1.5 eq), CuI (1.3 eq) and 375 (1 eq) 
in dry DMF (5 mL) was irradiated in a microwave at 100 °C for 60-120 min. After the 
reaction mixture was cooled to room temperature, the mixture was filtered; the filtrate 
was concentrated under reduced pressure. The solid was dissolved in methanol and silica 
gel was added. A dry silica gel plug was obtained after evaporation of the solvent. The 
plug was loaded on to a silica gel column and eluted with 2 % methanol in chloroform. 
2-Amino-4-oxo-6-isopropyl-5-phenylsulfanylthieno[2,3-d]pyrimidine (305). Using the 
general procedure above compound 305 (0.13 g, 82.3 %) was obtained as a brown solid 
by reacting 375 (0.167 g, 0.5 mmol), benzenethiol (0.083 g, 0.75 mmol), K2CO3 (0.103 g, 
0.75 mmol) and CuI (0.12 g, 0.65 mmol) in DMF (5 mL) was irradiated in a microwave 
at 100 °C for 60 min. Rf 0.38 (MeOH/CHCl3, 1:6); mp 269.8-270.2 °C; 
1
H NMR 
(DMSO-d6)  1.17-1.19 (d, 6 H, CH (CH3)2), 3.57-3.65 (m, 1 H, CH (CH3)2). 6.59 (s, 2 
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H, 2-NH2 exch), 6.98-7.24 (m, 5 H, C6H5 ), 10.74 (s, 1 H, 3-NH exch); HRMS (EI) calcd 
for C15H15N3OS2 m/z [M + H]
+
  = 318.0735, found m/z = 318.0739.  
2-Amino-6-isopropyl-5-[(4-nitrophenyl)sulfanyl]thieno[2,3-d]pyrimidin-4(3H)-one 
(306). Using the general procedure above compound 306 (0.108 g, 75.4 %) was obtained 
as a yellow solid by reacting 375 (0.134 g, 0.4 mmol), 4-nitrobenzenethiol (0.093 g, 0.6 
mmol), K2CO3 (0.083 g, 0.6 mmol) and CuI (0.099 g, 0.52 mmol) in DMF (5 mL) was 
irradiated in a microwave at 100 °C for 120 min. Rf  0.41 (MeOH/CHCl3, 1:6); mp 148.8-
149.3 °C; 
1
H NMR (DMSO-d6)  1.20-1.22 (d, 6 H, CH (CH3)2), 3.52-3.58 (m, 1 H, CH 
(CH3)2), 6.65 (s, 2 H, 2-NH2 exch), 7.17-7.19 (d, 2 H, C6H4), 8.07-8.09 (d, 2 H, C6H4), 
10.80 (s, 1 H, 3-NH exch); HRMS (EI) calcd for C15H14N4O3S2 m/z = 362.0507, found 
m/z = 362.0516.  
2-Amino-5-[(3,4-dichlorophenyl)sulfanyl]-6-isopropylthieno[2,3-d]pyrimidin-4(3H)-
one (307). Using the general procedure above compound 307 (0.172 g, 89.1 %) was 
obtained as a yellow solid by reacting 375 (0.167 g, 0.5 mmol), 3,4-dichlorobenzenethiol 
(0.134 g, 0.75 mmol), K2CO3 (0.103 g, 0.75 mmol) and CuI (0.124 g, 0.65 mmol) in 
DMF (5 mL) was irradiated in a microwave at 100 °C for 60 min. Rf 0.41 (MeOH/CHCl3, 
1:6); mp 205 °C; 
1
H NMR (DMSO-d6)  1.19-1.21 (d, 6 H, CH (CH3)2), 3.54-3.61 (m, 1 
H, CH (CH3)2), 6.65 (s, 2 H, 2-NH2 exch), 6.90, 6.92 (dd, 1 H, C6H3), 7.24 (s, 1 H, C6H3), 
7.46, 7.48 (d, 1 H, C6H3), 10.79 (s, 1 H, 3-NH exch);Anal. calcd. for (C15H13Cl2N3S2O · 
0.3 CH3OH): C, 46.41; H, 3.61; N, 10.61; S, 16.20; Cl, 17.91; found: C, 46.02; H, 3.43; 
N, 10.30; S, 16.41; Cl, 17.99. 
2-Amino-6-isopropyl-5-(1-naphthylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one (308). 
Using the general procedure above compound 308 (0.137 g, 74.9 %) was obtained as a 
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brown solid by reacting 375 (0.167 g, 0.5 mmol), naphthalene-1-thiol (0.12 g, 0.75 
mmol), K2CO3 (0.103 g, 0.75 mmol) and CuI (0.124 g, 0.65 mmol) in DMF (5 mL) was 
irradiated in a microwave at 100 °C for 90 min. Rf 0.34 (MeOH/CHCl3, 1:10); mp 243.7-
244 °C; 
1
H NMR (DMSO-d6)  1.17-1.19 (d, 6 H, CH (CH3)2), 3.59-3.62 (m, 1 H, CH 
(CH3)2), 6.61 (s, 2 H, 2-NH2 exch), 6.76, 6.78 (d, 1 H, C10H7), 7.29-7.33 (t, 1 H, C10H7), 
7.57-7.67 (m, 3 H, C10H7), 7.92, 7.94 (d, 1 H, C10H7), 8.20, 8.22 (d, 1 H, C10H7), 10.73 (s, 
1 H, 3-NH exch); HRMS (EI) calcd for C19H17N3OS2 m/z = 367.0812, found m/z = 
367.0813. 
2-Amino-6-isopropyl-5-(2-naphthylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one (309). 
Using the general procedure above compound 309 (0.152 g, 83.1 %) was obtained as a 
brown solid by reacting 375 (0.167 g, 0.5 mmol), naphthalene-2-thiol (0.12 g, 0.75 
mmol), K2CO3 (0.103 g, 0.75 mmol) and CuI (0.124 g, 0.65 mmol) in DMF (5 mL) was 
irradiated in a microwave at 100 °C for 90 min. Rf 0.38 (MeOH/CHCl3, 1:10); mp 180-
180.6 °C; 
1
H NMR (DMSO-d6)  1.19-1.21 (d, 6 H, CH (CH3)2), 3.62-3.69 (m, 1 H, CH 
(CH3)2), 6.61 (s, 2 H, 2-NH2 exch), 7.15, 7.17 (d, 1 H, C10H7), 7.42-7.45 (m, 3 H, C10H7), 
7.72-7.82 (m, 3 H, C10H7), 10.73 (s, 1 H, 3-NH exch); HRMS (EI) calcd for C19H17N3OS2 
m/z = 367.0813, found m/z = 367.0813. 
2-Amino-5-[(4-fluorophenyl)sulfanyl]-6-isopropylthieno[2,3-d]pyrimidin-4(3H)-one 
(310). Using the general procedure above compound 310 (0.147 g, 88 %) was obtained as 
a yellow solid by reacting 375 (0.167 g, 0.5 mmol), 4-fluorobenzenethiol (0.096 g, 0.75 
mmol), K2CO3 (0.103 g, 0.75 mmol) and CuI (0.124 g, 0.65 mmol) in DMF (5 mL) was 
irradiated in a microwave at 100 °C for 90 min. Rf 0.31 (MeOH/CHCl3, 1:10); mp 282.2-
282.4 °C; 
1
H NMR (DMSO-d6)  1.18-1.20 (d, 6 H, CH (CH3)2), 3.61-3.69 (m, 1 H, CH 
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(CH3)2), 6.60 (s, 2 H, 2-NH2 exch), 7.11-7.14 (m, 4 H, C6H4), 10.75 (s, 1 H, 3-NH exch); 
HRMS (EI) calcd for C15H14N3OS2F m/z = 355.0562, found m/z = 355.0559. 
2-Amino-5-[(4-methoxyphenyl)sulfanyl]-6-isopropylthieno[2,3-d]pyrimidin-4(3H)-
one (311). Using the general procedure above compound 311 (0.159 g, 91.4 %) was 
obtained as a light yellow solid by reacting 375 (0.167 g, 0.5 mmol), 4-methoxy 
benzenethiol (0.105 g, 0.75 mmol), K2CO3 (0.103 g, 0.75 mmol) and CuI (0.124 g, 0.65 
mmol) in DMF (5 mL) was irradiated in a microwave at 100 °C for 90 min. Rf 0.29 
(MeOH/CHCl3, 1:10); mp 241.6-242 °C; 
1
H NMR (DMSO-d6)  1.19 (m, 6 H, CH 
(CH3)2), 3.68 (br s, 4 H, OCH3 and CH (CH3)2), 6.58 (s, 2 H, 2-NH2 exch), 6.83 (br s, 2 
H, C6H4), 7.06 (br s, 2 H, C6H4),  10.75 (s, 1 H, 3-NH exch); Anal. calcd. for 
(C16H17N3S2O2 ·0.4 H2O): C, 54.18; H, 5.06; N, 11.85; S, 18.08; found: C, 54.25; H, 
4.81; N, 11.55; S, 17.85. 
 
4-(2-Amino-6-isopropyl-4-oxo-3,4-dihydro-thieno[2,3-d]pyrimidine-5-ylsulfanyl)-
benzoic acid methyl ester (382). To a suspension of 375 (0.24 g, 0.72 mmol), i-Pr2Net 
(0.18 g, 1.44 mmol) and DMF (5 mL) was added catalyst Pd2dba3 (0.016 g, 0.017 mmol), 
Xantphos (0.024 g, 0.034 mmol) and methyl 4-mercaptobenzoate (0.24 g, 1.44 mmol). 
The mixture was degassed twice and backfilled with nitrogen. The reaction mixture was 
irradiated in a microwave at 190 °C for 1 h. After the reaction mixture was cooled to 
room temperature, the mixture was filtered. The filtrate was concentrated under reduced 
pressure. The solid was dissolved in methanol and silica gel was added. A dry silica gel 
plug was obtained after evaporation of the solvent. The plug was loaded on to a silica gel 
column and eluted with 2 % methanol in chloroform and 382 (0.17 g, 64 %) was obtained 
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as a white solid. Rf 0.34 (MeOH/CHCl3, 1:6); mp 220.4-220.8 °C; 
1
H NMR (DMSO-d6)  
1.18-1.20 (d, 6 H, CH (CH3)2), 3.52-3.59 (m, 1 H, CH (CH3)2), 3.80 (s, 3 H, COOCH3), 
6.62 (s, 2 H, 2-NH2 exch), 7.06, 7.08 (d, 2 H, C6H4), 7.78, 7.80 (d, 2 H, C6H4), 10.77 (s, 1 
H, 3-NH exch); HRMS (EI) calcd for C17H17N3O3S2 m/z [M + Na]
+
 = 398.0609, found 
m/z = 398.0591.  
4-[(2-Amino-6-isopropyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-
yl)sulfanyl]benzoic acid (383). To a solution of 382 (0.08 g, 0.21 mmol) in ethanol (20 
mL) was added aqueous 1 N NaOH (10 mL) and the reaction mixture stirred at room 
temperature for 12 h. The ethanol was evaporated under reduced pressure and the residue 
was dissolved in water (5 mL). The solution was carefully acidified to pH 3 with the drop 
wise addition of 1 N HCl. The resulting suspension was left at 0 
o
C for an hour and then 
the residue was collected by filtration, washed with water (5 mL) and dried over P2O5 
under vacuum at 50 
o
C to afford 383 (0.075 g, 97.7 %) as a white solid. Rf 0.43 
(MeOH/CHCl3, 1: 6+ 1 drop of gl. HOAc); mp >350 °C; 
1
H NMR (DMSO-d6)  1.18-
1.20 (d, 6 H, CH (CH3)2), 3.53-3.60 (m, 1 H, CH (CH3)2), 6.64 (s, 2 H, 2-NH2 exch), 
7.03, 7.05 (d, 2 H, C6H4), 7.76, 7.78 (d, 2 H, C6H4), 10.78 (s, 1 H, 3-NH exch), 12.74 (s, 1 
H, COOH exch). 
Diethyl N-(4-{[2-amino-4-oxo-6-(propan-2-yl)-3,4-dihydrothieno[2,3-d]pyrimidin-5-
yl]sulfanyl}benzoyl)-L-glutamate (384). To a solution of 383 (0.05 g, 0.14 mmol) in 
anhydrous DMF (10 mL) was added N-methylmorpholine (0.017 g, 0.17 mmol) and 2-
chloro-4,6-dimethoxy-1,3,5-triazine (0.03 g, 0.17 mmol). The resulting mixture was 
stirred at room temperature for 2 h. N-methylmorpholine (0.017 g, 0.17 mmol) and 
diethyl-L- glutamate hydrochloride (0.034 g, 0.14 mmol) were added to the mixture. The 
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reaction mixture was stirred for an additional 3 h at room temperature and silica gel was 
added to this solution and the suspension evaporated under reduced pressure. The plug 
obtained was loaded on a silica gel column and eluted with 2% methanol in chloroform 
and 384 (0.072 g, 94.7 %) was obtained as a yellow solid. Rf 0.33 (MeOH/CHCl3, 1:6); 
mp > 300 °C; 
1
H NMR (DMSO-d6)  1.13-1.17 (t, 6 H, 2 COOCH2CH3), 1.18-1.20 (d, 6 
H, CH (CH3)2), 1.95-2.22 (m, 2 H Gluβ-CH2), 2.40-2.43 (t, 2 H, Gluγ-CH2), 3.53-3.60 
(m, 1 H, CH (CH3)2), 4.37-4.41 (m, 4 H, 2 COOCH2CH3), 4.45-4.52 (1 H, m, Gluα-CH), 
6.61 (s, 2 H, 2-NH2 exch), 7.02, 7.04 (d, 2 H, C6H4), 7.70, 7.72 (d, 2 H, C6H4), 8.60, 8.62 
(d, 1 H, CONH exch), 10.74 (s, 1 H, 3-NH exch); HRMS (EI) calcd for C25H30N4O6S2 
m/z [M + Na]+ = 569.1504, found m/z = 569.1511.  
N-{4-[(2-amino-6-isopropyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-
yl)sulfanyl]benzoyl}-L-glutamic acid (304). To a solution of 384 (0.072 g, 0.132 mmol) 
in ethanol (6 mL) was added aqueous 1 N NaOH (3 mL) and the reaction mixture stirred 
at room temperature for 3 h. The ethanol was evaporated under reduced pressure and the 
residue was dissolved in water (5 mL). The solution was cooled to 0 
o
C and carefully 
acidified to pH 3 with drop wise addition of 1 N HCl. The resulting suspension was left at 
0 
o
C for 2 h and the residue was collected by filtration. Washed with water (5 mL) and 
dried over P2O5/vacuum at 50 
o
C to afford 304 (0.053 g, 83%) as white solid. Rf 0.41 
(MeOH/CHCl3, 1:6+ 1 drop of gl. HOAc); mp 192.4-192.8 °C; 
1
H NMR (DMSO-d6)  
1.19-1.21 (d, 6 H, CH (CH3)2), 1.96-2.23 (m, 2 H Gluβ-CH2), 2.31-2.35 (t, 2 H, Gluγ-
CH2), 3.54-3.61 (m, 1 H, CH (CH3)2), 4.31-4.39 (1 H, m, Gluα-CH), 6.61 (s, 2 H, 2-NH2 
exch), 7.02, 7.04 (d, 2 H, C6H4), 7.70, 7.72 (d, 2 H, C6H4), 8.47, 8.49 (d, 1 H, CONH 
exch), 10.75 (s, 1 H, 3-NH exch), 12.40 (s, 2H, COOH exch); Anal. calcd. for 
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(C21H22N4S6O2 ·1.5 H2O): C, 48.73; H, 4.87; N, 10.82; S, 12.39; found: C, 48.59; H, 
5.01; N, 10.65; S, 12.08.  
 
Ethyl 2-amino-5-propylthiophene-3-carboxylate (386). A mixture of sulfur (1.92 g, 60 
mmol), isovaleraldehyde (5.17 g, 60 mmol), ethyl cyanoactetate (6.78 g, 60 mmol) and 
EtOH (100 mL) were placed in a round bottom flask and warmed to 45 
o
C and treated 
dropwise with morpholine (5.23 g, 60 mmol) over 15 min. The mixture was stirred for 4 
h at 45 
o
C and 24 h at room temperature. Unreacted sulfur was removed by filtration, and 
the filtrate was concentrated under reduced pressure to afford an orange oil. The residue 
was loaded on a silica gel column packed with silica gel and eluted with 10% ethyl 
acetate in hexane to afford 386 (9.97 g, 78%) as a orange liquid; Rf 0.66 (hexane/EtOAc 
3:1); 
1
H NMR (CDCl3)  0.93-0.97 (t, 3 H, CH2CH2CH3), 1.31-1.35 (t, 3 H, 
COOCH2CH3), 1.55-1.64 (m, 2 H, CH2CH2CH3), 2.53-2.57 (t, 2 H, CH2CH2CH3), 4.22-
4.28 (q, 2 H, COOCH2CH3), 5.78 (s, 2 H, NH2 exch), 6.63 (s, 1 H, 4-H). HRMS (EI) 
calcd for C10H15NO2S m/z = 213.0823, found m/z = 213.0828. 
2-Amino-6-propylthieno[2,3-d]pyrimidin-4(3H)-one (387). A mixture of 386 (2.1 g, 
9.8 mmol) and chloroformamidine hydrochloride (2.3 g, 29 mmol) in DMSO2 (7.5 g, 7.5 
mmol) was heated at 150 
o
C for 2 h. The mixture was cooled to room temperature and 
water (30 mL) was added and ammonium hydroxide was used to neutralize the 
suspension. The brown solid, obtained by filtration, was washed with water and dried 
over P2O5 vacuum. The solid was dissolved in methanol and silica gel was added. The 
plug was loaded on to a silica gel column and eluted with 5% methanol in chloroformto 
to afford 387 (1.63 g, 80%) as a yellow solid; mp > 300 
o
C; Rf 0.32 (MeOH/CHCl3, 1:6); 
1
H NMR (DMSO-d6)  0.89-0.93 (t, 3 H, CH2CH2CH3), 1.55-1.64 (m, 2 H, 
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CH2CH2CH3), 2.64-2.68 (t, 2 H, CH2CH2CH3). 6.45 (s, 2 H, 2-NH2 exch), 6.79 (s, 1 H, 5-
H), 10.82 (s, 1 H, 3-NH exch); Anal. calcd. for (C9H11N3SO · 0.2 CH3OH): C, 51.23; H, 
5.51; N, 19.48; S, 14.87; found: C, 51.26; H, 5.31; N, 19.34; S, 14.84. 
2-Amino-5-iodo-6-propylthieno[2,3-d]pyrimidin-4(3H)-one (388). To a mixture of 387 
(2.5 g, 11.9 mmol) in glacial acetic acid (60 mL) was added mercuric acetate (5.69 g, 
17.93 mmol) at room temperature. The mixture was heated at 100 
o
C for 3 h. Then the 
mixture was poured into a brine solution (60 mL) and stirred for 30 min. The yellow solid 
388 (4.2 g, 78.9%) was obtained by filtration was washed with water and hexane and 
dried over P2O5 vacuum; mp 252.7 
o
C. Compound 388 (3.5 g, 7.8 mmol) was dissolved 
in CH2Cl2 (100 mL) and I2 (3.85 g, 15.2 mmol) was added. The reaulting mixture attired 
for 5 h at room temperature. The mixture was washed with 2 N NaS2O3 and dried via 
MgSO4. The plug was loaded on to a silica gel column and eluted with 3% methanol in 
chloroformto to afford 389 (2.25 g, 86%) as a yellow solid; mp 241 
o
C; Rf 0.26 
(MeOH/CHCl3, 1:10); 
1
H NMR (DMSO-d6)  0.91-0.95 (t, 3 H, CH2CH2CH3), 1.53-1.63 
(m, 2 H, CH2CH2CH3), 2.65-2.68 (t, 2 H, CH2CH2CH3), 6.56 (s, 2 H, 2-NH2 exch), 10.91 
(s, 1 H, 3-NH exch). HRMS (EI) calcd for C9H10IN3SO m/z = 335.9668, found m/z = 
335.9641. 
General procedure for the synthesis of compounds 317-319 and 323. 
A mixture of appropriate arylthiols (1.5 eq), K2CO3 (1.5 eq), CuI (1.3 eq) and 389 (1 eq) 
in dry DMF (5 mL) was irradiated in a microwave at 100 °C for 60-120 min. After the 
reaction mixture was cooled to room temperature, the mixture was filtered; the filtrate 
was concentrated under reduced pressure. The solid was dissolved in methanol and silica 
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gel was added. A dry silica gel plug was obtained after evaporation of the solvent. The 
plug was loaded on to a silica gel column and eluted with 2 % methanol in chloroform. 
2-Amino-6-propyl-5-(1-naphthylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one (317). 
Using the general procedure above compound 317 (0.137 g, 74.9 %) was obtained as a 
yellow solid by reacting 389 (0.167 g, 0.5 mmol), naphthalene-1-thiol (0.12 g, 0.75 
mmol), K2CO3 (0.103 g, 0.75 mmol) and CuI (0.124 g, 0.65 mmol) in DMF (5 mL) was 
irradiated in a microwave at 100 °C for 90 min. Rf 0.39 (MeOH/CHCl3, 1:10); mp > 300 
°C; 
1
H NMR (DMSO-d6)  0.80-0.83 (t, 3 H, CH2CH2CH3), 1.49-1.56 (m, 2 H, 
CH2CH2CH3), 2.8-2.83 (t, 2 H, CH2CH2CH3), 6.59 (s, 2 H, 2-NH2 exch), 6.77,6.79 (d, 1 
H, C10H7), 7.28-7.32 (t, 1 H, C10H7), 7.55-7.66 (m, 3 H, C10H7), 7.91, 7.93 (d, 1 H, 
C10H7), 8.20, 8.22 (d, 1 H, C10H7), 10.73 (s, 1 H, 3-NH exch); HRMS (ESI, pos mode) 
m/z [M + H]
+
 calcd for C19H17N3OS2, 368.0886; found, 368.0891. 
 
2-Amino-6-propyl-5-(2-naphthylsulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one (318). 
Using the general procedure above compound 318 (0.152 g, 83.1 %) was obtained as a 
light brown solid by reacting 389 (0.167 g, 0.5 mmol), naphthalene-2-thiol (0.12 g, 0.75 
mmol), K2CO3 (0.103 g, 0.75 mmol) and CuI (0.124 g, 0.65 mmol) in DMF (5 mL) was 
irradiated in a microwave at 100 °C for 90 min. Rf 0.50 (MeOH/CHCl3, 1:10); mp 257.3-
257.6 °C; 
1
H NMR (DMSO-d6)  0.82-0.86 (t, 3 H, CH2CH2CH3), 1.50-1.60 (m, 2 H, 
CH2CH2CH3), 2.84-2.88 (t, 2 H, CH2CH2CH3), 6.57 (s, 2 H, 2-NH2 exch), 7.14, 7.17 (d, 1 
H, C10H7), 7.43-7.45 (m, 3 H, C10H7), 7.70-7.81 (m, 3 H, C10H7), 10.71 (s, 1 H, 3-NH 
exch); HRMS (ESI, pos mode) m/z [M + H]
+
 calcd for C19H17N3OS2, 368.0886; found, 
368.0886. 
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2-Amino-6-propyl-5-(4-bromophenyl sulfanyl)thieno[2,3-d]pyrimidin-4(3H)-one 
(319). Using the general procedure above compound 319 (0.147 g, 88 %) was obtained as 
a light brown solid by reacting 389 (0.167 g, 0.5 mmol), 4-chlorobenzenethiol (0.096 g, 
0.75 mmol), K2CO3 (0.103 g, 0.75 mmol) and CuI (0.124 g, 0.65 mmol) in DMF (5 mL) 
was irradiated in a microwave at 100 °C for 90 min. Rf 0.41(MeOH/CHCl3, 1:10); mp 
288.4-289.0 °C; 
1
H NMR (DMSO-d6)  0.83-0.86 (t, 3 H, CH2CH2CH3), 1.48-1.58 (m, 2 
H, CH2CH2CH3), 2.80-2.84 (t, 2 H, CH2CH2CH3), 6.58 (s, 2 H, 2-NH2 exch), 6.91, 6.93 
(d, 2 H, C6H4), 7.37, 7.40 (d, 2 H, C6H4), 10.74 (s, 1 H, 3-NH exch); HRMS (ESI, pos 
mode) m/z [M + H]
+
 calcd for C15H14BrN3OS2, 396.9824; found, 396.9815. 
2-Amino-6-propyl-5-[(2,5-dimethoxyphenyl)sulfanyl]-thieno[2,3-d]pyrimidin-4(3H)-
one (323). Using the general procedure above compound 323 (0.224 g, 74 %) was 
obtained as a light brown solid by reacting 389 (0.268 g, 0.8 mmol), 2,5-
dimethoxybenzenethiol (0.204 g, 1.2 mmol), K2CO3 (0.165 g, 1.2 mmol) and CuI (0.247 
g, 1.04 mmol) in DMF (10 mL) was irradiated in a microwave at 100 °C for 60 min. Rf 
0.41 (MeOH/CHCl3, 1:10); mp > 300 °C; 
1
H NMR (DMSO-d6)  0.83-0.87 (t, 3 H, 
CH2CH2CH3), 1.48-1.53 (m, 2 H, CH2CH2CH3), 2.77-2.81 (t, 2 H, CH2CH2CH3), 3.53 (s, 
3 H, OCH3), 3.80 (s, 3 H, OCH3), 5.94, 5.95 (d, 1 H, C6H3 ),  6.59-6.62 (d, 3 H, 2-NH2 
exch overlapped with 1 H in C6H3), 6.86, 6.88 (d, 1 H, C6H3), 10.77 (s, 1 H, 3-NH exch); 
HRMS (ESI, pos mode) m/z [M + H]
+
 calcd for C15H14BrN3OS2, 396.9824; found, 
396.9815. 
 General Procedure for the Synthesis of Compounds 397-403. 
To a 250 mL round bottom flask, fitted with a magnetic stir bar, were placed palladium 
diacetate (0.269 g, 1.2 mmol), the appropriate allyl alcohol (20 mmol), ethyl 4-
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iodobenzoate (5.52 g, 20 mmol), LiCl (0.848 g, 20 mmol), LiOAc (3.3 g, 50 mmol) and 
Bu4NCl (11.12 g, 40 mmol) and DMF (40 mL). The mixture was stirred vigorously at 70 
o
C for 24 h. The reaction mixture was cooled to room temperature and water (80 mL), 
ethyl acetate (100 mL) was added. The ethyl acetate layer was separated, washed with 
brine (30 mL x 3), dried over anhydrous sodium sulfate, and concentrated under reduced 
pressure to afford a brown oil. The residue was loaded on a silica gel column packed with 
silica gel and eluted with 5% ethyl acetate in hexane. The fractions containing the desired 
product (TLC) were pooled and evaporated to afford the product. 
Ethyl 4- (4-oxobutyl)benzoate (397). Using the general procedure 397 was obtained as a 
colorless liquid (4.11 g, 87.2 %); Rf 0.70 (hexane/EtOAc 3:1);
 1
H NMR (CDCl3): δ1.37-
1.41 (t, 3 H, COOCH2CH3), 1.96-2.01 (m, 2 H, CH2CH2CH2CHO), 2.36-2.49 (q, 2 H, 
CH2CH2CH2CHO), 2.69-2.76 (t, 2 H, CH2CH2CH2CHO), 4.36-4.38 (q, 2 H, 
COOCH2CH3), 7.23, 7.25 (d, 2 H, C6H4), 7.96, 7.99 (d, 2 H, C6H4), 9.77 (s, 1 H, CHO). 
This compound was unstable and could not be analyzed by HRMS and was used directly 
for the next step. 
Ethyl 4- (5-oxopentyl)benzoate (398). Using the general procedure 398 was obtained as 
a colorless liquid (4.36 g, 87.9 %); Rf 0.71 (hexane/EtOAc 3:1);
 1
H NMR (CDCl3): δ 
1.33-1.36 (t, 3 H, COOCH2CH3), 1.62-1.64 (m, 4 H, CH2CH2CH2CH2CHO), 2.38-2.42 
(m, 2 H, CH2CH2CH2CH2CHO), 2.66-2.71 (m, 2 H, CH2CH2CH2CH2CHO), 4.32-4.37 
(q, 2 H, COOCH2CH3), 7.22, 7.24 (d, 2 H, C6H4), 7.94, 7.96 (d, 2 H, C6H4), 9.79 (s, 1 H, 
CHO). HRMS (ESI, pos mode) m/z [M + Na]
+
 calcd for C14H18O3, 257.1154; found, 
257.1144. 
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Ethyl 4- (6-oxohexyl)benzoate (399). Using the general procedure 399 was obtained as a 
colorless liquid (3.25 g, 65.5 %); Rf 0.73 (hexane/EtOAc 3:1);
 1
H NMR (CDCl3): δ 1.22-
1.27 (t, 5 H, COOCH2CH3 and CH2CH2CH2CH2CH2CHO), 1.47-1.57 (m, 4 H, 
CH2CH2CH2CH2CH2CHO), 2.26-2.31 (m, 2 H, CH2CH2CH2CH2CH2CHO), 2.51-2.56 
(m, 2 H, CH2CH2CH2CH2CH2CHO), 4.19-4.26 (q, 2 H, COOCH2CH3), 7.09, 7.11 (d, 2 
H, C6H4), 7.81, 7.84 (d, 2 H, C6H4), 9.62 (s, 1 H, CHO). This compound was unstable 
and could not be analyzed by HRMS and was used directly for the next step. 
Ethyl 4- (7-oxoheptyl)benzoate (400). Using the general procedure 400 was obtained as 
a colorless liquid (4.3 g, 82.06 %); Rf 0.74 (hexane/EtOAc 3:1);
 1
H NMR (CDCl3): δ 
1.17-1.27 (m, 7 H, COOCH2CH3 and CH2CH2CH2CH2CH2CH2CHO), 1.44-1.55 (m, 4 H, 
CH2CH2CH2CH2CH2CH2CHO), 2.25-2.31 (m, 2 H, CH2CH2CH2CH2CH2CH2CHO), 
2.49-2.54 (t, 2 H, CH2CH2CH2CH2CH2CH2CHO), 4.19-4.26 (q, 2 H, COOCH2CH3), 
7.09, 7.11 (d, 2 H, C6H4), 7.82, 7.85 (d, 2 H, C6H4), 9.61 (s, 1 H, CHO). This compound 
was unstable and could not be analyzed by HRMS and was used directly for the next 
step. 
 
Ethyl 4- (8-oxooctyl)benzoate (401). Using the general procedure 401 was obtained as a 
colorless liquid (4.63 g, 88.3 %); Rf 0.76 (hexane/EtOAc 3:1);
 1
H NMR (CDCl3): δ 1.32-
1.42 (m, 9 H, COOCH2CH3 and CH2CH2CH2CH2CH2CH2CH2CHO), 1.50-1.68 (m, 4 H, 
CH2CH2CH2CH2CH2CH2CH2CHO),2.13-2.45 (m,2 H, 
CH2CH2CH2CH2CH2CH2CH2CHO), 2.59-2.68 (m, 2 H, 
CH2CH2CH2CH2CH2CH2CH2CHO), 4.34-4.41 (q, 2H, COOCH2CH3), 7.22, 7.24 (d, 2 H, 
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C6H4), 7.94, 7.97 (d, 2 H, C6H4), 9.36 (s, 1 H, CHO). This compound was unstable and 
could not be analyzed by HRMS and was used directly for the next step. 
Ethyl 4- (9-oxononyl)benzoate (402). Using the general procedure 402 was obtained as 
a colorless liquid (4.53 g, 78.1 %); Rf 0.76 (hexane/EtOAc 3:1);
 1
H NMR (CDCl3): δ 
1.34-1.53 (m, 11 H, COOCH2CH3 and CH2CH2CH2 
CH2CH2CH2CH2CH2CHO), 1.60-1.63 (m, 4 H, CH2CH2CH2CH2CH2CH2CH2CH2CHO), 
2.33-2.41 (m, 2 H, CH2CH2CH2CH2CH2CH2CH2CH2CHO), 2.62-2.65 (t, 2 H,  
CH2CH2CH2CH2CH2CH2 CH2CH2CHO), 4.33-4.37 (q, 2 H, COOCH2CH3), 7.22, 7.23 
(d, 2 H, C6H4), 7.94, 7.96 (d, 2 H, C6H4), 9.35 (s, 1 H, CHO). HRMS (ESI, pos mode) 
m/z [M + K]
+ 
calcd for C18H26O3, 329.1519; found, 329.1498. 
Ethyl 4- (10-oxodecyl)benzoate (403). Using the general procedure 403 was obtained as 
a colorless liquid (5.05 g, 83.5 %); Rf 0.77 (hexane/EtOAc 3:1);
 1
H NMR (CDCl3): δ 
1.29-1.38 (m, 13 H, COOCH2CH3 and CH2CH2CH2CH2CH2CH2CH2CH2CH2CHO), 
1.52-1.56 (m, 4 H, CH2CH2CH2CH2CH2CH2CH2CH2CH2CHO), 2.23-2.30 (m, 2 H,  
CH2CH2CH2CH2CH2CH2CH2CH2CH2CHO), 2.52-2.55 (t, 2 H, 
CH2CH2CH2CH2CH2CH2CH2CH2CH2CHO), 4.23-4.27 (q, 2 H, COOCH2CH3), 7.22, 
7.24 (d, 2 H, C6H4), 7.94, 7.96 (d, 2 H, C6H4), 9.56 (s, 1 H, CHO). HRMS (ESI, pos 
mode) m/z [M + Na]
+ 
calcd for C19H28O3, 327.1936; found, 327.1950. 
General Procedure for the Synthesis of Compounds 404-410. 
 
A mixture of sulfur (1 mmol), the appropriate aldehyde (1 mmol), ethyl cyanoactetate  (1 
mmol) and EtOH (5 mL) were placed in a round bottom flask and warmed to 45 
o
C and 
treated dropwise with morpholine  (1 mmol) over 15 min. The mixture was stirred for 5 h 
at 45 
o
C and 24 h at room temperature. Unreacted sulfur was removed by filtration, and 
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the filtrate was concentrated under reduced pressure to afford an orange oil. The residue 
was loaded on a silica gel column packed with silica gel and eluted with 10% ethyl 
acetate in hexane. The fractions containing the desired product (TLC) were pooled and 
evaporated to afford the products. 
Ethyl 2-amino-5-{2-[4- (ethoxycarbonyl)phenyl]ethyl}thiophene-3-carboxylate (404). 
Compound 404 (3.68 g, 67.65 %) was obtained as an orange liquid by reacting 397 (3.7 
g, 15.67 mmol) with sulfur (0.5 g, 15.67 mmol) and ethyl cyanoactetate (1.78 g, 15.67 
mmol) as described in the General Procedure above; Rf 0.68 (hexane/EtOAc 3:1);
 1
H 
NMR (CDCl3): δ 1.30-1.34 (t, 3 H, COOCH2CH3), 1.36-1.41 (t, 3 H, COOCH2CH3), 
2.88-2.97 (m, 4 H, C6H4-CH2CH2), 4.21-4.27 (q, 2 H, COOCH2CH3), 4.33-4.40 (q, 2 H, 
COOCH2CH3), 5.79 (s, 2 H, NH2exch), 6.63 (s, 1 H, 4-H), 7.23, 7.26 (d, 2 H, C6H4), 
7.95, 7.98 (d, 2 H, C6H4). HRMS (ESI, pos mode) m/z [M + Na]
+ 
calcd for C18H21NO4S, 
370.1089; found, 370.1112. 
Ethyl 2-amino-5-{3-[4- (ethoxycarbonyl) phenyl]propyl}thiophene-3-carboxylate 
(405). Compound 405 (1.49 g, 65.32 %) was obtained as an orange liquid by reacting 398 
(1.58 g, 6.31 mmol), sulfur  (0.20 g, 6.31 mmol) and ethyl cyanoactetate (0.71 g, 6.31 
mmol) as described in the General Procedure above; Rf 0.69 (hexane/EtOAc 3:1);
 1
H 
NMR (CDCl3): δ 1.32-1.36 (t, 3 H, COOCH2CH3), 1.37-1.42 (t, 3 H, COOCH2CH3) 
1.88-1.98 (p, 2 H, C6H4-CH2CH2CH2), 2.59-2.64 (t, 2 H, C6H4-CH2CH2CH2), 2.69-2.74 
(t, 2 H, C6H4-CH2CH2CH2), 4.23-4.30 (q, 2 H, COOCH2CH3), 4.34-4.41 (q, 2 H, 
COOCH2CH3), 5.80 (s, 2 H, NH2 exch), 6.65 (s, 1 H, 4-H), 7.23, 7.26 (d, 2 H, C6H4), 
8.00, 8.03 (d, 2 H, C6H4). HRMS (ESI, pos mode) m/z [M + Na]
+ 
calcd for C19H23NO4S, 
384.1245; found, 384.1281. 
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Ethyl 2-amino-5-{4-[4- (ethoxycarbonyl)phenyl]butyl}thiophene-3-carboxylate  
(406). 
Compound 406 (2.99 g, 66.73 %) was obtained as an orange liquid by reacting 399 (2.96 
g, 11.92 mmol), sulfur (0.38 g, 11.92 mmol) and ethyl cyanoactetate (1.35 g, 11.92 
mmol) as described in the General Procedure above; Rf 0.71 (hexane/EtOAc 3:1);
 1
H 
NMR (CDCl3): δ 1.27-1.32 (t, 3 H, COOCH2CH3), 1.33-1.37 (t, 3 H, COOCH2CH3), 
1.57-1.69 (m, 4 H, C6H4-CH2CH2CH2CH2), 2.54-2.59 (t, 2 H, C6H4-CH2CH2CH2CH2), 
2.62-2.67 (t, 2 H, C6H4-CH2CH2CH2CH2), 4.18-4.25 (q, 2 H, COOCH2CH3), 4.29-4.36 
(q, 2 H, COOCH2CH3), 5.73 (s, 2 H, NH2 exch), 6.58 (s, 1 H, 4-H), 7.18, 7.21 (d, 2 H, 
C6H4), 7.90, 7.93 (d, 2 H, C6H4). HRMS (ESI, pos mode) m/z [M + Na]
+ 
calcd for 
C20H25NO4S, 398.1402; found, 398.1392. 
Ethyl 2-amino-5-{5-[4- (ethoxycarbonyl) phenyl]pentyl}thiophene-3-carboxylate  
(407). Compound 407 (2.62 g, 63.17 %) was obtained as an orange liquid by reacting 400 
(2.8 g, 10.67 mmol), sulfur (0.34 g, 10.67 mmol) and ethyl cyanoactetate (1.20 g, 10.67 
mmol) as described in the General Procedure above; Rf 0.71 (hexane/EtOAc 3:1);
 1
H 
NMR (CDCl3): δ 1.37-1.47 (m, 8 H, 2COOCH2CH3 and C6H4-CH2CH2CH2CH2 CH2 ), 
1.62-1.76 (m, 4 H, C6H4-CH2CH2CH2CH2CH2), 2.60-2.65 (t, 2 H, C6H4-
CH2CH2CH2CH2CH2), 2.69-2.74  (t, 2 H, C6H4-CH2CH2CH2CH2CH2), 4.28-4.35 (q, 2 H, 
COOCH2CH3), 4.39-4.46 (q, 2 H, COOCH2CH3), 5.85 (s, 2 H, NH2 exch), 6.66 (s, 1 H, 
4-H), 7.28, 7.30 (d, 2 H, C6H4), 8.00, 8.03 (d, 2 H, C6H4). HRMS (ESI, pos mode) m/z 
[M + Na]
+ 
calcd for C21H27NO4S, 412.1559; found, 412.1537. 
Ethyl 2-amino-5-{6-[4- (ethoxycarbonyl)phenyl]hexyl}thiophene-3-carboxylate  
(408).Compound 408 (3.62 g, 68.86 %) was obtained as an orange liquid by reacting 401 
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(3.6 g, 13.03 mmol), sulfur (0.42 g,13.03 mmol) and ethyl cyanoactetate (1.47 g,13.03 
mmol) as described in the General Procedure above; Rf 0.73 (hexane/EtOAc 3:1); 
1
H 
NMR (CDCl3): δ 1.31-1.41 (m, 10 H, 2COOCH2CH3 and C6H4-CH2CH2CH2CH2 
CH2CH2), 1.46-1.66 (m, 4 H, C6H4-CH2CH2CH2CH2CH2CH2), 2.53-2.58 (t, 2 H, C6H4-
CH2CH2CH2CH2CH2CH2), 2.62-2.69 (t, 2 H, C6H4- CH2CH2CH2CH2CH2CH2), 4.22-4.29 
(q, 2 H, COOCH2CH3), 4.33-4.40 (q, 2 H, COOCH2CH3), 5.77 (s, 2 H, NH2 exch), 6.62 
(s, 1 H, 4-H), 7.22, 7.26 (d, 2 H, C6H4), 7.94, 7.97 (d, 2 H, C6H4).HRMS (ESI, pos mode) 
m/z [M + Na]
+ 
calcd for C22H29NO4S, 426.1715; found, 426.1688. 
Ethyl 2-amino-5-{7-[4- (ethoxycarbonyl) phenyl]heptyl}thiophene-3-carboxylate  
(409). Compound 409 (1.94 g, 63.5 %) was obtained as an orange liquid by reacting 402 
(2.1 g, 7.2 mmol), sulfur (0.23 g, 7.2 mmol) and ethyl cyanoactetate (0.81 g, 7.2 mmol) 
as described in the General Procedure above; Rf 0.72 (hexane/EtOAc 3:1);
 1
H NMR 
(CDCl3): δ 1.29-1.41 (m, 12 H, 2COOCH2CH3 and C6H4-CH2CH2CH2CH2CH2 
CH2CH2),1.46-1.66 (m, 4 H, C6H4-CH2CH2CH2CH2CH2CH2CH2),2.51-2.58 (t, 2 H, 
C6H4-CH2CH2CH2CH2CH2CH2CH2), 2.60-2.71 (t, 2 H, C6H4- 
CH2CH2CH2CH2CH2CH2CH2), 4.20-4.27 (q, 2 H, COOCH2CH3), 4.31-4.38 (q, 2 H, 
COOCH2CH3), 5.86 (s, 2 H, NH2 exch), 6.60 (s, 1 H, 4-H), 7.20, 7.23 (d, 2 H, C6H4), 
7.94, 7.96 (d, 2 H, C6H4). HRMS (ESI, pos mode) m/z [M + Na]
+ 
calcd for C23H31NO4S, 
440.1872; found, 440.1837. 
Ethyl 2-amino-5-{8-[4- (ethoxycarbonyl)phenyl]octyl}thiophene-3-carboxylate  
(410).  
Compound 410 (4.77 g, 62.4 %) was obtained as an orange liquid by reacting 403 (5.4 g, 
17.7 mmol), sulfur (0.57 g, 17.7 mmol) and ethyl cyanoactetate (2.0 g, 17.7 mmol) as 
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described in the General Procedure above; Rf 0.74 (hexane/EtOAc 3:1);
 1
H NMR 
(CDCl3): δ 1.30-1.43 (m, 14 H, 2COOCH2CH3 and C6H4-CH2CH2CH2CH2CH2CH2 
CH2CH2), 1.47-1.66 (m, 4 H, C6H4-CH2CH2CH2CH2CH2CH2CH2CH2), 2.53-2.58 (t, 2H, 
C6H4-CH2CH2CH2CH2CH2CH2CH2CH2), 2.62-2.67 (t, 2 H, C6H4- 
CH2CH2CH2CH2CH2CH2CH2CH2), 4.21-4.28 (q, 2 H, COOCH2CH3), 4.32-4.39 (q, 2 H, 
COOCH2CH3), 5.77 (s, 2 H, NH2 exch), 6.61 (s, 1 H, 4-H), 7.21, 7.24 (d, 2 H, C6H4), 
7.94, 7.97 (d, 2 H, C6H4). HRMS (ESI, pos mode) m/z [M + Na]
+ 
calcd for C24H33NO4S, 
454.2028; found, 454.2016. 
General Procedure for the Synthesis of Compounds 411-417. 
A mixture of appropriate thiophene and chloroformamidine hydrochloride (1:4) in 
DMSO2 was heated at 140  C for 4 h.   The mixture was cooled to room temperature and 
water (15 mL) was added.Ammonium hydroxide was used to neutralize the suspension. 
The brown solid, obtained by filtration, was washed with water and dried over P2O5 
vacuum. The solid was dissolved in methanol and silica gel was added. A dry silica gel 
plug was obtained after evaporation of the solvent. The plug was loaded on to a silica gel 
column and eluted with 5% methanol in chloroform. The fractions containing the desired 
product (TLC) were pooled and evaporated to afford the products. 
 
Ethyl 4-[2- (2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)ethyl]benzoate  
(411). Using the General Procedure above compound 411 (0.73 g, 71.51 %) was obtained 
as a yellow solid by reacting 404 (0.7 g, 2.96 mmol) and chloroformamidine 
hydrochloride (1.30 g, 11.85 mmol); mp 274.6-275.9 °C; Rf 0.53 (MeOH/CHCl3, 1:6);
 1
H 
NMR (DMSO-d6): δ 1.28-1.33 (t, 3 H, COOCH2CH3), 2.98-3.04 (m, 4 H, C6H4-
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CH2CH2), 4.25-4.32 (q, 2 H, COOCH2CH3), 6.46 (s, 2 H, 2-NH2 exch), 6.77 (s, 1 H, 5-
H), 7.37, 7.40 (d, 2 H, C6H4), 7.85, 7.88 (d, 2 H, C6H4), 10.81 (s, 1 H, 3-NH exch). Anal. 
calcd. for (C17H17N3O3S2): C, 59.46; H, 4.99; N, 12.24; S, 9.34; found: C, 59.44; H, 5.06; 
N, 12.08; S, 9.23. 
Ethyl 4-[3- (2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)propyl]benzoate  
(412). Using the General Procedure above compound 412 (0.43 g, 81.13 %) was obtained 
as a yellow solid by reacting 405 (0.54 g, 1.49 mmol) and chloroformamidine 
hydrochloride (0.68 g, 5.9 mmol); mp 224.4-225.3 °C; Rf 0.53 (MeOH/CHCl3, 1:6);
 1
H 
NMR (DMSO-d6): δ 1.28-1.33 (t, 3 H, COOCH2CH3), 1.86-1.96 (p, 2 H, C6H4-
CH2CH2CH2), 2.68-2.74 (m, 4 H, C6H4-CH2CH2CH2) 4.26-4.33 (q, 2 H, COOCH2CH3), 
6.46 (s, 2 H, 2-NH2 exch), 6.82 (s, 1 H, 5-H), 7.35, 7.37 (d, 2 H, C6H4), 7.87, 7.89 (d, 2 
H, C6H4), 10.81 (s, 1 H, 3-NH exch). Anal. calcd. for (C18H19N3O3S · 0.4 CH3OH): C, 
59.69; H, 5.61; N, 11.35; S, 8.66; found: C, 59.73; H, 5.21; N, 11.55; S, 8.60. 
Ethyl 4-[4- (2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl]benzoate  
(413).   Using the General Procedure above compound 413 (1.05 g, 76.51 %) was 
obtained as a yellow solid by reacting 406 (1.40 g, 3.71 mmol) and chloroformamidine 
hydrochloride (1.70 g, 14.84 mmol); mp 273.5-275 °C; Rf 0.54 (MeOH/CHCl3, 1:6);
 1
H 
NMR (DMSO-d6): δ 1.27-1.32 (t, 3 H, COOCH2CH3), 2.47-2.52 (m, 4 H, C6H4-
CH2CH2CH2CH2), 2.65-2.73 (m, 4 H, C6H4-CH2CH2CH2CH2), 4.24-4.32 (q, 2 H, 
COOCH2CH3), 6.44 (s, 2 H, 2-NH2 exch), 6.78 (1 H, s, 5-H), 7.31, 7.34 (d, 2 H, C6H4), 
7.84, 7.87 (d, 2 H, C6H4), 10.84 (s, 1 H, 3-NH exch). Anal. calcd. for (C19H21N3O3S · 0.2 
H2O): C, 60.84; H, 5.75; N, 11.20; S, 8.55; found: C, 60.86; H, 5.64; N, 11.56; S, 8.62. 
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Ethyl 4-[5- (2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)pentyl]benzoate  
(414). Using the General Procedure above compound 414 (0.56 g, 54.37 %) was obtained 
as a yellow solid by reacting 407 (1.08 g, 2.76 mmol) and chloroformamidine 
hydrochloride (1.58 g, 13.8 mmol); mp 219.3-220.1 °C; Rf 0.55 (MeOH/CHCl3, 1:6);
 1
H 
NMR (DMSO-d6):δ 1.27-1.31 (t, 5 H, COOCH2CH3 and C6H4-CH2CH2CH2CH2CH2), 
1.54-1.64 (m, 4 H, C6H4-CH2CH2CH2CH2CH2), 2.59-2.69 (m, 4 H, C6H4-
CH2CH2CH2CH2CH2), 4.24-4.31 (q, 2 H, COOCH2CH3), 6.45 (s, 2 H, 2-NH2 exch), 6.78 
(s, 1 H, 5-H), 7.31, 7.34 (d, 2 H, C6H4), 7.83, 7.86 (d, 2 H, C6H4), 10.86 (1 H, s, 3-NH 
exch). Anal. calcd. for (C20H23N3O3S): C, 62.32; H, 6.01; N, 10.90; S, 8.32; found: C, 
62.48; H, 6.08; N, 10.79; S, 8.31. 
Ethyl 4-[6- (2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)hexyl]benzoate  
(415). Using the General Procedure above compound 415 (0.78 g, 67.24 %) was obtained 
as a yellow solid by reacting 408 (1.18 g, 2.91 mmol) and chloroformamidine 
hydrochloride (1.30 g, 11.64 mmol); mp 196.8-197.4 °C; Rf 0.53 (MeOH/CHCl3, 1:6);
 1
H 
NMR (DMSO-d6):δ 1.27-1.32 (m, 7 H, COOCH2CH3 and C6H4-
CH2CH2CH2CH2CH2CH2), 1.50-1.61 (m, 4 H, C6H4-CH2CH2CH2CH2CH2CH2), 2.50-
2.71 (m, 4 H, C6H4-CH2CH2CH2 CH2CH2CH2), 4.25-4.32 (q, 2 H, COOCH2CH3), 6.53 
(s, 2 H, 2-NH2 exch), 6.85 (s, 1 H, 5-H), 7.36, 7.39 (d, 2 H, C6H4), 7.91, 7.94 (d, 2 H, 
C6H4), 10.82 (1 H, s, 3-NH exch). Anal. calcd. for (C21H25N3O3S · 0.2 H2O): C, 62.02; H, 
6.39; N, 10.33; S, 7.88; found: C, 62.42; H, 6.48; N, 11.06; S, 7.74. 
Ethyl 4-[7- (2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)heptyl]benzoate  
(416). Using the General Procedure above compound 416 (0.67 g, 67.7 %) was obtained 
as a yellow solid by reacting 409 (1 g, 2.4 mmol) and chloroformamidine hydrochloride 
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(1.4 g, 12 mmol); mp 190.2-192.1 °C; Rf  0.55 (MeOH/CHCl3, 1:6);
 1
H NMR (DMSO-
d6):δ 1.16-1.33 (m, 9 H, COOCH2CH3 and C6H4-CH2CH2CH2 CH2CH2CH2CH2), 1.56 
(m, 4 H, C6H4-CH2CH2CH2CH2CH2CH2CH2), 2.50-2.69 (m, 4 H, C6H4-
CH2CH2CH2CH2CH2CH2CH2CH2), 4.25-4.32 (q, 2 H, COOCH2CH3), 6.46 (s, 2 H, 2-
NH2 exch), 6.76 (s, 1 H, 5-H), 7.30, 7.33 (d, 2 H, C6H4), 7.85, 7.87 (d, 2 H, C6H4), 10.83 
(s, 1 H, 3-NH exch). HRMS (ESI, pos mode) m/z [M + Na]
+ 
calcd for C22H27N3O3S, 
436.5266; found, 436.5239. 
Ethyl 4-[8- (2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)octyl]benzoate  
(417). Using the General Procedure above compound 417 (1.52 g, 70.3 %) was obtained 
as a yellow solid by reacting 410 (2.18 g, 5.05 mmol) and chloroformamidine 
hydrochloride (2.3 g, 20.2 mmol); 274.5-276.2 °C; Rf 0.54  (MeOH/CHCl3, 1:6);
 1
H 
NMR (DMSO-d6):δ 1.13-1.33 (m, 11H, COOCH2CH3 and C6H4-CH2CH2CH2 
CH2CH2CH2CH2CH2), 1.55 (m, 4 H, C6H4-CH2CH2CH2CH2CH2CH2CH2CH2), 2.50-2.72 
(m, 4 H, C6H4-CH2CH2CH2CH2CH2CH2CH2), 4.25-4.32 (q, 2 H, COOCH2CH3), 6.46 (s, 
2 H, 2-NH2 exch), 6.78 (s, 1 H, 5-H), 7.31, 7.33 (d, 2 H, C6H4), 7.85, 7.87 (d, 2 H, C6H4), 
10.84 (1 H, s, 3-NH exch). HRMS (ESI, pos mode) m/z [M + Na]
+ 
calcd for 
C23H29N3O3S, 450.1827; found, 450.1790. 
 
General Procedure for the Synthesis of Compounds 418-424. 
 
To a solution of 411-417 in ethanol (10-50 mL) was added aqueous 1 N NaOH and the 
reaction mixture stirred at room temperature for 12 h. The ethanol was evaporated under 
reduced pressure and the residue was dissolved in water (5-10 mL). The solution was 
carefully acidified to pH 3 with the drop wise addition of 1 N HCl.  The resulting 
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suspension was left at 0
 o
C for an hour and then the residue was collected by filtration, 
washed with water (5 mL) and dried over P2O5/vacuum at 50
 o
C to afford the free acids 
418-424. 
4-[2- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)ethyl]benzoic acid  
(418).   Using the General Procedure described above compound 418 (0.529 g, 95.0 %) 
was obtained as a white solid from 411 (0.61 g, 1.77 mmol) by hydrolysis in ethanol (50 
mL) and 1 N NaOH (25 mL); mp >300 °C; Rf 0.55 (MeOH/CHCl3, 1:6 + 1 drop of gl. 
HOAc);
 1
H NMR (DMSO-d6): δ 2.97-2.99 (t, 2 H, C6H4-CH2CH2), 3.02-3.41 (t, 2 H, 
C6H4-CH2CH2), 6.50 (s, 2 H, 2-NH2 exch), 6.78 (s, 1 H, 5-H), 7.35, 7.38 (d, 2 H, C6H4), 
7.83, 7.86 (d, 2 H, C6H4), 10.85 (1 H, s, 3-NH exch), 12.76 (1 H, s,COOH exch). Anal. 
calcd. for (C15H13N3O3S · 0.6 HCl): C, 53.42; H, 4.06; N, 12.46; S, 9.51; Cl, 1.85; found: 
C, 53.59; H, 3.93; N, 12.41; S, 9.34; Cl, 1.88. 
4-[3- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)propyl]benzoic acid  
(419). Using the General Procedure described above compound 419 (0.18 g, 92.6 %) was 
obtained as a white solid from 412 (0.22 g, 0.60 mmol) under hydrolysis in ethanol (20 
mL) and 1 N NaOH (10 mL); mp 292.7-293.4 °C; Rf 0.52  (MeOH/CHCl3, 1:6 + 1 drop 
of gl. HOAc);
 1
H NMR (DMSO-d6): δ 1.85-1.95 (m, 2 H, C6H4-CH2CH2CH2), 2.66-2.73 
(m, 4 H, C6H4-CH2CH2CH2), 6.58 (s, 2 H, 2-NH2 exch), 6.82 (s, 1 H, 5-H), 7.35, 7.39 (d, 
2 H, C6H4), 7.85, 7.88 (d, 2 H, C6H4), 10.94 (s, 1 H, 3-NH exch), 12.79 (s, 1 H, COOH 
exch). Anal. calcd. for (C16H15N3O3S · 0.7 CH3OH): C, 57.01; H, 5.10; N, 11.94; S, 9.11; 
found: C, 56.79; H, 4.75; N, 11.92; S, 9.20. 
4-[4- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl]benzoic acid 
(420).     Using the General Procedure described above compound 420 (0.138 g, 93.6 %) 
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was obtained as a yellow solid 413 (0.16 g, 0.43 mmol) under hydrolysis in ethanol (15 
mL) and 1 N NaOH (7 mL); mp >300°C; Rf 0.52 (MeOH/CHCl3, 1:6 + 1 drop of gl. 
HOAc);
 1
H NMR (DMSO-d6): δ 1.59-1.62 (m, 4 H, C6H4-CH2CH2CH2CH2), 2.65-2.75 
(m, 4 H, C6H4-CH2CH2 CH2CH2), 6.46 (s, 2 H, 2-NH2 exch), 6.79 (s, 1 H, 5-H), 7.29, 
7.32 (d, 2 H, C6H4), 7.83, 7.86 (d, 2 H, C6H4), 10.83 (s, 1 H, 3-NH exch), 12.77 (s, 1 H, 
COOH exch). Anal. calcd. for (C17H17N3O3S · 0.5 H2O): C, 57.94; H, 5.15; N, 11.92; S, 
9.10; found: C, 58.15; H, 5.02; N, 11.92; S, 9.05. 
4-[5- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)pentyl]benzoic acid  
(421). Using the General Procedure described above compound 421 (0.199 g, 93.3  %) 
was obtained as a white solid from 414 (0.23 g, 0.60 mmol) under hydrolysis in ethanol 
(20 mL) and 1 N NaOH (10 mL); mp 259.4-260 °C; Rf 0.52 (MeOH/CHCl3, 1:6 + 1 drop 
of  HOAc);
 1
H NMR (DMSO-d6): δ 1.28-1.38 (m, 2 H, C6H4-CH2CH2CH2CH2CH2), 
1.56-1.66 (m, 4 H, C6H4-CH2CH2 CH2CH2CH2), 2.61-2.71 (p, 4 H, C6H4-
CH2CH2CH2CH2CH2), 6.45 (s, 2 H, 2-NH2 exch), 6.79 (s, 1 H, 5-H), 7.29, 7.32 (d, 2 H, 
C6H4), 7.83, 7.85 (d, 2 H, C6H4), 10.82 (s, 1 H, 3-NH exch), 12.77 (s, 1 H, COOH exch). 
Anal. calcd. for (C18H19N3O3S · 0.4 H2O): C, 59.29; H, 5.47; N, 11.52; S, 8.79; found: C, 
59.48; H, 5.38; N, 11.43; S, 9.15. 
 
4-[6- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)hexyl]benzoic acid  
(422). Using the General Procedure described above compound 422 (0.141 g, 95.2 %) 
was obtained as a yellow solid from 415 (0.16 g, 0.40 mmol) and ethanol (15 mL) and 1 
N NaOH (7 mL); mp 282-283.8 °C; Rf 0.52 (MeOH/CHCl3, 1:6 + 1 drop of HOAc);
 1
H 
NMR (DMSO-d6): δ 1.31-1.32 (m, 4 H, C6H4-CH2CH2CH2CH2CH2CH2), 1.51-1.60 (m, 4 
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H, C6H4-CH2CH2CH2CH2CH2CH2), 2.59-2.69 (p, 4 H, C6H4-CH2CH2CH2CH2CH2CH2), 
6.45 (s, 2 H, 2-NH2 exch), 6.78 (s, 1 H, 5-H), 7.28, 7.31 (d, 2 H, C6H4), 7.83, 7.85 (d, 2 
H, C6H4), 10.82 (s, 1 H, 3-NH exch), 12.76 (s, 1 H, COOH exch). Anal. calcd. for 
(C19H21N3O3S): C, 61.44; H, 5.70; N, 11.31; S, 8.63; found: C, 61.18; H, 5.73; N, 11.05; 
S, 8.46. 
4-[7- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)heptyl]benzoic acid  
(423). Using the General Procedure described above compound 423 (0.22 g, 94.9 %) was 
obtained as a white solid from 416 (0.25 g, 0.60 mmol) and ethanol (20 mL) and 1 N 
NaOH (10 mL); mp 233.8-235 °C; Rf 0.51 (MeOH/CHCl3, 1:6 + 1 drop of gl. HOAc);
 1
H 
NMR (DMSO-d6): δ 1.29 (m, 6 H, C6H4-CH2CH2CH2CH2CH2CH2CH2), 1.53-1.58 (m, 4 
H, C6H4-CH2CH2CH2CH2CH2CH2CH2), 2.60-2.69 (m, 4 H, C6H4-CH2CH2CH2 
CH2CH2CH2CH2), 6.46 (s, 2 H, 2-NH2 exch), 6.78 (s, 1 H, 5-H), 7.29, 7.31 (d, 2 H, 
C6H4), 7.83, 7.85 (d, 2 H, C6H4), 10.83 (s, 1 H, 3-NH exch), 12.74 (s, 1 H, COOH exch). 
HRMS (ESI, pos mode) m/z [M + Na]
+ 
calcd for C20H23N3O3S, 408.1358; found, 
408.1380. 
4-[8- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)octyl]benzoic acid 
(424).   Using the General Procedure described above compound 424 (0.22 g, 92.8 %) 
was obtained as a yellow solid from 417 (0.26 g, 0.60 mmol) and ethanol (20 mL) and 1 
N NaOH (9 mL). It is yellow solid; Rf 0.53 (MeOH/CHCl3, 1:6 + 1 drop of gl. HOAc);
 1
H 
NMR (DMSO-d6): δ 1.29  (m, 8 H, C6H4-CH2CH2CH2CH2CH2CH2CH2CH2), 1.56  (m, 4 
H, C6H4-CH2CH2CH2CH2CH2CH2CH2CH2), 2.60-2.69 (m, 4 H, C6H4-CH2CH2CH2CH2 
CH2CH2CH2CH2), 6.46 (s, 2 H, 2-NH2 exch), 6.78 (s, 1 H, 5-H), 7.29, 7.31 (d, 2 H, 
C6H4), 7.83, 7.85 (d, 2 H, C6H4), 10.83 (s, 1 H, 3-NH exch), 12.75 (s, 1 H, COOH exch). 
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HRMS (ESI, pos mode) m/z [M + Na]
+ 
calcd for C21H25N3O3S, 422.1514; found, 
422.1553. 
General Procedure for the Synthesis of Compound 425-431. 
To a solution of418-424 (0.1 mmol) in anhydrous DMF (5-10 mL) was added N-
methylmorpholine (0.12 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (0.12 mmol). 
The resulting mixture was stirred at room temperature for 2 h. N-methylmorpholine (0.12 
mmol) and diethyl-L- glutamate hydrochloride (0.1 mmol) were added to the mixture. 
The reaction mixture was stirred for an additional 3 h at room temperature and silica gel 
was added to this solution and the suspension evaporated under reduced pressure. The 
plug obtained was loaded on a silica gel column and eluted with 2% methanol in 
chloroform. The fractions containing the desired product (TLC) were pooled and 
evaporated to afford the products. 
Diethyl N-{4-[2- (2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)ethyl] 
benzoy l}-L-glutamate  (425). Using the General Procedure described above compound 
425 (0.114 g, 71.5 %) was obtained as a white solid from 418 (0.126 g, 0.40 mmol); mp 
153.4-154 °C; Rf 0.63 (MeOH/CHCl3, 1:6);
 1
H NMR (DMSO-d6): δ 1.14-1.21 (m, 6 H, 
2COOCH2CH3),1.95-2.23 (m, 2 H, Gluβ-CH2), 2.41-2.46 (t, 2 H, Gluγ-CH2), 2.97-3.05 
(m, 4 H, C6H4-CH2CH2), 4.00-4.06 (q, 2 H, 2COOCH2CH3 ), 4.08-4.14 (q, 2 H, 
COOCH2CH3 ), 4.38-4.45 (m, 1 H, Gluα-CH), 6.45 (s, 2 H, 2-NH2 exch), 6.79 (s, 1 H, 5-
H), 7.33, 7.36 (d, 2 H, C6H4), 7.77, 7.80 (d, 2 H, C6H4), 8.63-8.66 (d, 1 H, CONH exch), 
10.81 (s, 1 H, 3-NH exch). Anal. calcd. for (C24H28N4O6S): C, 57.59; H, 5.64; N, 11.19; 
S, 6.41; found: C, 57.42; H, 5.77; N, 11.00; S, 6.36. 
Diethyl N-{4-[3-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)propyl] 
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benzoyl}-L-glutamate (426). Using the General Procedure described above compound 
426 (0.106 g, 73.1 %) was obtained as a yellow solid from 419 (0.10 g, 0.30 mmol); mp 
122.5-123.2 °C; Rf 0.63 (MeOH/CHCl3, 1:6);
 1
H NMR (DMSO-d6): δ 1.15-1.21 (m, 6 H, 
2COOCH2CH3), 1.89-1.93 (m, 2 H, C6H4-CH2CH2CH2), 1.99-2.11 (m, 2 H, Gluβ-CH2), 
2.41-2.45 (t, 2 H, Gluγ-CH2), 2.68-2.71 (m, 4 H, C6H4-CH2CH2CH2), 4.00-4.13 (m, 4 H, 
2COOCH2CH3 ), 4.41-4.45 (m, 1 H, Gluα-CH), 6.47 (s, 2 H, 2-NH2 exch), 6.82 (s, 1 H, 
5-H), 7.30, 7.33 (d, 2 H, C6H4), 7.79, 7.82 (d, 2 H, C6H4), 8.64-8.66 (d, 1 H, CONH 
exch), 10.86 (1 H, s, 3-NH exch). Anal. calcd. for (C25H30N4O6S · 0.2 H2O): C, 57.94; H, 
5.91; N, 10.81; S, 6.19; found: C, 57.81; H, 5.88; N, 10.88; S, 6.06. 
Diethyl N-{4-[4- (2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl] 
benzoyl}-L-glutamate  (427). Using the General Procedure described above compound 
427 (0.134 g, 67.0 %) was obtained as a white solid from 420 (0.13 g, 0.38 mmol); mp 
166.8-167.3 °C; Rf 0.64 (MeOH/CHCl3, 1:6);
 1
H NMR (DMSO-d6): δ 1.13-1.20 (m, 6 H, 
2COOCH2CH3), 1.57-1.62 (m, 4 H, C6H4-CH2CH2CH2CH2), 1.95-2.12 (m, 2 H, Gluβ-
CH2), 2.40-2.45 (t, 2 H, Gluγ-CH2), 2.65-2.75 (m, 4 H, C6H4-CH2CH2CH2CH2), 4.00-
4.13 (m, 4 H, 2COOCH2CH3 ), 4.38-4.45 (m, 1 H, Gluα-CH), 6.46 (s, 2 H, 2-NH2 exch), 
6.79 (s, 1 H, 5-H), 7.35, 7.38 (d, 2 H, C6H4), 7.84, 7.87 (d, 2 H, C6H4), 8.63-8.65 (d, 1 H, 
CONH exch), 10.85 (s, 1 H, 3-NH exch). Anal. calcd. for (C26H32N4O6S): C, 59.07; H, 
6.10; N, 10.60; S, 6.07; found: C, 59.07; H, 6.18; N, 10.47; S, 5.97. 
Diethyl N-{4-[5- (2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)pentyl] 
benzoyl}-L-glutamate (428). Using the General Procedure described above compound 
428 (0.108 g, 68.7 %) was obtained as a white solid from 421 (0.10 g, 0.29 mmol); mp 
144.2-144.8 °C; Rf 0.64 (MeOH/CHCl3, 1:6);
 1
H NMR (DMSO-d6): δ 1.14-1.21 (m, 8 H, 
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2COOCH2CH3 and C6H4-CH2CH2CH2CH2CH2), 1.57-1.66 (p, 4 H, C6H4-
CH2CH2CH2CH2CH2), 1.93-2.17 (m, 2 H, Gluβ-CH2), 2.41-2.46 (t, 2 H, Gluγ-CH2), 
2.61-2.72 (p, 4 H, C6H4-CH2CH2CH2CH2CH2), 4.01-4.14 (m, 4 H, 2COOCH2CH3 ), 
4.38-4.46 (m, 1 H, Gluα-CH), 6.46 (s, 2 H, 2-NH2 exch), 6.79 (s, 1 H, 5-H), 7.29, 7.31 (d, 
2 H, C6H4), 7.78, 7.80 (d, 2 H, C6H4), 8.63, 8.66 (d, 1 H, CONH exch), 10.83 (s, 1 H, 3-
NH exch). HRMS (ESI, pos mode) m/z [M + Na]
+ 
calcd for C27H34NO4S, 565.2097; 
found, 565.2134. 
Diethyl N-{4-[6- (2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)hexyl] 
benzoyl}-L-glutamate (429). Using the General Procedure described above compound 
429 (0.170 g, 80.57 %) was obtained as a white solid from 422 (0.14 g, 0.38 mmol); mp 
153.7-154.4 °C; Rf 0.64 (MeOH/CHCl3, 1:6);
 1
H NMR (DMSO-d6): δ 1.12-1.19 (m, 6 H, 
2COOCH2CH3), 1.30-1.32 (m, 4 H, C6H4-CH2CH2CH2CH2CH2CH2), 1.54-1.58 (m, 4 H, 
C6H4-CH2CH2CH2 CH2CH2CH2), 1.94-2.14 (m, 2 H, Gluβ-CH2), 2.39-2.44 (t, 2 H, Gluγ-
CH2), 2.58-2.69 (m, 4 H, C6H4-CH2CH2CH2CH2CH2CH2), 3.99-4.12 (m, 4 H, 
2COOCH2CH3 ), 4.36-4.45 (m, 1 H, Gluα-CH), 6.45 (s, 2 H, 2-NH2 exch), 6.78 (s, 1 H, 
5-H), 7.27, 7.30 (d, 2 H, C6H4), 7.77, 7.80 (d, 2 H, C6H4), 8.63, 8.65 (d, 1 H, CONH 
exch), 10.86 (s, 1 H, 3-NH exch). Anal. calcd. for (C28H36N4O6S): C, 60.41; H, 6.52; N, 
10.06; S, 5.76; found: C, 60.42; H, 6.59; N, 10.07; S, 5.61. 
Diethyl N-{4-[7- (2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)heptyl] 
benzoyl}-L-glutamate (430). Using the General Procedure described above compound 
430 (0.183 g, 66.8 %) was obtained as a semisolid from 423 (0.19 g, 0.48 mmol); Rf 0.65 
(MeOH/CHCl3, 1:6);
 
It was used directly in the next step without further characterization. 
Diethyl N-{4-[8- (2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)octyl] 
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benzoyl}-L-glutamate (431). Using the General Procedure described above compound 
431 (0.170 g, 68.20 %) was obtained as a yellow solid from 424 (0.16 g, 0.40 mmol); Rf 
0.64 (MeOH/CHCl3, 1:6);
 1
H NMR (DMSO-d6): δ 1.12-1.19 (m, 6 H, 2COOCH2CH3), 
1.32-1.56 (m, 8 H, C6H4-CH2CH2CH2CH2CH2CH2CH2CH2), 1.58-1.62 (m, 4 H, C6H4-
CH2CH2CH2CH2CH2CH2CH2CH2), 1.98-2.24 (m, 2 H, Gluβ-CH2), 2.41-2.45 (t, 2 H, 
Gluγ-CH2), 2.59-2.69 (m, 4 H, C6H4-CH2CH2CH2CH2CH2CH2CH2CH2), 4.01- 4.12 (4 H, 
m, 2COOCH2CH3 ), 4.38-4.47 (m, 1 H, Gluα-CH), 6.46 (s, 2 H, 2-NH2 exch), 6.78 (s, 1 
H, 5-H), 7.27, 7.29 (d, 2 H, C6H4), 7.78, 7.80 (d, 2 H, C6H4), 8.63, 8.65 (d, 1 H, CONH 
exch), 10.83 (s, 1 H, 3-NH exch). HRMS (ESI, pos mode) m/z [M + Na]
+ 
calcd for 
C30H40N4O6S, 607.7212; found, 607.7233.        
General Procedure for the Synthesis of Compounds 324-330. 
To a solution of 425-431 in ethanol (5-10 mL) was added aqueous 1 N NaOH and the 
reaction mixture stirred at room temperature for 3 h. The ethanol was evaporated under 
reduced pressure and the residue was dissolved in water (5-10 mL). The solution was 
cooled to 0
 o
C and carefully acidified to pH 3 with drop wise addition of 1 N HCl. The 
resulting suspension was left at 0
 o
C for 12 h and the residue was collected by filtration. 
Washed with water (5 mL) and dried over P2O5/vacuum at 50
 o
C to afford the free acids 
324-330. 
N-{4-[2- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)ethyl]benzoyl}-L-
glutamic acid (324). Using the General Procedure described above compound 324 
(0.064 g, 97.7 %) was obtained from 425 (0.075 g, 0.15 mmol) as a white solid; mp 
167.7-168.4 °C; Rf 0.62 (MeOH/CHCl3, 1:6 + 1 drop of gl. HOAc);
 1
H NMR (DMSO-
d6): δ 1.89-2.12 (m, 2 H, Gluβ-CH2), 2.32-2.37 (t, 2 H, Gluγ-CH2), 2.97-3.04 (m, 4 H, 
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C6H4-CH2CH2), 4.34-4.44 (m, 1 H, Gluα-CH), 6.45 (s, 2 H, 2-NH2 exch), 6.79 (s, 1 H, 5-
H), 7.32, 7.36 (d, 2 H, C6H4), 7.78, 7.81 (d, 2 H, C6H4), 8.51-8.53 (d, 1 H, CONH exch), 
10.81 (s, 1 H, 3-NH exch), 12.40 (s, 2 H, 2COOH exch). Anal. calcd. for (C20H20N4O6S · 
0.5 H2O): C, 52.97; H, 4.67; N, 12.36; S, 7.07; found: C, 52.92; H, 4.75; N, 12.11; S, 
6.82. 
N-{4-[3- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)propyl]benzoyl}-L-
glutamic acid  (325). Using the General Procedure described above compound 325 
(0.071 g, 96.5 %) was obtained from 426 (0.083 g, 0.16 mmol) as a white solid; mp 
155.5-156.1 °C; Rf 0.62 (MeOH/CHCl3, 1:6 + 1 drop of HOAc);
 1
H NMR (DMSO-d6): δ 
1.91-2.10 (m, 4 H, Gluβ-CH2 and C6H4-CH2CH2CH2 ), 2.32-2.36 (t, 2 H, Gluγ-CH2), 
2.66-2.73 (q, 4 H, C6H4-CH2CH2CH2), 4.37-4.38 (m, 1 H, Gluα-CH), 6.47 (s, 2 H, 2-NH2 
exch), 6.81 (s, 1 H, 5-H), 7.30, 7.32 (d, 2 H, C6H4), 7.79, 7.82 (d, 2 H, C6H4), 8.50, 8.53 
(d, 1 H, CONH exch), 10.83 (s, 1 H, 3-NH exch), 12.51 (s, 2 H, 2COOH exch). Anal. 
calcd. for (C21H22N4O6S · 0.5 CH3OH): C, 54.42; H, 5.10; N, 11.81; S, 6.76; found: C, 
54.32; H, 5.20; N, 11.0652; S, 6.38. 
 
N-{4-[4- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl]benzoyl}-L-
glutamic acid  (326).  Using the General Procedure described above compound 326 
(0.086 g, 95.8 %) was obtained from 427 (0.10 g, 0.19 mmol) as a yellow solid; mp 
154.5-154.9° C; Rf 0.64 (MeOH/CHCl3, 1:6 + 1 drop of HOAc);
 1
H NMR (DMSO-d6): δ 
1.61-1.62 (m, 4 H, C6H4-CH2CH2CH2CH2 ), 1.91-2.10 (m, 2 H, Gluβ-CH2), 2.32-2.37 (t, 
2 H, Gluγ-CH2), 2.66-2.73 (q, 4 H, C6H4-CH2CH2CH2CH2), 4.36-4.41 (m, 1 H, Gluα-
CH), 6.46 (s, 2 H, 2-NH2 exch), 6.79 (s, 1 H, 5-H), 7.28, 7.30 (d, 2 H, C6H4), 7.78, 7.81 
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(d, 2 H, C6H4), 8.51, 8.54 (d, 1 H, CONH exch), 10.83 (s, 1 H, 3-NH exch), 12.41 (s, 2 H, 
2COOH exch). Anal. calcd. for (C22H24N4O6S · 0.5 H2O): C, 54.88; H, 5.23; N, 11.64; S, 
6.66; found: C, 55.11; H, 5.10; N, 11.35; S, 6.48. 
N-{4-[5- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)pentyl]benzoyl}-L-
glutamic acid  (327).  Using the General Procedure described above compound 327 
(0.071 g, 97.9 %) was obtained from 428 (0.080 g, 0.15 mmol) as a white solid; mp 
132.6-133 °C; Rf 0.64 (MeOH/CHCl3, 1:6 + 1 drop of gl. HOAc);
 1
H NMR (DMSO-d6): 
δ 1.16-1.23 (m, 2 H, C6H4-CH2CH2CH2CH2CH2 ), 1.59-1.63 (m, 4 H, C6H4-
CH2CH2CH2CH2CH2 ), 1.89-2.12 (m, 2 H, Gluβ-CH2), 2.32-2.37 (t, 2 H, Gluγ-CH2), 
2.59-2.71 (m, 4 H, C6H4-CH2CH2CH2CH2CH2), 4.37-4.39 (m, 1 H, Gluα-CH), 6.47 (s, 2 
H, 2-NH2 exch), 6.79 (s, 1 H, 5-H), 7.35, 7.37 (d, 2 H, C6H4), 7.85, 7.88 (d, 2 H, C6H4), 
8.56, 8.59 (d, 1 H, CONH exch), 10.83 (s, 1 H, 3-NH exch), 12.47 (s, 2 H, 2COOH 
exch). Anal. calcd. for (C23H26N4O6S · 0.5 C2H5OH): C, 56.57; H, 5.74; N, 10.99; S, 
6.29; found: C, 56.65; H, 5.57; N, 10.67; S, 6.42. 
 
N-{4-[6- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)hexyl]benzoyl}-L-
glutamic acid (328). Using the General Procedure described above compound 328 
(0.086 g, 98.6 %) was obtained from 429 (0.098 g, 0.17 mmol) as a solid; mp 139.7-
141.1 °C; Rf  0.64 (MeOH/CHCl3, 1:6 + 1 drop of gl. HOAc);
 1
H NMR (DMSO-d6): δ 
1.32 (s, 4 H, C6H4-CH2 CH2CH2CH2CH2CH2), 1.57 (s, 4 H, C6H4-
CH2CH2CH2CH2CH2CH2 ), 1.93-2.09 (m, 2 H, Gluβ-CH2), 2.33-2.35 (m, 2 H, Gluγ-
CH2), 2.62-2.68 (m,4 H, C6H4-CH2CH2CH2CH2CH2CH2), 4.38-4.39 (m, 1 H, Gluα-CH), 
6.47 (s, 2 H, 2-NH2 exch), 6.78 (s, 1 H, 5-H), 7.35, 7.37 (d, 2 H, C6H4), 7.85, 7.87 (d, 2 
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H, C6H4), 8.57, 8.60 (d, 1 H, CONH exch), 10.85 (s, 1 H, 3-NH exch), 12.40 (s, 2 H, 
2COOH exch). Anal. calcd. for (C24H28N4O6S · 0.4 H2O): C, 56.77; H, 5.72; N, 11.03; S, 
6.32; found: C, 57.03; H, 5.63; N, 10.71; S, 6.15. 
N-{4-[7- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)heptyl]benzoyl}-L-
glutamic acid (329). Using the General Procedure described above compound 329 
(0.287 g, 97.9 %) was obtained from 430 (0.326 g, 0.57 mmol) as a yellow solid; mp 
134.9-135.5 °C; Rf 0.64 (MeOH/CHCl3, 1:6 + 1 drop of gl. HOAc);
 1
H NMR (DMSO-
d6): δ 1.35 (m, 6 H, C6H4-CH2 CH2CH2CH2CH2CH2CH2), 1.59 (s, 4 H, C6H4-
CH2CH2CH2CH2CH2CH2CH2 ), 1.90-2.08 (m, 2 H, Gluβ-CH2), 2.32-2.35 (m, 2 H, Gluγ-
CH2), 2.59-2.68 (m, 4 H, C6H4-CH2CH2CH2CH2CH2CH2CH2), 4.36-4.40 (m, 1 H, Gluα-
CH), 6.44 (s, 2 H, 2-NH2 exch), 6.77 (s, 1 H, 5-H), 7.26, 7.28 (d, 2 H, C6H4), 7.77, 7.79 
(d, 2 H, C6H4), 8.50, 8.51 (d, 1 H, CONH exch), 10.82 (s, 1 H, 3-NH exch), 12.38 (s, 2 H, 
2COOH exch). Anal. calcd. for (C25H30N4O6S · 0.5 H2O): C, 57.35; H, 5.97; N, 10.70; S, 
6.12; found: C, 56.97; H, 6.07; N, 10.57; S, 6.03. 
 
N-{4-[8- (2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)octyl]benzoyl}-L-
glutamic acid (330). Using the General Procedure described above compound 330 
(0.087 g, 97.6 %) was obtained from 431 (0.1 g, 0.17 mmol) as a brown solid; mp 122.2-
123 °C; Rf  0.66 (MeOH/CHCl3, 1:6 + 1 drop of gl. HOAc);
 1
H NMR  (DMSO-d6): δ 1.38 
(m, 8 H, C6H4-CH2CH2CH2CH2CH2CH2CH2CH2), 1.57 (s, 4 H, C6H4-
CH2CH2CH2CH2CH2CH2CH2CH2 ), 1.92-2.11 (m, 2 H, Gluβ-CH2), 2.32-2.35 (m, 2 H, 
Gluγ-CH2), 2.59-2.68 (m,4 H, C6H4-CH2CH2CH2 CH2CH2CH2CH2CH2), 4.35-4.39 (m, 1 
H, Gluα-CH), 6.44 (s, 2 H, 2-NH2 exch), 6.77 (s, 1 H, 5-H), 7.26, 7.28 (d, 2 H, C6H4), 
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7.77, 7.79 (d, 2 H, C6H4), 8.50-8.51 (d, 1 H, CONH exch), 10.81 (s, 1 H, 3-NH exch), 
12.80 (s, 2 H, 2COOH exch). Anal. calcd. for (C26H32N4O6S · 0.6 H2O): C, 57.89; H, 
6.20; N, 10.38; S, 5.94; found: C, 57.64; H, 6.15; N, 10.35; S, 6.14.  
Methyl 5-bromothiophene-2-carboxylate (439). Thionyl chloride (2.64 g, 1.6 mL, 22 
mmol) was added dropwise to a stirred solution of 408 (2.07 g, 10 mmol) in MeOH (20 
mL) while maintaining the internal temperature below 12 
o
C. When addition was 
complete the mixture was left to stand at room temperature for 12h to obtain white solid. 
And the filtrate was concentrated under reduced pressure to afford white solid. The solid 
was washed with hexane and ethyl ether to afford 13 (2.05 g, 93%) as white solid; mp 
59.5-61.0 
o
C; Rf 0.55 (hexane/EtOAc 3:1); 
1
H NMR (DMSO-d6)  3.80 (s, 3 H), 7.36, 
7.37 (d, 1 H), 7.63, 7.64 (d, 1 H).  
Methyl 5-(6-hydroxyhex-1-yn-1-yl)thiophene-2-carboxylate (451). A mixture of 439 
(0.66 g, 3 mmol), hex-5-yn-1-ol (0.323 g, 3.3 mmol), PdCl2 (0.033 g), PPh3 (0.132 g), 
CuI (0.033 g), NEt3 (15 mL) and CH3CN (2.5 mL) was irradiated to 100 
o
C for 10 min 
under microwave. The reaction mixture was then made in to plug and loaded on a silica 
gel column and eluted with hexane/EtOAc 3:1 to afford 451 (1.19 g, 83%) as a colorless 
liquid: Rf 0.21 (hexane/EtOAc 2:1); 
1
H NMR (DMSO-d6)  1.54 (m, 4 H), 2.48 (m, 2 H), 
3.39-3.42 (t, 2 H). 3.80 (s, 3 H), 7.25, 7.26 (d, 1 H), 7.69, 7.70 (d, 1 H).  
Methyl 5-(6-oxohex-1-yn-1-yl)thiophene-2-carboxylate (452). A solution of CH2Cl2 (8 
mL) and oxalyl chloride (0.31 g, 3.3 mmol) was placed in a 50 mL 3-neck round bottom 
flask with an ballon and two dropping funnels containing DMSO (0.51 mL) dissolved in 
CH2Cl2 (2 mL) and 451(0.716 g, 3 mmol) in CH2Cl2 (4 mL). The DMSO was added to 
the stirred oxalyl chloride solution at -60
o
C. The reaction mixture was stirred for 2 min 
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and 451 was added within 5 min. Stirring was continued for an additional 15 min. NEt3 
(2.3 mL) was added and the reaction mixture was stirred for 5 min and the allowed to 
warm to room temperature. CH2Cl2 (10 mL) was added to the reaction mixture and then 
washed with H2O (3 mL)  for 3 times. The organic layer was then dried over anhydrous 
Na2SO4  to give 452 (0.62 g, 87%)  as a colorless liquid; Rf 0.16 (hexane/EtOAc 3:1); 
1
H 
NMR (DMSO-d6)  1.79-1.84 (p, 2 H), 2.51-2.55 (t, 2 H), 2.57-2.60 (t, 2 H), 3.82 (s, 3 
H), 7.28, 7.29 (d, 1 H), 7.71, 7.72 (d, 1 H), 9.70-9.71 (t, 1 H, CHO). This compound was 
used directly for next step of reaction without further characterization.  
Methyl 5-{4-[5-amino-4-(ethoxycarbonyl)thiophen-2-yl]but-1-yn-1-yl}thiophene-2-
carboxylate (453). A mixture of 452 (0.78 g, 3.3 mmol), sulfur (0.11 g, 3.3 mmol), ethyl 
cyanoactetate (0.37 g, 3.3 mmol) and EtOH (20 mL) were placed in a round bottom flask 
and warmed to 45 
o
C and treated dropwise with morpholine (0.29 g, 3.3 mmol) over 15 
min. The mixture was stirred for 4 h at 45 
o
C and 24 h at room temperature. Unreacted 
sulfur was removed by filtration, and the filtrate was concentrated under reduced pressure 
to afford an orange oil. The residue was loaded on a silica gel column packed with silica 
gel and eluted with 10% ethyl acetate in hexane to afford 453 (0.48 g, 40%) of  as a 
orange liquid; Rf 0.38 (hexane/EtOAc 3:1); 
1
H NMR (DMSO-d6)  1.21-1.24 (t, 3 H), 
2.68-2.72 (t, 2 H), 2.79-2.82 (t, 2 H), 3.81 (s, 3 H, COOCH3), 4.11-4.17 (q, 2 H), 6.64 (s, 
1 H), 7.16 (s, 2 H, 2-NH2 exch), 7.25, 7.26 (d, 1 H), 7.70, 7.71 (d, 1 H). 
Methyl 5-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)but-1-yn-1-
yl]thiophene-2-carboxylate (454). A mixture of 453 (0.4 g, 1.1 mmol) and 
chloroformamidine hydrochloride (0.5 g, 4.4 mmol) in DMSO2 (2 g, 2.04 mmol) was 
heated at 150 
o
C for 2 h. The mixture was cooled to room temperature and water (10 mL) 
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was added. Then ammonium hydroxide was used to neutralize the suspension. The brown 
solid, obtained by filtration, was washed with water and dried over P2O5 vacuum. The 
solid was dissolved in methanol and silica gel was added. The plug was loaded on to a 
silica gel column and eluted with 5% methanol in chloroformto to afford 454 (0.2g, 52%) 
as a brown solid; mp > 300 
o
C; Rf 0.32 (MeOH/CHCl3 1:6); 
1
H NMR (DMSO-d6)  2.66-
2.72 (m, 2 H), 2.79-2.82 (m, 2 H), 3.81 (s, 3 H), 6.46 (s, 2 H, 2-NH2 exch), 7.20, 7.21 (d, 
1 H), 7.62, 7.63 (d, 1 H), 7.7 (s, 1 H), 10.83 (s, 1 H, 3-NH exch). This compound was 
used directly for next step of reaction without further characterization. 
5-[4-(2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)but-1-yn-1-
yl]thiophene-2-carboxylic acid (455). To a solution of 454 (0.16 g, 0.44 mmol) in 
ethanol (16 mL) was added aqueous 1 N NaOH (8 mL) and the reaction mixture stirred at 
room temperature for 12 h. The ethanol was evaporated under reduced pressure and the 
residue was dissolved in water (5 mL). The solution was carefully acidified to pH 3 with 
the drop wise addition of 1 N HCl. The resulting suspension was left at 0 
o
C for an hour 
and then the residue was collected by filtration, washed with water (5 mL) and dried over 
P2O5/vacuum at 50 
o
C to afford 455 (0.142 g, 94 %) as a brown solid; mp >300 °C; Rf 
0.43 (MeOH/CHCl3, 1:6+ 1 drop of HOAc); 
1
H NMR (DMSO-d6)  2.68-2.75 (m, 2 H), 
2.80-2.82 (m, 2 H), 6.47 (s, 2 H, 2-NH2 exch), 7.20, 7.21 (d, 1 H), 7.62, 7.63 (d, 1 H), 7.7 
(s, 1 H), 10.85 (s, 1 H, 3-NH exch), 13.19 (s, 1 H, COOH exch). This compound was 
used directly for next step of reaction without further characterization. 
Diethyl N-({5-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)but-1-yn-1-
yl]thiophen-2-yl}carbonyl)-L-glutamate (456). To a solution of 455 (0.13 g, 0.38 
mmol) in anhydrous DMF (15 mL) was added N-methylmorpholine (0.045 g, 0.45 mmol) 
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and 2-chloro-4,6-dimethoxy-1,3,5-triazine (0.079 g, 0.45 mmol). The resulting mixture 
was stirred at room temperature for 2 h. N-methylmorpholine (0.045 g, 0.45 mmol) and 
diethyl-L- glutamate hydrochloride (0.09 g, 0.376 mmol) were added to the mixture. The 
reaction mixture was stirred for an additional 3 h at room temperature and silica gel was 
added to this solution and the suspension evaporated under reduced pressure. The plug 
obtained was loaded on a silica gel column and eluted with 2% methanol in chloroform 
and 456 (0.155 g, 78 %) was obtained as a brown solid; mp 187.6-188.8 °C; Rf 0.31 
(MeOH/CHCl3, 1:6); 
1
H NMR (DMSO-d6)  1.13-1.19 (t, 6 H), 1.95-2.23 (m, 2 H Gluβ-
CH2), 2.40-2.44 (t, 2 H, Gluγ-CH2), 2.65-2.72 (m, 2 H), 3.02-3.05 (m, 2 H), 4.01--4.13 
(m, 4 H), 4.41 (m, 1 H, Gluα-CH), 6.48 (s, 2 H, 2-NH2 exch), 6.86, 6.88 (d, 1 H), 7.38, 
7.40 (d, 1 H), 7.78, 7.79(d, 1 H), 8. 63, 8.71 (d, 1 H, CONH exch), 10.89 (s, 1 H, 3-NH 
exch). 
N-({5-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)but-1-yn-1-
yl]thiophen-2-yl}carbonyl)-L-glutamic acid (457). To a solution of 456 in ethanol (8 
mL) was added aqueous 1 N NaOH (4 mL) and the reaction mixture stirred at room 
temperature for 3 h. The ethanol was evaporated under reduced pressure and the residue 
was dissolved in water (5 mL). The solution was cooled to 0 
o
C and carefully acidified to 
pH 3 with drop wise addition of 1 N HCl. The resulting suspension was left at 0 
o
C for 2 
h and the residue was collected by filtration. Washed with water (5 mL) and dried over 
P2O5/vacuum at 50 
o
C to afford 457 (0.083 g, 92%) as light yellow solid; mp 158.9-161.1 
°C; Rf 0.29 (MeOH/CHCl3, 1:6+ 1 drop of gl. HOAc); 
1
H NMR (DMSO-d6)  1.89-2.13 
(m, 2 H Gluβ-CH2), 2.31-2.35 (t, 2 H, Gluγ-CH2), 2.62-2.72 (m, 2 H), 3.02-3.05 (m, 2 H), 
4.34 (1 H, m, Gluα-CH), 6.46 (s, 2 H, 2-NH2 exch), 6.86-6.88(d, 1 H), 7.24, 7.25 (d, 1 H), 
192 
 
7.78, 7.79 (d, 1 H), 8.62, 8.71 (d, 1 H, CONH exch), 10.83 (s, 1 H, 3-NH exch), 12.52 (s, 
2H, COOH exch); HRMS (ESI, pos mode) m/z [M + H]
+
 calcd for C20H18N4O6S2, 
475.0668; found, 475.0757. 
Methyl 5-(6-hydroxyhexyl)thiophene-2-carboxylate (458). To a Parr hydrogenation 
bottle was added 451 (0.714 g, 3 mmol), 10% Pd/C (0.07 g) and MeOH (30 mL). 
Hydrogenation was carried out at 55 psi for 24 h. After filtration, the organic phase was 
evaporated at vacuum to afford 458 (0.662 g, 92%)  as a colorless liquid; Rf 0.11 
(hexane/EtOAc 3:1); 
1
H NMR (DMSO-d6)  1.27-1.31 (m, 4 H), 1.38 (m, 2 H), 1.61 (m, 
2 H), 2.79-2.83 (t, 2 H), 3.34-3.37 (t, 3 H), 3.77 (s, 3 H), 6.93, 6.95 (d, 1 H), 7.62, 7.63 
(d, 1 H). This compound was used directly for next step of reaction without further 
characterization. 
Methyl 5-(6-oxohexyl)thiophene-2-carboxylate(459). A solution of CH2Cl2 (8 mL) and 
oxalyl chloride (0.31 g, 3.3 mmol) was placed in a 50 mL 3-neck round bottom flask with 
an ballon and two dropping funnels containing DMSO (0.51 mL) dissolved in CH2Cl2 (2 
mL) and 458 (0.728 g, 3 mmol) in CH2Cl2 (4 mL). The DMSO was added to the stirred 
oxalyl chloride solution at -60
o
C. The reaction mixture was stirred for 2 min and 458 was 
added within 5 min. Stirring was continued for an additional 15 min. NEt3 (2.3 mL) was 
added and the reaction mixture was stirred for 5 min and the allowed to warm to room 
temperature. CH2Cl2 (10 mL) was added to the reaction mixture and then washed with 
H2O (3 mL) for 3 times. The organic layer was then dried over anhydrous Na2SO4  to give 
459 (0.605 g , 83%) as a colorless liquid; Rf 0.2 (hexane/EtOAc 3:1); 
1
H NMR (DMSO-
d6)  1.27-1.32 (m, 2 H), 1.49-1.53 (t, 2 H), 1.59-1.65 (t, 2 H),  2.39-2.43 (t, 2 H), 2.79-
2.83 (t, 2 H), 3.77 (s, 3 H), 6.94, 6.95 (d, 1 H), 7.62, 7.63 (d, 1 H), 9.63 (t, 1 H, CHO). 
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This compound was used directly for next step of reaction without further 
characterization. 
Methyl 5-{4-[5-amino-4-(ethoxycarbonyl)-2-thienyl]butyl}thiophene-2-carboxy 
late (460). A mixture of 459 (0.8g, 3.3 mmol), sulfur (0.11 g, 3.3 mmol), ethyl 
cyanoactetate (0.38 g, 3.3 mmol) and EtOH (20 mL) were placed in a round bottom flask 
and warmed to 45 
o
C and treated dropwise with morpholine (0.29 g, 3.3 mmol) over 15 
min. The mixture was stirred for 4 h at 45 
o
C and 24 h at room temperature. Unreacted 
sulfur was removed by filtration, and the filtrate was concentrated under reduced pressure 
to afford an orange oil. The residue was loaded on a silica gel column packed with silica 
gel and eluted with 10% ethyl acetate in hexane to afford 460 (0.77 g, 63%) as a orange 
liquid; Rf 0.35 (hexane/EtOAc 3:1); 
1
H NMR (DMSO-d6)  1.20-1.24 (t, 3 H), 1.49-1.56 
(m, 2 H), 1.60-1.67 (m, 2 H), 2.52-2.56 (t, 2 H), 2.83-2.86 (t, 2 H), 3.77 (s, 3 H), 4.10-
4.15 (q, 2 H), 6.49 (s, 1 H), 6.94, 6.95 (d, 1 H), 7.10 (s, 2 H, 2-NH2 exch), 7.62, 7.63 (d, 1 
H). This compound was used directly for next step of reaction without further 
characterization. 
Methyl 5-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl] 
thiophene-2-carboxylate (461). A mixture of 460 (0.69 g, 1.87 mmol) and 
chloroformamidine hydrochloride (0.86 g, 7.49 mmol) in DMSO2 (4 g, 4.08 mmol) was 
heated at 150 
o
C for 2 h. The mixture was cooled to room temperature and water (10 mL) 
was added. Then ammonium hydroxide was used to neutralize the suspension. The brown 
solid, obtained by filtration, was washed with water and dried over P2O5 vacuum. The 
solid was dissolved in methanol and silica gel was added. The plug was loaded on to a 
silica gel column and eluted with 5% methanol in chloroformto to afford 461 (0.58 g , 
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85%) as a yellow solid; mp > 300 
o
C; Rf 0.30 (MeOH/CHCl3, 1:6); 
1
H NMR (DMSO-d6) 
 1.59-1.68 (m, 4 H), 2.70-2.74 (t, 2 H), 2.85-2.88 (t, 2 H), 3.77 (s, 3 H), 6.45 (s, 2 H, 2-
NH2 exch), 6.79 (s, 1 H), 6.95, 6.96 (d, 1 H), 7.62, 7.63 (d, 1 H), 10.82 (s, 1 H, 3-NH 
exch). This compound was used directly for next step of reaction without further 
characterization. 
5-[4-(2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl]thiophene-2-
carboxylic acid (462). To a solution of 461 (0.41 g, 1.13 mmol) in ethanol (40 mL) was 
added aqueous 1 N NaOH (20 mL) and the reaction mixture stirred at room temperature 
for 12 h. The ethanol was evaporated under reduced pressure and the residue was 
dissolved in water (15 mL). The solution was carefully acidified to pH 3 with the drop 
wise addition of 1 N HCl. The resulting suspension was left at 0 
o
C for an hour and then 
the residue was collected by filtration, washed with water (15 mL) and dried over 
P2O5/vacuum at 50 
o
C to afford 462 (0.38 g, 97 %) as a yellow solid; mp >300 °C; Rf 
0.35 (MeOH/CHCl3, 1:6+ 1 drop of gl. HOAc); 
1
H NMR (DMSO-d6)  1.64 (m, 4 H), 
2.71-2.74 (t, 2 H), 2.83-2.86 (t, 2 H), 6.45 (s, 2 H, 2-NH2 exch), 6.79 (s, 1 H), 6.90, 6.91 
(d, 1 H), 7.53, 7.54 (d, 1 H), 10.83 (s, 1 H, 3-NH exch), 12.84 (s, 1 H, COOH exch). This 
compound was used directly for next step of reaction without further characterization. 
Diethyl N-({5-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-
yl)butyl]thiophen-2-yl}carbonyl)-L-glutamate (463). To a solution of 462 (0.34 g, 0.97 
mmol) in anhydrous DMF (20 mL) was added N-methylmorpholine (0.12 g, 1.16 mmol) 
and 2-chloro-4,6-dimethoxy-1,3,5-triazine (0.20 g, 1.16 mmol). The resulting mixture 
was stirred at room temperature for 2 h. N-methylmorpholine (0.045 g, 0.45 mmol) and 
diethyl-L- glutamate hydrochloride (0.23 g, 0.97mmol) were added to the mixture. The 
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reaction mixture was stirred for an additional 3 h at room temperature and silica gel was 
added to this solution and the suspension evaporated under reduced pressure. The plug 
obtained was loaded on a silica gel column and eluted with 2% methanol in chloroform 
and 463 (0.388 g, 75 %) was obtained as a light yellow solid; mp 155.7-156.6 °C; Rf 0.33 
(MeOH/CHCl3, 1:6); 
1
H NMR (DMSO-d6)  1.13-1.19 (t, 6 H), 1.64 (m, 4 H), 1.93-2.13 
(m, 2 H Gluβ-CH2), 2.38-2.42 (t, 2 H, Gluγ-CH2), 2.71-2.74 (t, 2 H), 2.81-2.84 (t, 2 H), 
4.01--4.13 (m, 4 H), 4.33-4.39 (m, 1 H, Gluα-CH), 6.44 (s, 2 H, 2-NH2 exch), 6.79(s, 1 
H), 6.87, 6.88 (d, 1 H), 7.66, 7.67 (d, 1 H), 8.59, 8.61 (d, 1H, CONH exch), 10.81 (s, 1 H, 
3-NH exch). This compound was used directly for next step of reaction without further 
characterization. 
N-({5-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl]thiophen-2-
yl}carbonyl)-L-glutamic acid (333). To a solution of 463 (0.52 g, 0.97 mmoL) in 
ethanol (40 mL) was added aqueous 1 N NaOH (20 mL) and the reaction mixture stirred 
at room temperature for 3 h. The ethanol was evaporated under reduced pressure and the 
residue was dissolved in water (15 mL). The solution was cooled to 0 
o
C and carefully 
acidified to pH 3 with drop wise addition of 1 N HCl. The resulting suspension was left at 
0 
o
C for 2 h and the residue was collected by filtration. Washed with water (15 mL) and 
dried over P2O5/vacuum at 50 
o
C to afford 333 (0.43 g, 94%) as white solid; mp 116.4-
117.8 °C; Rf 0.25 (MeOH/CHCl3, 1:6+ 1 drop of gl. HOAc); 
1
H NMR (DMSO-d6)  1.64 
(m, 4 H), 1.85-2.07 (m, 2 H Gluβ-CH2), 2.30-2.34 (t, 2 H, Gluγ-CH2), 2.71-2.74 (t, 2 H), 
2.81-2.84 (t, 2 H), 4.31 (1 H, m, Gluα-CH), 6.41 (s, 2 H, 2-NH2 exch), 6.79 (s, 1 H), 6.87, 
6.88 (d, 1 H), 7.66, 7.67 (d, 1 H), 8.47, 8.49 (d, 1 H, CONH exch), 10.82 (s, 1 H, 3-NH 
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exch), 12.44 (s, 2H, COOH exch); Anal. calcd. for (C20H22N4S2O6 ·1.2 H2O): C, 48.03; 
H, 4.92; N, 11.20; S, 12.82; found: C, 47.76; H, 4.92; N, 11.20; S, 12.82.  
General Procedure for the Synthesis of Compounds 335-338. 
To a solution of 464 (0.1 mmol) in anhydrous DMF (5-10 mL) was added N-
methylmorpholine (0.12 mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (0.12 mmol). 
The resulting mixture was stirred at room temperature for 2 h. N-methylmorpholine (0.12 
mmol) and amines (0.1 mmol) were added to the mixture. The reaction mixture was 
stirred for an additional 3 h at room temperature and silica gel was added to this solution 
and the suspension evaporated under reduced pressure. The plug obtained was loaded on 
a silica gel column and eluted with 2% methanol in chloroform. The fractions containing 
the desired product (TLC) were pooled and evaporated to afford the appropriate esters.  
To a solution of esters in ethanol (5-10 mL) was added aqueous 1 N NaOH and the 
reaction mixture stirred at room temperature for 3 h. The ethanol was evaporated under 
reduced pressure and the residue was dissolved in water (5-10 mL). The solution was 
cooled to 0
 o
C and carefully acidified to pH 3 with drop wise addition of 1 N HCl. The 
resulting suspension was left at 0
 o
C for 12 h and the residue was collected by filtration. 
Washed with water (5 mL) and dried over P2O5/vacuum at 50
 o
C to afford the free acids 
335-338. 
(2S)-2-({4-[4-(2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl]benzoyl} 
amino)butanoic acid (335). Using the General Procedure described above compound 
335 (0.04 g, 67.9 %) was obtained as a light yellow solid; mp 164.4-165.3 °C; Rf 0.39 
(MeOH/CHCl3, 1:6 + 1 drop of gl. HOAc);
 1
H NMR (DMSO-d6): δ 0.93-0.97 (t, 3 H, γ-
CH3), 1.61-1.63 (m, 4 H, C6H4-CH2CH2CH2CH2 ), 1.73-1.93 (m, 2 H, -CH2), 2.66-2.76 
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(m, 4 H, C6H4-CH2CH2CH2CH2), 4.25-4.31 (m, 1 H, α-CH), 6.46 (s, 2 H, 2-NH2 exch), 
6.80 (s, 1 H, 5-H), 7.29, 7.31 (d, 2 H, C6H4), 7.80, 7.82 (d, 2 H, C6H4), 8.46, 8.48 (d, 1 H, 
CONH exch), 10.83 (s, 1 H, 3-NH exch), 12.53 (s, 1 H, COOH exch). Anal. calcd. for 
(C21H24N4O4S · 0.5 H2O): C, 57.65; H, 5.76; N, 12.81; S, 7.33; found: C, 57.72; H, 5.70; 
N, 12.54; S, 7.13. 
N-{4-[4-(2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl]benzoyl} 
norvaline (336). Using the General Procedure described above compound 336 (0.072 g, 
63.3 %) was obtained as a light yellow solid; mp 139.7-141.5 °C; Rf 0.40 (MeOH/CHCl3, 
1:6 + 1 drop of gl. HOAc);
 1
H NMR (DMSO-d6): δ 0.88-0.92 (t, 3 H, δ-CH3), 1.35-1.44 
(m, 2 H, γ-CH2), 1.61-1.65 (m, 4 H, C6H4-CH2CH2CH2CH2 ), 1.74-1.80 (q, 2 H, -CH2), 
2.66-2.69 (t, 2 H, C6H4-CH2CH2CH2CH2), 2.72-2.75 (t, 2 H, C6H4-CH2CH2CH2CH2), 
4.34-4.39 (m, 1 H, α-CH), 6.47 (s, 2 H, 2-NH2 exch), 6.80 (s, 1 H, 5-H), 7.28, 7.30 (d, 2 
H, C6H4), 7.80, 7.82 (d, 2 H, C6H4), 8.47, 8.49 (d, 1 H, CONH exch), 10.84 (s, 1 H, 3-NH 
exch), 12.55 (s, 1 H, COOH exch). Anal. calcd. for (C22H26N4O4S · 0.5 H2O): C, 58.52; 
H, 6.03; N, 12.41; S, 7.10; found: C, 58.12; H, 5.87; N, 12.25; S, 6.95. 
3-({4-[4-(2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl]benzoyl} 
amino)butanoic acid (337). Using the General Procedure described above compound 
337 (0.062 g, 65.5 %) was obtained as a yellow solid; mp 180.1-181.8 °C; Rf 0.40 
(MeOH/CHCl3, 1:6 + 1 drop of gl. HOAc);
 1
H NMR (DMSO-d6): δ 1.16-1.18 (d, 3 H, α-
CH3), 1.60-1.62 (m, 4 H, C6H4-CH2CH2CH2CH2 ), 2.36-2.42 (q, 1 H, -CH ), 2.54-2.60 
(q, 1 H, -CH ), 2.64-2.67 (t, 2 H, C6H4-CH2CH2CH2CH2), 2.71-2.74 (t, 2 H, C6H4-
CH2CH2CH2CH2), 4.29-4.36 (m, 1 H, α-CH), 6.47 (s, 2 H, 2-NH2 exch), 6.79 (s, 1 H, 5-
H), 7.26, 7.28 (d, 2 H, C6H4), 7.73, 7.75 (d, 2 H, C6H4), 8.20, 8.22 (d, 1 H, CONH exch), 
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10.84 (s, 1 H, 3-NH exch), 12.16 (s, 1 H, COOH exch). Anal. calcd. for (C21H24N4O4S · 
0.4 H2O): C, 57.89; H, 5.74; N, 12.86; S, 7.36; found: C, 57.89; H, 5.56; N, 12.64; S, 
7.20. 
4-({4-[4-(2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl]benzoyl} 
amino)butanoic acid (338). Using the General Procedure described above compound 
338 (0.063 g, 66.7 %) was obtained as a yellow solid; mp 250.4-251.6 °C; Rf 0.31 
(MeOH/CHCl3, 1:6 + 1 drop of gl. HOAc);
 1
H NMR (DMSO-d6): δ 1.60-1.62 (m, 4 H, 
C6H4-CH2CH2CH2CH2 ), 1.71-1.78 (p, 2 H, -CH2), 2.25-2.29 (t, 1 H, γ-CH2), 2.64-2.67 
(t, 2 H, C6H4-CH2CH2CH2CH2), 2.72-2.75 (t, 2 H, C6H4-CH2CH2CH2CH2), 3.23-3.28 (q, 
2 H, -CH2), 6.47 (s, 2 H, 2-NH2 exch), 6.80 (s, 1 H, 5-H), 7.26, 7.28 (d, 2 H, C6H4), 
7.74, 7.76 (d, 2 H, C6H4), 8.38-8.41 (t, 1 H, CONH exch), 10.84 (s, 1 H, 3-NH exch), 
12.05 (s, 1 H, COOH exch). Anal. calcd. for (C21H24N4O4S · 0.8 C2H5OH): C, 58.33; H, 
6.24; N, 12.04; S, 6.89; found: C, 58.49; H, 5.98; N, 11.83; S, 6.68.  
2-Methylthieno[3,2-d]pyrimidin-4(3H)-one (467). To a stirred solution of 466 (1.57 g, 
10 mmol) in CH3CN (20 mL), HCl gas was bulbed and the mixture was allowed to stir at 
room temperature for 2h. Some white solid was precipitated and was collected by 
filtration, and the filtrate was concentrated under reduced pressure to afford white solid. 
White solid was recrystallized in methanol and 467 (0.8 g, 50%) was obtained; mp 236.4-
236.7 
o
C; Rf 0.33 (MeOH/CHCl3, 1:10); 
1
H NMR (DMSO-d6)  2.37 (s, 3 H, 2-CH3), 
7.30, 7.31(d, 1 H), 8.12, 8.14 (d, 1 H), 12.38 (s, 1 H, 3-NH exch).    
4-Chloro-2-methylthieno[3,2-d]pyrimidine (468) A stirred mixture of 467 (0.6 g, 3.6 
mmol) and POCl3 (10 mL) was refluxed for 2 h. Then solvent was removed under 
reduced pressure to afford brown residue. The residue was loaded on a silica gel column 
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packed with silica gel and eluted with 25% ethyl acetate in hexane to afford 468 (0.5 g, 
76%) as white powder; mp 81-81.4 
o
C; Rf 0.56 (hexane/EtOAc 1:1); 
1
H NMR (DMSO-
d6)  2.37 (s, 3 H, 2-CH3), 7.30, 7.31 (d, 1 H), 8.13, 8.14 (d, 1 H). This compound was 
used directly for next step of reaction without further characterization. 
N-(4-Methoxyphenyl)-N,2-dimethylthieno[3,2-d]pyrimidin-4-amine (342) A mixture 
of 468 (0.184 g, 1 mmol), 4-methoxy-N-methylaniline (0.15 g, 1.1 mmol) and 
n
BuOH (7 
mL) was refluxed. After completion of the reaction, as indicated by TLC, the reaction 
solvent was removed under reduced pressure. The residue was loaded on a silica gel 
column packed with silica gel and eluted with 25% ethyl acetate in hexane to afford 342 
(0.23 g, 81%) as light brown powder; mp 137.5-137.9 
o
C; Rf 0.56 (hexane/EtOAc 1:1); 
1
H NMR (DMSO-d6)  2.54 (s, 3 H, 2-CH3 ), 3.49 (s, 3 H, OCH3), 3.84 (s, 3 H, N-CH3), 
7.04, 7.06 (d, 2 H, C6H4), 7.18, 7.19 (d, 1 H), 7.37, 7.39 (d, 2 H, C6H4), 7.85, 7.86 (d, 1 
H). Anal. calcd. for (C15H15N3SO•0.2 H2O): C, 62.35; H, 5.37; N, 14.54; S, 11.10; found: 
C, 62.48; H, 5.37; N, 14.47; S, 11.25. 
N-(4-Methoxyphenyl)-2-methylthieno[3,2-d]pyrimidin-4-amine (343) A mixture of 
468 (0.184 g, 1 mmol), 4-methoxyaniline (0.12 g, 1.1 mmol) and n-BuOH (7 mL) was 
refluxed. After completion of the reaction, as indicated by TLC, the reaction solvent was 
removed under reduced pressure. The residue was loaded on a silica gel column packed 
with silica gel and eluted with 25% ethyl acetate in hexane to afford 343 (0.22 g, 82%) as 
light brown powder; mp 117.8-118.2 
o
C; Rf 0.50 (hexane/EtOAc 1:1); 
1
H NMR (DMSO-
d6)  2.49 (s, 3 H, 2-CH3), 3.78(s, 3 H, OCH3), 6.95, 6.97 (d, 2 H, C6H4), 7.32, 7.33 (d, 1 
H), 7.60, 7.62 (d, 2 H, C6H4), 8.10, 8.12 (d, 1 H), 9.52 (s, 1 H, NH exch ). Anal. calcd. for 
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(C14H13N3SO•0.2 C6H14): C, 63.26; H, 5.52; N, 14.56; S, 11.11; found: C, 63.05; H, 5.27; 
N, 14.69; S, 11.17. 
 
6-Methoxy-1-(2-methylthieno[3,2-d]pyrimidin-4-yl)-1,2,3,4-tetrahydroquinoline 
(344) A mixture of 468 (0.4 g, 2.17 mmol), 6-methoxy-1,2,3,4-tetrahydroquinoline 
(0.177g, 1.08 mmol) and nBuOH (10 mL) was refluxed. After completion of the reaction, 
as indicated by TLC, the reaction solvent was removed under reduced pressure. The 
residue was loaded on a silica gel column packed with silica gel and eluted with 20% 
ethyl acetate in hexane to afford 344 (0.218 g, 65%) of  as white powder; mp 127.5-128 
o
C; Rf 0.21 (hexane/EtOAc 1:1); 
1
H NMR (DMSO-d6)  1.89-1.96 (m, 2 H), 2.56 (s, 3 H, 
2-CH3), 2.69-2.72 (t, 2 H), 3.78(s, 3 H, OCH3), 3.99-4.02 (t, 2 H), 6.75-6.78 (dd, 1 H, 
C6H3), 6.89 (s, 1 H, C6H3), 7.00, 7.02 (d, 1 H, C6H3), 7.25, 7.27 (d, 1 H), 7.93, 7.94 (d, 1 
H). Anal. calcd. for (C17H17N3SO): C, 65.57; H, 5.50; N, 13.49; S, 10.30; found: C, 
65.67; H, 5.46; N, 13.49; S, 10.30. 
Methyl 3-(formylamino)thiophene-2-carboxylate (469).  Fomic acid (12 mL) was 
added to acetic anhydride (18 mL) while cooling in an ice bath. Compound 466 (3.09 g, 
19.8 mmol) was added to the cold solution in a small portions. The cooling bath was 
removed and the resulting suspension was stirred at room temperature for 4h. The 
mixture was diluted with water (30 mL) and white needle solid 469 (3.36 g, 93%) was 
collected by filtration; mp 90.5 
o
C; Rf 0.58 (hexane/EtOAc 1:1); 
1
H NMR (DMSO-d6)  
3.85 (s, 3 H, COOCH3), 7.90, 7.91(d, 1 H), 7.99, 8.01(d, 1 H), 8.42 (s, 1 H), 10.38 (s, 1 
H, exch). This compound was used directly for next step of reaction without further 
characterization. 
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Thieno[3,2-d]pyrimidin-4(3H)-one (470).  To a solution of ammonium formate (3.4 g, 
54 mmol) in formamide (5 mL) at 150
 o
C was added 469 (1.85 g, 10mmol) as a solid in 
small portions.  The resulting solution was heated at 150
 o
C for 4 h and then allowed to 
stand at room temperature for 12 h. The precipitate that formed was collected by filtration 
to give 470 (1.21 g, 80%) as white needles; mp 215.8-216.4 
o
C; Rf 0.23 (MeOH/CHCl3, 
1:10); 
1
H NMR (DMSO-d6)  7.40, 7.41(d, 1 H), 8.16 (s, 1 H, 2-H), 8.18, 8.19 (d, 1 H), 
12.48 (s, 1 H, 3-NH exch). This compound was used directly for next step of reaction 
without further characterization. 
4-Methoxythieno[3,2-d]pyrimidine (471).  A stirred mixture of 470 (0.7 g, 4.6 mmol) 
and POCl3 (12 mL) was refluxed for 2 h. Then solvent was removed under reduced 
pressure to afford brown residue. The residue was loaded on a silica gel column packed 
with silica gel and eluted with 2% methanol in CHCl3 to afford 471 (0.55 g, 72%) as 
white powder; mp 100.5 
o
C; Rf 0.43 (hexane/EtOAc 1:1); 
1
H NMR (DMSO-d6)  4.13 (s, 
3 H, OCH3), 7.60, 7.61 (d, 1 H), 8.35, 8.36 (d, 1 H), 8.78 (s, 1 H, 2-H). Anal. calcd. for 
(C7H6N2SO): C, 50.59; H, 3.64; N, 16.86; S, 19.29; found: C, 50.60; H, 3.61; N, 16.79; S, 
19.22. 
4-Chlorothieno[3,2-d]pyrimidine (472).  A stirred mixture of 470 (0.15 g, 1 mmol) and 
POCl3 (6 mL) was refluxed for 2 h. Then solvent was removed under reduced pressure to 
afford brown residue. The residue was loaded on a silica gel column packed with silica 
gel and eluted with 25% ethyl acetate in hexane to afford 472 (0.15 g, 89%) as white 
powder. The whole process should avoid using of methanol; mp 62.8-63.2 °C; Rf 0.34 
(hexane/EtOAc 3:1); 
1
H NMR (DMSO-d6)  7.77, 7.78 (d, 1 H), 8.61, 8.62 (d, 1 H), 9.06 
(s, 1 H, 2-H). 
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N-(4-Methoxyphenyl)-N-methylthieno[3,2-d]pyrimidin-4-amine (474).  A mixture of 
472 (0.141 g, 0.83 mmol), 4-methoxy-N-methylaniline (0.114 g, 0.83 mmol) and n-
BuOH (7 mL) was refluxed. After completion of the reaction, as indicated by TLC, the 
reaction solvent was removed under reduced pressure. The residue was loaded on a silica 
gel column packed with silica gel and eluted with 25% ethyl acetate in hexane to afford 
474 (0.175 g, 78%) as light brown powder; mp 132.6-133.0 
o
C; Rf 0.49 (hexane/EtOAc 
1:1); 
1
H NMR (DMSO-d6)  3.49 (s, 3 H, OCH3), 3.84 (s, 3 H, N-CH3), 7.05, 7.07 (d, 2 
H, C6H4), 7.27, 7.29 (d, 1 H), 7.38, 7.41 (d, 2 H, C6H4), 7.90, 7.91 (d, 1 H), 8.58 (s, 1 H, 
2-H). Anal. calcd. for (C14H13N3SO): C, 61.97; H, 4.83; N, 15.49; S, 11.82; found: C, 
61.95; H, 4.76; N, 15.38; S, 11.70.  
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Appendix 
The biological evaluations of the analogs listed in the following tables were performed by 
Dr. Roy L. Kisliuk (Department of Biochemistry, Tufts University School of Medicine) 
against rhTS,
 
rhDHFR,
 
 E. coli TS and E. coli DHFR;
 
 Dr. Sherry F. Queener 
(Department of Pharmacology and Toxicology, Indiana University School of Medicine) 
against rat liver (rl)DHFR, P. carinii DHFR, T. gondii DHFR, and M. avium DHFR; 
Dr.Vivian Cody (Hauptman-Woodward Medical Research Institute). 
Table 13. Inhibition concentration (IC50, µM) against isolated TS and DHFR
 a
 of 285-
294 
  TS 
(µM) 
  DHFR 
(µM) 
 
Compound human
b
 E. coli
b
 T. gondi
c
i human
d
 E. coli
e
 T. 
gondii
c
 
285 >29(0) >29(0) >29(0) 35 0.035 1.4 
286 >24(0) >24(0) >24(0) >29(38) 0.044 1.5 
287 >25(19) >25(0) >25(0) 30 0.18 0.13 
288 >25(10) >25(10
) 
>25(0) >30(25) 0.09 0.2 
289 >22(7) >22(0) >22(0) 10 0.09 0.29 
290 >23(38) >23(0) >23(0) 27 0.081 1.3 
291 22 >22(15
) 
>22(0) >26(39) 0.16 2.1 
292 >24(31) >24(0) >24(0) >29(17) 0.044 2.9 
293 >23(41) >23(24
) 
>23(33) >28(10) 0.084 0.34 
294 >2.4(0) >2.4(0) >2.4(0) >29(40) 0.0087 0.26 
Pemetrexed
 g
 9.5 76 2.8 6.6 230 0.43 
MTX nd nd nd 0.022 0.0045 0.025 
  PDDF 
h
 0.085 0.017 0.17 2.1 63 0.11 
Raltitrexed 0.17 1.9 0.36 11 22 2.2 
Trimethoprim nd nd nd >50 0.01 6.8 
a The percent inhibition was determined at a minimum of four inhibitor concentrations within 20% of the 
50% point. The standard deviations for determination of 50% points were within ± 10% of the value given. 
b Kindly provided by Dr. Frank Maley, New York State Department of Health. c Kindly provided by Dr. 
Karen Anderson, Yale Univerisy, New Haven CT. d Kindly provided by Dr. J. H. Freisheim, Medical 
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College of Ohio, Toledo, OH. e Kindly provided by Dr. R. L. Blakley, St. Jude Children‟s hospital, 
Memphis TN. nd = not determined. gj Kindly provided by Dr. Chuan Shih, Eli Lilly and Co. h Kindly 
provided by Dr. M. G. Nair, University of South Alabama.  
 
Table 14. Inhibitory concentrations (IC50, µM) against isolated DHFR
a
 and  
selectivity ratios
b
 of 285-294 
 Inhibition concentration (IC50, µM) Selectivity ratio (IC50/IC50) 
Compoun
d 
P. carinii  T. gondii M. avium rat liver rl/pc rl/tg rl/ma 
285 6.7 2.7 0.11 1.4 0.21 0.52 12.73 
286 7.3 3.2 0.086 8.6 1.18 2.69 100 
287 1.9 0.63 0.15 0.88 0.46 1.4 5.87 
288 5.2 2.4 0.24 4.9 0.94 2.04 20.42 
289 1.7 0.25 0.23 0.33 0.19 1.32 1.43 
290 1.63 0.282 0.022 1.64 1 5.82 73.80 
291 5.9 0.99 0.43 1.8 0.31 1.85 4.19 
292 4.9 3.4 0.09 7.1 1.45 2.09 78.89 
293 4.4 5.1 0.41 5 1.14 0.98 12.2 
294 10.2 2.99 1.35 3 0.29 1 2.22 
TMQ 0.042 0.01 0.0015 0.003 0.07 0.3 2 
TMP 12 2.8 0.3 180 14 65 610 
a These assays were carried out at 37 °C under conditions ofsubstrate (90 µM dihydrofolic acid) and 
cofactor (119 µM NADPH)in the presence of 150 mM KCl.9  b Selectivity Ratios [(IC50 rlDHFR)/(IC50 
pcDHFR), (IC50 rlDHFR)/(IC50 tgDHFR), and (IC50 rlDHFR)/(IC50 maDHFR)] 
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Table 15. Inhibitory Concentrations of 301 (IC50 in µM) against TS and DHFR.
a
 
 TS( µM)  DHFR( µM) 
compound human
b
 
E. coli
b
 T. 
gondii
c
 
 human
d
 E. coli
e
 T. 
gondii
c
 
PDDF
f
 0.072 0.027 0.09  nd Nd nd 
296
g
 0.085 0.085 nd  nd Nd nd 
297
h
 0.042 nd nd  2.2 Nd nd 
298 0.26 0.82 1.7  >20(35) 15 1.4 
299 0.8 0.85 3.7  >20(24) >20(38) 1.8 
300
 
 0.068 0.017 0.14  0.09 0.4 0.02 
301
 
 0.034 0.05 0.17  0.1 0.4 0.01 
PMX
i
 9.5 76 2.8  6.6 2300 0.43 
MTX Nd nd nd  0.022 0.0066 0.022 
 
a The percent inhibition was determined at a minimum of four inhibitor concentrations within 20% of the 
50% point. The standard deviations for determination of 50% points were within ± 10% of the value given. 
b Kindly provided by Dr. Frank Maley, New York State Department of Health. c Kindly provided by Dr. 
Karen Anderson, Yale Univerisy, New Haven CT. d Kindly provided by Dr. J. H. Freisheim, Medical 
College of Ohio, Toledo, OH. e Kindly provided by Dr. R. L. Blakley, St. Jude Children‟s hospital, 
Memphis TN. f Kindly provided by Dr. M. G. Nair, University of South Alabama. g Kindly provided by Dr. 
J. J. McGuire, Roswell Park Cancer Institute, Buffalo, NY. h Data derived from ref 20.  i Kindly provided 
by Dr. Chuan Shih, Eli Lilly and Co. nd = not determined 
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Table 16. Inhibition concentration (IC50, µM) against isolated TS and DHFR
 a
 of 304-
311 
  TS (µM)      DHFR 
(µM) 
 
       compound huma
n
b
 
E. coli
b
 T.gondi
i
c
 
 human
d
 E. coli
e
 T. 
gondii
c
 
304 0.08 0.06   0.096  0.95 >19 (43) 0.19 
305 3.8 22 14  >32 (12) >3.2 (0) >3.2 (41) 
306 0.32 1.2 1.2  > 2.8 (0) > 2.8 (0) > 2.8 
(44) 
307 1.1 2.1 1.9  >2.5 (0) >2.5 (0) 1.8 
308 12 > 23(38) > 38 
(21) 
 > 2.7 (0) > 2.7 (0) 2.1 
309 0.46 2.3 2.1  > 2.7 (0) > 2.7 (0) 2.2 
310 1.3 10 6.3  > 30 (23) > 3.0 (0) 3.0 
311 0.35 2.3 2.5  > 28 (0) > 2.8 (0) > 2.8 
(44) 
Pemetrexed
g
 9.5 76 2.8  6.6 230 0.43 
PDDF
j
 0.085 0.019 0.43  1.9 23 0.22 
MTX nd nd nd  0.02 0.0088 0.033 
Trimethoprim nd nd nd  >340 
(22) 
0.01 6.8 
 
a The percent inhibition was determined at a minimum of four inhibitor concentrations within 20% of the 
50% point. The standard deviations for determination of 50% points were within ± 10% of the value given. 
b Kindly provided by Dr. Frank Maley, New York State Department of Health. c Kindly provided by Dr. 
Karen Anderson, Yale Univerisy, New Haven CT. d Kindly provided by Dr. J. H. Freisheim, Medical 
College of Ohio, Toledo, OH. e Kindly provided by Dr. R. L. Blakley, St. Jude Children‟s hospital, 
Memphis TN. nd = not determined. g Kindly provided by Dr. Chuan Shih, Eli Lilly and Co. j Kindly 
provided by Dr. M. G. Nair, University of South Alabama.  
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Table 17. Inhibition concentration (IC50, µM) against isolated TS and DHFR
 a
 of 317-
319. 
  TS 
(µM) 
     DHFR   
    (µM) 
  
       
Compound 
huma
b
 E. coli
b
 T. 
gondii
c
 
 huma
d
 E. coli
e
 T. 
gondii
c
 
DHFR 
Selectivity 
(rh/tg) 
317 >1.4 
(16) 
>1.4 
(24) 
>1.4 
(15) 
 17.0 > 17 (0) 0.017 1000 
318 0.21 2.3 1.8  > 2.6 
(0) 
> 2.6 (0) 0.023 >113  
319 0.23 >2.1 
(25) 
1.1  2.2 > 25 (17) 0.02 110 
PMX
i
 9.5 76 2.8  6.6 230 0.43 15  
PDDF
j
 0.085 0.019 0.43  1.9 23 0.22 8.6  
MTX nd Nd nd  0.02 0.0088 0.033 0.6  
Trimethop
rim 
nd Nd nd  >340 
(22) 
0.01 6.8 >50 
 aThe percent inhibition was determined at a minimum of four inhibitor concentrations within 20% of the 
50% point. The standard deviations for determination of 50% points were within ± 10% of the value given. 
b Kindly provided by Dr. Frank Maley, New York State Department of Health. c Kindly provided by Dr. 
Karen Anderson, Yale Univerisy, New Haven CT. d Kindly provided by Dr. J. H. Freisheim, Medical 
College of Ohio, Toledo, OH. e Kindly provided by Dr. R. L. Blakley, St. Jude Children‟s hospital, 
Memphis TN. nd = not determined. i Kindly provided by Dr. Chuan Shih, Eli Lilly and Co. j Kindly 
provided by Dr. M. G. Nair, University of South Alabama.  
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Table 18. Inhibition concentration (IC50 in µM) against TS and DHFR
a 
of 324-330 
  TS  
(µM) 
   DHFR(µ
M) 
 
       compound huma
n
b
 
E. coli
b
 T. 
gondii
c
 
 human
d
 
E. coli
e
 T. gondii
c
 
324 >18(4
2) 
>18(32) >18(24)  0.44 >22(15) 0.11 
325 >18(1
4) 
>18(9) >18(14)  21 >210(24) 1.7 
326 >17(3
1) 
>17(3) >17(16)  2.1       >21(0) 0.17 
327 >17(3
6) 
>17(17) >17(33)  2.0 >20(0) 0.14 
328 >17(3
8) 
>17(17) >17(22)  1.0 >20(0) 0.01 
329 14 >16(17) 0.16  0.24 >19(21) 0.019 
330 7.0 15 5.0  0.23 >19 (30) 0.019 
MTX 20 >18(12) 27  0.022 0.0066 0.019 
Pemetrexed
f
 9.5 76 2.8  6.6 230 0.43 
PDDF
g
 0.085 0.019 0.43  1.9 23 0.22 
Pyrimethamine nd nd nd  6.0 2.0 0.2 
Trimethoprim nd nd nd  0.038 0.02 2.9 
 
a The percent inhibition was determined at a minimum of four inhibitor concentrations within 20% of the 
50% point. The standard deviations for determination of 50% points were within ± 10% of the value given. 
nd = not determined. Numbers in parentheses indicate the % inhibition at the concentration tested. b Kindly 
provided by Dr. Frank Maley, New York State Department of Health. c Kindly provided by Dr. Karen 
Anderson, Yale Univerisy, New Haven CT. d Kindly provided by Dr. J. H. Freisheim, Medical College of 
Ohio, Toledo, OH. e Kindly provided by Dr. R. L. Blakley, St. Jude Children‟s hospital, Memphis TN. f 
Kindly provided by Dr. Chuan Shih, Eli Lilly and Co. g Kindly provided by Dr. M. G. Nair, University of 
South Alabama 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 19. IC50s (nM) for thienopyrimidine compounds 324 to 330 in cell proliferation inhibition of RFC- and FR-expressing 
cell lines.  
Antifolate 
(number CH2, n) 
hRFC hFRα hFRβ hRFC/ FRα  hRFC/ FRα  
PC43-10 R2 RT16  
RT16 
(+FA) 
D4 
D4 
(+FA) 
KB 
KB 
(+FA) 
IGROV1 
IGROV1 
(+FA) 
324 (n=2) >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 
325 (n=3) >1000 >1000 13(3.4) >1000 112(12) >1000 23(5.5) >1000 4.7(1.9) >1000 
326 (n=4) >1000 >1000 9(2.9) >1000 20(3.9) >1000 4.9(1.3) >1000 5.9(1.9) >1000 
327 (n=5) >1000 >1000 56(9.8) >1000 56(13) >1000 132(23) >1000 25(1.7) >1000 
328 (n=6) >1000 >1000 108(17) >1000 364(46) >1000 310(54) >1000 334(59) >1000 
329 (n=7) >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 
330 (n=8) >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 >1000 
Methotrexate 12(1.1) 216(8.7) 114(31) 461(62) 106(11) 211(43) 6.0(0.6) 20(2.4) 21(3.4) 22(2.1) 
Pemetrexed 138(13) 894(93) 42(9) 388(68) 60(8) 254(78) 68(12) 327(103) 102(25) 200(18) 
Raltitrexed 6.3(1.3) >1000 15(5) >1000 22(10) 746(138) 5.9(2.2) 22(5) 12.6(3.3) 20(4.3) 
Lometrexol 12(2.3) >1000 12(8) 188(41) 2.6(1.0) 275(101) 1.2(0.6) 31(7) 3.1(0.9) 16(6) 
Trimetrexate 25(7.3) 6.7(1.3) 13(1) 4.1(1) 11(4.2) 6.1(1.9) 58(18) 155(38) 12(4) 8.6(1.9) 
OSI-7904 11(3.3) >1000 277(81) >1000 52(12) >1000 5.8(3.5) 32(15) 5.2(1.7) 6.9(1.6) 
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 Table 20. Inhibition concentration (IC50 in µM) against TS and DHFR
a 
of 335-38. 
  TS  (µM)    DHFR(µM)  
       compound human
b
 E. coli
b
 T. gondii
c
  human
d
 E. coli
e
 T. gondii
c
 
335 >19(27) >19(0) >19(0)  2.3  >23(0) 0.046 
336 >18(21) >18(10) >18(0)  4.0 >22(0) 0.15 
337 >19(19) >19(19) >19(0)  2.3 >23(14) 0.046 
338 >19(35) >19(20) >19(16)  2.3 >23(19) 0.046 
MTX 20 >18(12) 27  0.02 0.0073 0.022 
Pemetrexed
f
 9.5 76 2.8  6.6 230 0.43 
PDDF
g
 0.085 0.019 0.018  1.9 23 0.22 
Pyrimethamine nd nd nd  6.0 2.0 0.2 
Trimethoprim nd nd nd  0.038 0.02 2.9 
 
a The percent inhibition was determined at a minimum of four inhibitor concentrations within 20% of the 50% point. The standard deviations for 
determination of 50% points were within ± 10% of the value given. nd = not determined. Numbers in parentheses indicate the % inhibition at the 
concentration tested. b Kindly provided by Dr. Frank Maley, New York State Department of Health. c Kindly provided by Dr. Karen Anderson, Yale 
Univerisy, New Haven CT. d Kindly provided by Dr. J. H. Freisheim, Medical College of Ohio, Toledo, OH. e Kindly provided by Dr. R. L. Blakley, St. 
Jude Children‟s hospital, Memphis TN. f Kindly provided by Dr. Chuan Shih, Eli Lilly and Co. g Kindly provided by Dr. M. G. Nair, University of 
South Alabama 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Table 21. FRα binding percentages and IC50s (nM) for thienopyrimidine compounds 335-338 in cell proliferation inhibition of 
RFC- , PCFT- and FR-expressing cell lines.  
2
6
5
 
  
Antifolate 
 
FRα 
binding 
% 
RFC hFRα RFC/ FRα RFC/ FRα PCFT 
  PC43-10 R2 RT16 RT16 
(+FA) 
KB KB 
(+FA) 
IGROV
1 
IGROV1 
(+FA) 
R2/PCFT4 R2/VC 
335 19.4 N N 25 N N nd nd nd >1000 >1000 
336 16.7 N N 13 N N nd nd nd >1000 >1000 
337 35.2 N N 66 N N nd nd nd >1000 >1000 
338 36.1 N N 60 N N nd nd nd >1000 >1000 
Methotrexate nd 12(1.1) 216 
(8.7) 
114 
(31) 
461(62) 6.0 
(0.6) 
20(2.4) 21(3.4) 22(2.1) 120.5(16.8) >1000 
Pemetrexed nd 138(13) 894 
(93) 
42(9) 388(68) 68(12) 327 
(103) 
102(25) 200(18) 13.2(2.4) 974.0(18.1) 
Raltitrexed nd 6.3(1.3) >1000 15(5) >1000 5.9 
(2.2) 
22(5) 12.6 
(3.3) 
20(4.3) 99.5(11.4) >1000 
Lometrexol nd 12(2.3) >1000 12(8) 188(41) 1.2 
(0.6) 
31(7) 3.1(0.9) 16(6) 248.0(18.2) >1000nM 
Trimetrexate nd 25(7.3) 6.7 
(1.3) 
13(1) 4.1(1) 58(18) 155(38) 12(4) 8.6(1.9) nd nd 
 
FR experiments, cytotoxicity assays were performed in the absence and presence of 200 nM folic acid (FA). The data shown are mean values 
from three experiments (plus/minus SEM in parentheses). N = not active. nd = not determined. IC50 data of classical antifolate compounds, 
methotrexate, pemetrexed, raltitrexed, lometrexol, trimetrexate were previously published from our laboratory. For the FRα binding 
experiments, 250 nM of unlabeled ligand was used as competitor with 3H-folic acid (50 nM) for binding. The numbers shown represent the 
percent of 3H-bound normalized to cell numbr. The protocol is based on our previous publications. 
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 Table 22. Inhibition concentration (IC50 in µM) against TS and DHFR
a 
of 333. 
  TS  (µM)    DHFR(µM)  
       compound human
b
 E. coli
b
 T. gondii
c
  human
d
 E. coli
e
 T. gondii
c
 
333 6.8 >17 (23) 17  2.0 >20 (14) 0.063 
MTX 20 >18(12) 27  0.02 0.0073 0.022 
Pemetrexed
f
 9.5 76 2.8  6.6 230 0.43 
PDDF
g
 0.085 0.019 0.018  1.9 23 0.22 
Pyrimethamine nd nd nd  6.0 2.0 0.2 
Trimethoprim nd nd nd  0.038 0.02 2.9 
 
a The percent inhibition was determined at a minimum of four inhibitor concentrations within 20% of the 50% point. The standard deviations for 
determination of 50% points were within ± 10% of the value given. nd = not determined. Numbers in parentheses indicate the % inhibition at the 
concentration tested. b Kindly provided by Dr. Frank Maley, New York State Department of Health. c Kindly provided by Dr. Karen Anderson, Yale 
Univerisy, New Haven CT. d Kindly provided by Dr. J. H. Freisheim, Medical College of Ohio, Toledo, OH. e Kindly provided by Dr. R. L. Blakley, St. 
Jude Children‟s hospital, Memphis TN. f Kindly provided by Dr. Chuan Shih, Eli Lilly and Co. g Kindly provided by Dr. M. G. Nair, University of 
South Alabama 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 23. FRα binding percentages and IC50s (nM) for thienopyrimidine compounds 333 in cell proliferation inhibition of 
RFC- , PCFT- and FR-expressing cell lines.  
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Antifolate 
 
FRα 
binding 
% 
RFC hFRα RFC/ FRα RFC/ FRα PCFT 
  PC43
-10 
R2 RT1
6 
RT16 
(+FA) 
KB KB 
(+FA) 
IGRO
V1 
IGROV
1 (+FA) 
R2/PC
FT4 
R2/VC 
333 nd >1000 >1000 3.1 nd 2.1 nd 12.8 nd >1000 >1000 
Methotrexate nd 12 
(1.1) 
216 
(8.7) 
114 
(31) 
461(62) 6.0 
(0.6) 
20 
(2.4) 
21 
(3.4) 
22 
(2.1) 
120.5 
(16.8) 
>1000 
Pemetrexed nd 138 
(13) 
894 
(93) 
42 
(9) 
388(68) 68 
(12) 
327 
(103) 
102 
(25) 
200 
(18) 
13.2 
(2.4) 
974.0 
(18.1) 
Raltitrexed nd 6.3 
(1.3) 
>1000 15 
(5) 
>1000 5.9 
(2.2) 
22(5) 12.6 
(3.3) 
20 
(4.3) 
99.5 
(11.4) 
>1000 
Lometrexol nd 12 
(2.3) 
>1000 12 
(8) 
188(41) 1.2 
(0.6) 
31(7) 3.1 
(0.9) 
16(6) 248.0 
(18.2) 
>1000n
M 
Trimetrexate nd 25 
(7.3) 
6.7 
(1.3) 
13 
(1) 
4.1(1) 58 
(18) 
155 
(38) 
12 
(4) 
8.6 
(1.9) 
nd nd 
 
FR experiments, cytotoxicity assays were performed in the absence and presence of 200 nM folic acid (FA). The data shown are mean values from three 
experiments (plus/minus SEM in parentheses). N = not active. nd = not determined. IC50 data of classical antifolate compounds, methotrexate, 
pemetrexed, raltitrexed, lometrexol, trimetrexate, 2 and 3, were previously published from our laboratory.9 For the FRα binding experiments, 250 nM of 
unlabeled ligand was used as competitor with 3H-folic acid (50 nM) for binding. The numbers shown represent the percent of 3H-bound normalized to 
cell numbr. The protocol is based on our previous publications. 
2
6
8
 
